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Intestinal diseases and their corresponding clinical signs are a common reason for a dog to 
be presented to a veterinary hospital. Diarrhea represents one of the characteristic clinical 
signs of intestinal disease and can be classified as small bowel diarrhea, large bowel 
diarrhea, or mixed small and large bowel diarrhea (ALLENSPACH 2010a, HALL and 
GERMAN 2010). Small bowel diarrhea is characterized by typical clinical signs that include 
increased fecal volume, normal to only mildly increased frequency of defecation, melena, 
and in some cases steatorrhea, as well as weight loss (HALL and GERMAN 2010). Large 
bowel diarrhea, on the other hand, is associated with an increased frequency of defecation, 
tenesmus, fecal urgency, often with mucus in the stool, and in some cases also 
hematochezia (ALLENSPACH 2010a). However, a clear differentiation between the two 
forms of diarrhea is not always possible, especially because many dogs show a combination 
of small and large bowel diarrhea. 
In addition to diarrhea, also vomiting, weight loss, poor appetite (hyporexia or anorexia), 
abdominal pain, borborygmus, or flatulence are common clinical signs in dogs with chronic 
intestinal disease (HALL and GERMAN 2010). However, none of these clinical signs are 
pathognomonic for intestinal disease. Therefore, a thorough patient history followed by a 
clinical and clinicopathological evaluation are essential in order to exclude other 
extragastrointestinal diseases (e.g., pancreatic disease, chronic liver disease, chronic renal 
disease, or several endocrine disorders) as a cause of the patient’s clinical signs. 
Intestinal diseases can be categorized into acute or chronic diseases (HALL and GERMAN 
2010). Infectious gastroenteritides (e.g., viral, bacterial, parasitic, or fungal enteritis), the 
acute hemorrhagic diarrhea syndrome (formerly known as idiopathic hemorrhagic enteritis) 
(BURROWS 1977, UNTERER et al. 2014, MORTIER et al. 2015), self-limiting acute 
gastroenteritis of unknown origin, acute transit disorders (e.g., ileus), dietary indiscretion, and 
toxin ingestion are the main causes of acute gastrointestinal clinical signs in dogs 
(ALLENSPACH and GASCHEN 2011). 
Chronic inflammatory enteropathies (CIE), which are characterized by persistent or recurrent 
clinical signs of gastrointestinal disease for at least 3 weeks’ duration (GERMAN et al. 
2003a, WASHABAU et al. 2010), together with intestinal neoplasia and chronic parasitic 
diseases, are a common cause of chronic intestinal signs in dogs. Based on the response to 
treatment, chronic inflammatory enteropathies are categorized into food-responsive diarrhea 
(FRD), antibiotic-responsive diarrhea (ARD), and idiopathic inflammatory bowel disease 
(IBD) (GERMAN et al. 2003a, ALLENSPACH et al. 2007, DANDRIEUX 2016, ERDMANN 




(ALLENSPACH et al. 2007, MANDIGERS et al. 2010), whereas dogs with ARD require the 
use of an antibiotic for clinical signs to resolve (GERMAN et al. 2003a, WESTERMARCK et 
al. 2005, KILPINEN et al. 2011). IBD is defined by the presence of chronic gastrointestinal 
signs, histologic evidence of intestinal inflammation, and the need for anti-inflammatory and / 
or immunosuppressive treatment (GERMAN et al. 2003a, DAY et al. 2008, WASHABAU et 
al. 2010, ALLENSPACH et al. 2016).  
Until today, the exact pathogenesis of IBD in companion animals remains elusive. Recent 
studies support the hypothesis that a combination of a genetic predisposition (BURGENER 
et al. 2008, KATHRANI et al. 2010, ALLENSPACH et al. 2010b, KATHRANI et al. 2011, 
KATHRANI et al. 2012, KATHRANI et al. 2014), dietary and environmental factors, and the 
intestinal microbiota can contribute to the development of IBD in dogs (SIMPSON and 
JERGENS 2011, HEILMANN and ALLENSPACH 2017). Recently, the role of the intestinal 
microbiota in particular has attracted a large amount of attention and intestinal or fecal 
dysbiosis has been demonstrated in dogs with IBD, reflected mainly by an increase in 
Proteobacteria and a decrease in Faecalibacterium spp. compared to healthy dogs 
(SUCHODOLSKI et al. 2010, SUCHODOLSKI et al. 2012a, HONNEFFER et al. 2014, 
MINAMOTO et al. 2015, CASSMANN et al. 2016). 
To the author’s knowledge, there are no studies that evaluate the possibility of differences in 
the intestinal microbiota in dogs diagnosed with IBD and dogs with FRD. Therefore, the first 
objective of this study was to compare the duodenal and colonic mucosal microbiota 
between dogs with IBD and dogs diagnosed with FRD. Further, the intestinal mucosal 
microbiota in each dog was evaluated before and after the induction phase of treatment to 
determine the possibility of an effect of treatment on the intestinal microbial composition. 
In addition to the further understanding of the role of microbial changes in canine patients 
with IBD, the search for potential novel treatment options that can modulate the intestinal 
microbiome is of particular clinical importance. The use of probiotics in canine IBD has 
become increasingly popular, and the use of probiotic mixtures in particular has shown 
promising results (SAUTER et al. 2005, ROSSI et al. 2014). Polyunsaturated fatty acids 
(PUFAs) were demonstrated to have immunomodulatory and anti-inflammatory properties 
both in humans (SIMOPOULOS 2002, CALDER 2013, UNGARO et al. 2017) and in 
veterinary patients (MUELLER et al. 2004, ABBA et al. 2005, ONTSOUKA et al. 2010, 
BAUER 2011, ONTSOUKA et al. 2012), and are commonly used in the treatment of canine 
dermatologic diseases, such as atopic dermatitis (MUELLER et al. 2004, ABBA et al. 2005). 
Despite the beneficial effects seen in nongastrointestinal diseases, there are only few studies 
investigating the effect of dietary supplementation of PUFAs in dogs with CIE. Preliminary 




PUFAs can improve cholesterol homeostasis (ONTSOUKA et al. 2010) and can modulate 
the expression of genes regulating fatty acid uptake in the duodenum (ONTSOUKA et al. 
2012). In order to shed more light on this aspect of CIE pathogenesis, the second objective 
of our study was to assess the systemic phospholipid profile (i.e., the circulating lipidome) of 
dogs with FRD or IBD both before and after treatment including supplemental PUFAs. 
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2 REVIEW OF LITERATURE 
2.1 Chronic Inflammatory Enteropathies in Dogs 
2.1.1 Definition 
2.1.1.1 Diagnostic Criteria and Disease Classification 
Chronic inflammatory enteropathies (CIE) are characterized by persistent or recurrent clinical 
signs of gastrointestinal disease, such as diarrhea, vomiting, inappetence, weight loss, 
abdominal pain, borborygmus or flatulence, for more than 3 weeks (GERMAN et al. 2003a, 
SIMPSON and JERGENS 2011, DANDRIEUX 2016, ERDMANN and HEILMANN 2017). A 
diagnosis of CIE also requires that no other underlying extraintestinal (e.g., pancreatic, 
hepatic, renal, or endocrine disorders) or intestinal diseases (e.g., endoparasites, infectious 
disease, motility disorders, or intestinal neoplasia) has been identified (SIMPSON and 
JERGENS 2011, DANDRIEUX 2016). The third criterion is that there is histologic evidence of 
intestinal inflammation, which is one of the cornerstones of CIE diagnosis and also further 
classification. Based on the quality of the inflammatory infiltrate and the predominant 
population of inflammatory cells, CIEs are histologically classified as either 
lymphoplasmacytic, eosinophilic, or mixed inflammation (GERMAN et al. 2003a, DAY et al. 
2008, WASHABAU et al. 2010). 
CIE can further be classified based on the patient’s response to treatment as either food-
responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD), or idiopathic inflammatory 
bowel disease (IBD) (GERMAN et al. 2003a, ALLENSPACH et al. 2007, DANDRIEUX 2016, 
ERDMANN and HEILMANN 2017). In dogs with FRD, clinical signs resolve after dietary 
modification alone (ALLENSPACH et al. 2007, MANDIGERS et al. 2010), whereas dogs with 
ARD show a long-lasting response to dietary management and the use of an antibiotic, for 
example metronidazole or tylosin (GERMAN et al. 2003a, WESTERMARCK et al. 2005, 
KILPINEN et al. 2011). IBD is characterized by chronic gastrointestinal signs of 
undetermined etiology, histologic evidence of intestinal inflammation, failure to achieve 
clinical remission with an elimination diet and / or antibiotic trial, and the need for anti-
inflammatory and / or immunosuppressive treatment (GERMAN et al. 2003a, DAY et al. 
2008, WASHABAU et al. 2010). Thus, IBD is also referred to as immunosuppressant-
responsive (IRD) or steroid-responsive diarrhea (SRD) (ALLENSPACH et al. 2016, 
DANDRIEUX 2016), though complete remission is not achieved in all dogs with IRD / SRD. 
Several dog breeds appear to be predisposed to the development of CIE. These include 
German shepherd dogs, which are overrepresented among dogs diagnosed with ARD (BATT 
et al. 1991, GERMAN et al. 2003a, ALLENSPACH et al. 2010b), Irish Setters with gluten-
sensitive enteropathy (GARDEN et al. 2000), and Soft Coated Wheaten Terriers with protein-
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losing enteropathy (PLE) and / or protein-losing nephropathy (LITTMAN et al. 2000). Such 
breed predilections raise the suspicion of genetic factors contributing to the development of 
CIE, though an association with genetic defects or mutations has to date not been identified. 
 
2.1.1.2 Clinical Disease Activity 
Dogs with CIE can present with a variety of clinical signs and disease severities depending 
on the affected site or sites and the degree of inflammation within the gastrointestinal tract 
(JERGENS et al. 1992, JERGENS et al. 2003, CRAVEN et al. 2004, ALLENSPACH et al. 
2007, DANDRIEUX 2016). Frequent clinical signs are vomiting, diarrhea, inappetence, 
abdominal pain and weight loss (GERMAN et al. 2003a, DANDRIEUX 2016). These variable 
clinical signs and disease severities make an objective patient assessment and accurate 
evaluation of the response to treatment difficult. Therefore, two scoring indices have been 
developed in order to assess the clinical degree of illness, which is referred to as clinical 
disease activity, and aid in the management of clinical patients:  
• canine inflammatory bowel disease activity index (CIBDAI) (JERGENS et al. 2003) 
• canine chronic enteropathy clinical activity index (CCECAI) (ALLENSPACH et al. 
2007). 
Both clinical scoring systems include the criteria attitude / activity, appetite, vomiting, stool 
consistency, stool frequency, and weight loss. The CCECAI additionally includes the serum 
albumin concentration, presence of ascites / peripheral edema, and pruritus (ALLENSPACH 
et al. 2007). All criteria are scored on a scale of 0 - 3 according to the degree of alteration 
from normal in a specific patient (e.g., appetite: 0 = normal, 1 = slightly decreased, 2 = 
moderately decreased, 3 = severely decreased) (JERGENS et al. 2003, ALLENSPACH et al. 
2007). The scores for each individual criterion add up to the total activity index score. Based 
on this score, the severity of disease is defined as clinically insignificant (score 0 - 3), mild 
(score 4 - 5), moderate (score 6 - 8), severe (CIBDAI score > 9; CCECAI score 9 - 11) 
(JERGENS et al. 2003, ALLENSPACH et al. 2007), or very severe disease (CCECAI score ≥ 
12) (ALLENSPACH et al. 2007). A high clinical activity index has been associated with a 
negative outcome (ALLENSPACH et al. 2007). 
On the basis of these clinical activity indices a patient’s disease status should be regularly 
assessed in order to evaluate the response to treatment and guide further treatment 
decisions. Clinical response to treatment is reflected by the change in the activity index score 
where full remission is defined as a change in the total score of > 75%, partial response as a 
change between 25 - 75%, and a lack of response if the change in the total score is < 25% 
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(JERGENS et al. 2010, HEILMANN et al. 2016). Thus, the clinical activity index scores and 
the overall treatment response can aid in the prognostication of canine CIE. 
 
2.1.1.3 Clinicopathologic Findings 
There are no pathognomonic findings on the complete blood count (CBC) or the biochemistry 
profile in dogs with CIE (HALL and GERMAN 2010b). However, a CBC and biochemistry 
panel should always be performed in order to exclude extraintestinal diseases (HALL and 
GERMAN 2010). Moreover, albeit not pathognomonic, several hematologic and biochemical 
abnormalities have been reported in dogs with CIE (CRAVEN et al. 2004, ALLENSPACH et 
al. 2007, DANDRIEUX 2016). One retrospective study on canine inflammatory bowel disease 
revealed anemia in 12%, neutrophilia in 7%, and eosinophilia in 4% of dogs (CRAVEN et al. 
2004), whereat anemia may be the result of chronic blood loss or chronic inflammation. Dogs 
with intestinal protein loss, especially albumin, are categorized as protein-losing enteropathy 
(PLE) (HALL and GERMAN 2010, DANDRIEUX 2016). Hypoalbuminemia has been 
identified as a risk factor for a negative outcome (CRAVEN et al. 2004, ALLENSPACH et al. 
2007) leaving patients with PLE with a more guarded prognosis. The vitamins folate and 
cobalamin are absorbed in the intestine, with cobalamin being absorbed in the ileum. Thus, 
intestinal inflammation can result in decreased absorption and a subsequent deficiency of 
these vitamins (HALL and GERMAN 2010). Hypocobalaminemia is of particular importance, 
as hypocobalaminemia at the time of CIE diagnosis is also associated with a negative 
outcome even after a correction of the serum cobalamin deficiency through cobalamin 
supplementation (ALLENSPACH et al. 2007). Additionally, low serum concentrations of 
vitamin D at the time of diagnosis have been shown to be a negative prognostic factor for 
dogs with CIE (TITMARSH et al. 2015). However, until now there is no information on how 
vitamin D supplementation affects vitamin D deficient patients and the disease outcome 
(DANDRIEUX 2016). Mildly elevated liver enzyme activities are often encountered on the 
biochemistry profile of dogs with CIE, and this might be due to a secondary impairment of the 
liver by the intestinal inflammation (reactive hepatitis). Lastly, hypomagnesemia and 
hypocalcemia have been reported in dogs with CIE, especially in Yorkshire terriers with PLE 
(KIMMEL et al. 2000). 
 
2.1.1.4 Endoscopic Criteria 
Intestinal biopsy is crucial to provide evidence of intestinal inflammation – a cornerstone of 
the diagnosis of CIE (DAY et al. 2008, WASHABAU et al. 2010). Biopsies can be obtained by 
flexible endoscopy, laparoscopy, or exploratory laparotomy (WASHABAU et al. 2010, 
ERDMANN and HEILMANN 2017). Endoscopy is the least invasive method of biopsy and 
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allows for direct visual assessment of mucosal changes and targeted sampling of mucosal 
tissue specimens (WASHABAU et al. 2010, JERGENS et al. 2016). Furthermore, endoscopy 
permits collection of multiple tissue specimens and thus increases the likelihood of detecting 
a localized disease (WASHABAU et al. 2010, JERGENS et al. 2016). However, one major 
limitation of endoscopic biopsies is the access to only certain segments of the 
gastrointestinal tract, which are the esophagus, stomach, duodenum, ileum, and colon. Also, 
endoscopic biopsies typically contain mucosa but do not allow for evaluation of lesions in the 
tunica muscularis. Thus, full-thickness biopsies are necessary if deeper layers of the mucosa 
or the entire wall of the intestine need to be evaluated (WASHABAU et al. 2010, JERGENS 
et al. 2016). The intestinal mucosa is evaluated endoscopically by assessing the mucosal 
appearance, friability, granularity, erosions or ulcerations, hyperemia, lymphatic dilatation, 
and possible mass lesions (SLOVAK et al. 2015, JERGENS et al. 2016). If no lesions are 
visible, the mucosa is considered as endoscopically normal. Friability describes immoderate 
bleeding induced by manipulation with the endoscope or the biopsy forceps (SLOVAK et al. 
2015, JERGENS et al. 2016), whereas granularity refers to an altered texture of the mucosa 
(SLOVAK et al. 2015, JERGENS et al. 2016). Erosions are superficial mucosal defects with 
hemorrhage (SLOVAK et al. 2015, JERGENS et al. 2016), and hyperemia describes the 
degree of mucosal redness. Multifocal or diffuse white dots or speckles within the mucosa 
are defined as lymphatic dilatation or lymphangiectasia, and a mass is an abnormal growth 
of tissue extending into the gastrointestinal lumen (SLOVAK et al. 2015, JERGENS et al. 
2016). In addition to the mucosal appearance, the ability to insufflate the bowel 
endoscopically is assessed (ALLENSPACH et al. 2007). SLOVAK et al. (2015) developed an 
endoscopic activity score for canine IBD including quantitative and qualitative assessment of 
friability, granularity, erosions and lymphatic dilatations. Such a score can aid in assessing 
the severity of endoscopic findings. Severe endoscopic disease in the duodenum has been 
reported to be significantly associated with a negative outcome (ALLENSPACH et al. 2007). 
It should be emphasized that there is no correlation between the severity of endoscopic and 
histologic lesions (ALLENSPACH et al. 2007, HEILMANN et al. 2014). 
 
2.1.1.5 Histopathologic Criteria 
In healthy dogs, the duodenal mucosa exhibits long, slender and uniform villi, and uniform 
crypts aligned perpendicularly to the surface (DAY et al. 2008). Lymphocytes and plasma 
cells occupy approximately 25% of the area of one 40x magnified microscopic field of the 
lamina propria of villi and there may be 1-2 lymphocytes detected between the crypts (DAY 
et al. 2008). Approximately 2-3 eosinophils per 40x magnified microscopic field are 
considered as a normal finding and neutrophils, which can be difficult to detect during routine 
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histopathology, should not be present in moderate or high numbers in the lamina propria 
under normal conditions (GERMAN et al. 1999, DAY et al. 2008). Figure 1 illustrates the 
histopathologic appearance of normal duodenal mucosa. 
 
Figure 1. Duodenum with normal mucosa. This picture is printed by courtesy of Dr. Romy 
Heilmann; © 2014; Gastrointestinal Laboratory, Texas A&M University, College Station, TX, 
USA. 
The colonic mucosa does not contain villi and is composed of a single layer of columnar 
epithelium, perpendicular and mainly uniform crypts, and numerous goblet cells (DAY et al. 
2008). At most five lymphocytes and plasma cells should be present between crypts in 
healthy dogs. One or two eosinophils within the lamina propria are considered normal, and 
neutrophils should not be present in moderate or high numbers (GERMAN et al. 1999, DAY 
et al. 2008). 
In addition to cellular infiltrates within the epithelium and the lamina propria, morphological 
abnormalities are assessed and graded to assess chronicity or further categorize 
inflammatory enteropathies (DAY et al. 2008, WASHABAU et al. 2010). Typical 
morphological changes of the duodenum include epithelial injury, villous stunting, crypt 
distention, lacteal dilation, and mucosal fibrosis (figures 2 - 4) (WASHABAU et al. 2010). In 
the colonic mucosa the presence of surface epithelial injury, crypt hyperplasia, crypt dilation 
and distortion, and mucosal fibrosis and atrophy are structural criteria that can aid in further 
classifying the disease (figures 5 and 6) (WASHABAU et al. 2010). Based on the severity of 
inflammatory cell infiltration and structural abnormalities, a distinction is made between mild, 
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moderate and severe / marked histologic disease in accordance with published guidelines 
(DAY et al. 2008, WASHABAU et al. 2010). Interestingly, histologic lesion severity has been 
demonstrated to not be correlated with clinical response to treatment and overall patient 
outcome (CRAVEN et al. 2004, ALLENSPACH et al. 2007, GARCIA-SANCHO et al. 2007, 
SCHREINER et al. 2008). Biochemical variables, namely hypoalbuminemia and 
hypocobalaminemia, and the severity of endoscopic lesions in the duodenum appear to be 
more relevant instead and have been shown to be associated with a negative outcome 
(ALLENSPACH et al. 2007). 
 
Figure 2. Duodenum with moderate crypt hyperplasia and a moderate increase in plasma 
cells in the lamina propria. Courtesy of Dr. Romy Heilmann; © 2014; Gastrointestinal 
Laboratory, Texas A&M University, College Station, TX, USA. 
 




Figure 3. Image of duodenal villi. The villi are slightly widened and have a dilated lacteal. 
There are infiltrates of lymphocytes and plasma cells. © 2014 Dr. Romy Heilmann; 
Gastrointestinal Laboratory, Texas A&M University, College Station, TX, USA. 
 
 
Figure 4. Diffuse, severe, chronic mixed (lymphoplasmacytic, eosinophilic and neutrophilic) 
duodenitis with numerous crypt abscesses and severe villous atrophy. This picture is printed 
by courtesy of Dr. Romy Heilmann; © 2014; Gastrointestinal Laboratory, Texas A&M 
University, College Station, TX, USA. 




Figure 5. Image of the colon with loss of cryptal structure with some mild hyperplasia and 
distortion, decreased goblet cells and mild to moderate inflammatory infiltration of the lamina 
propria. © 2014 Dr. Romy Heilmann; Gastrointestinal Laboratory, Texas A&M University, 
College Station, TX, USA. 
 
It should be emphasized that the different chronic inflammatory enteropathies – food-
responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD), and idiopathic inflammatory 
bowel disease (IBD) – can display very similar histologic lesions, and consequently, these 
conditions cannot be distinguished by histopathology alone (GERMAN et al. 2003a, 
ALLENSPACH et al. 2007, DANDRIEUX 2016). 




Figure 6. Extensive infiltration and expansion of the colonic lamina propria by numerous 
histiocytes with multifocal surface erosion and occasional ulceration. Courtesy of Dr. Romy 
Heilmann; © 2014; Gastrointestinal Laboratory, Texas A&M University, College Station, TX, 
USA. 
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2.1.2 Idiopathic Inflammatory Bowel Disease 
2.1.2.1 Pathogenesis 
Idiopathic inflammatory bowel disease (IBD) is a collective term to describe gastrointestinal 
disorders that have the following characteristics (GERMAN et al. 2003a, WASHABAU et al. 
2010, DANDRIEUX 2016): 
• chronic gastrointestinal signs (duration of > 3 weeks) 
• histologic evidence of mucosal inflammation 
• thorough diagnostic investigation and exclusion of other possible causes for chronic 
gastrointestinal signs 
• failure to respond to appropriately designed therapeutic trials (i.e. antiparasitic 
medication, elimination diet, antimicrobial treatment) 
• response to anti-inflammatory and / or immunosuppressive drugs. 
The specific triggers leading to the development of IBD are still unknown, but recent studies 
in both human and companion animal medicine support the hypothesis of IBD pathogenesis 
involving the interplay of genetic host susceptibility, the intestinal microenvironment, dietary 
and environmental factors, and an exaggerated immune-response (SIMPSON and 
JERGENS 2011, DANDRIEUX 2016). 
The fact that certain breeds of dogs are predisposed to develop IBD supports the hypothesis 
of a genetic effect on the development of IBD. Such predispositions have been reported, for 
instance, for the German shepherd dog (KATHRANI et al. 2010, KATHRANI et al. 2011), the 
Basenji (BREITSCHWERDT et al. 1980, MACLACHLAN et al. 1988), the Norwegian 
Lundehund (KOLBJØRNSEN et al. 1994), the Chinese Shar-Pei (GRÜTZNER et al. 2010) 
and the Yorkshire terrier (KIMMEL et al. 2000, SIMMERSON et al. 2014). However, until now 
no breed-independent etiologic genetic mutations or defects have been detected (SIMPSON 
and JERGENS 2011). 
Toll-like receptors (TLR) are pattern-recognition receptors that recognize microbe-associated 
molecular pattern molecules (MAMPs) as well as endogenous damage-associated molecular 
patterns (DAMPs) (HEILMANN and ALLENSPACH 2017). These receptors are part of the 
innate immune system. The upregulation of selected TLRs (TLR2, TLR4, and TLR9) and the 
downregulation of TLR5 in duodenal and colonic mucosa in dogs with IBD as well as the 
absence of significant changes after therapy despite obvious clinical improvement of dogs 
might suggest a genetic predisposition (BURGENER et al. 2008, MCMAHON et al. 2010, 
ALLENSPACH et al. 2010b). NOD2 (nucleotide oligomerization domain 2) is another innate 
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immune receptor that has been investigated for a possible association with the pathogenesis 
of canine IBD following the discovery that mutations in the NOD2 gene are associated with 
Crohn’s disease in humans (XAVIER and PODOLSKY 2007, PACKEY and SARTOR 2008). 
Single nucleotide polymorphisms have also been detected in the canine NOD2 gene, and 
their increased frequency in dogs with IBD would also suggest a genetic basis of host 
susceptibility to the development of IBD (KATHRANI et al. 2014). 
The intestinal microbiome might also play a role in the development of IBD either indirectly 
via interaction with dysregulated pattern recognition receptors or directly via pathogenic 
mechanisms. Invasive E.coli for example have been demonstrated to be linked to the 
development of histiocytic ulcerative colitis in Boxer dogs. This condition represents a special 
form of CIE that often responds to treatment with fluoroquinolones (MANSFIELD et al. 2009). 
Further, current consensus is that a change in the intestinal microbial composition also plays 
a role in the pathogenesis of IBD. Intestinal dysbiosis characterized by an increase in 
Proteobacteria (SUCHODOLSKI et al. 2012a, SUCHODOLSKI et al. 2012b, HONNEFFER et 
al. 2014, MINAMOTO et al. 2015) and a decrease in Faecalibacterium spp. (SUCHODOLSKI 
et al. 2012b) and Clostridia (SUCHODOLSKI et al. 2010) has been revealed in dogs with 
IBD. 
Dietary constituents may also contribute to gastrointestinal inflammation. One example is the 
enteropathy induced by ingestion of gluten diagnosed in the Irish Setter breed (GARDEN et 
al. 2000). Mucosal reactions seen during gastrointestinal endoscopy have been reported in 
Soft Coated Wheaten Terriers after intragastric administration of food extracts containing 
milk, and adverse food reactions were detected in these dogs during a dietary trial with food 
ingredients such as corn, tofu, cottage cheese, milk, or lamb (VADEN et al. 2000). 
Furthermore, a study by MANDIGERS et al. (2010) revealed that dogs with chronic 
enteropathies showed a positive response to a hydrolyzed protein diet. All three studies 
support the hypothesis that dietary components present an important factor in the 
pathogenesis of IBD. 
All these potential causes of IBD, either individually or as part of a complex interaction 
among these factors, can result in an exaggerated immune-response with resultant chronic 
inflammation. However, it is reasonable to assume that an overreactive immune system in 
itself could be the source of inflammation. Until today, the exact causal relationships between 
potential factors of IBD pathogenesis remain elusive (SIMPSON and JERGENS 2011) and 
further research is needed to evaluate these aspects. 
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2.1.2.2 Diagnosis and Treatment  
A diagnosis of IBD can only be reached when several criteria have been considered. First, 
the patient signalment and a thorough history to evaluate clinical signs, diet, eating behavior, 
and environmental factors are gathered. Second, a thorough physical examination is 
performed, and the possibility of endoparasite infections and other causes of chronic 
gastroenterocolitis need to be excluded via clinicopathologic tests, diagnostic imaging, and 
fecal examination (SIMPSON and JERGENS 2011, DANDRIEUX 2016). Third, empirical 
therapeutic treatment with antiparasitic and antimicrobial medication and at least three to four 
weeks of a dietary trial with an elimination diet have been performed and did not lead to a 
significant clinical improvement (WASHABAU et al. 2010, SIMPSON and JERGENS 2011, 
DANDRIEUX 2016). Fourth, gastrointestinal biopsy specimens have been obtained and 
revealed histologic evidence of inflammation in accordance with published guidelines (DAY 
et al. 2008, WASHABAU et al. 2010), whereby lymphoplasmacytic inflammation represents 
the most common histologic finding. Lastly, resolution or significant improvement of clinical 
signs (clinical remission) is seen after anti-inflammatory and / or immunosuppressive 
treatment (WASHABAU et al. 2010, SIMPSON and JERGENS 2011, DANDRIEUX 2016). 
Additionally, several biomarkers (e.g., cobalamin, methylmalonic acid, folate, alpha1-
proteinase inhibitor, calprotectin, S100A12, 3-bromotyrosine, and N-methylhistamine) have 
been evaluated in dogs with CIE in the past decade. Despite not being pathognomonic, 
these biomarkers can aid in the diagnostic evaluation and patient monitoring in dogs with CIE 
(HEILMANN and STEINER 2018).  
Immunosuppressant drugs represent the mainstay of treatment in dogs with idiopathic IBD 
(DANDRIEUX 2016) and are given in addition to a dietary modification. Thus, idiopathic IBD 
is also referred to as immunosuppressant-responsive enteropathy (IRE). Glucocorticoids are 
currently the first-line option in the treatment of primary inflammatory and autoimmune 
diseases in dogs (VIVIANO 2013), and prednisolone at a dose of 1 mg/kg given twice daily 
(BID) has been proven to be an effective induction treatment in dogs with CIE (JERGENS et 
al. 2010). Commonly, this dose is slowly tapered over several weeks to the lowest effective 
dose (top-down approach) once the patient’s clinical signs are controlled (JERGENS et al. 
1992). Nevertheless, some dogs develop severe adverse effects (e.g., iatrogenic 
hyperadrenocorticism with corresponding clinical signs, gastrointestinal ulceration, 
pronounced muscular atrophy, opportunistic infections) (VIVIANO 2013) or are refractory to 
glucocorticosteroids and thus require other or additional immunosuppressant drugs to control 
clinical signs of idiopathic IBD (DANDRIEUX 2016). Cyclosporine, a calcineurin inhibitor, has 
been shown to be an effective alternative in the treatment of CIE (ALLENSPACH et al. 2006, 
ALLENSPACH et al. 2007). Cyclosporine is widely used for its steroid-sparing effect in 
combination with prednisolone or as a rescue treatment option in steroid-refractory IBD 
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cases (ALLENSPACH et al. 2006, HALL and GERMAN 2010). The main disadvantage of 
using cyclosporine is its rather high expense when compared to glucocorticosteroids. A 
recent study, evaluating chlorambucil in combination with prednisolone in the treatment of 
dogs with CIE and protein-losing enteropathy, revealed chlorambucil to also be an effective 
immunosuppressive treatment option in dogs with IBD (DANDRIEUX et al. 2013). However, 
larger studies comparing the effect of different immunosuppressants (e.g., cyclosporine, 
mycophenolate, azathioprine, chlorambucil, or leflunomide) in a randomized and blinded 
fashion are currently lacking. Thus, the usefulness of these treatment options or even a 
combination thereof in the management of canine CIE cannot be definitively determined at 
this time. Because of a hypercoagulable state in dogs with PLE the treatment of those dogs 
with IBD and PLE should also include a platelet aggregation inhibitor (e.g., clopidogrel) 
(GOODWIN et al. 2011, ERDMANN and HEILMANN 2017).  
Some cases of IBD may not respond to treatment regardless of the specific treatment plan 
and therefore carry a guarded prognosis (DANDRIEUX 2016). Risk factors that have been 
reported to be associated with a negative outcome are a high clinical disease activity index, 
severe endoscopic disease in the duodenum, hypoalbuminemia, and hypocobalaminemia 
(ALLENSPACH et al. 2007). The severity of clinical disease and response to treatment can 
be assessed using established clinical scoring systems – the canine IBD activity index 
(CIBDAI) (JERGENS et al. 2003) and the canine chronic enteropathy clinical activity index 
(CCECAI) (ALLENSPACH et al. 2007) (q.v. chapter 2.1.1.2 clinical disease activity). 
 
2.1.3 Food-Responsive Diarrhea 
2.1.3.1 Pathogenesis 
Food-responsive diarrhea (FRD) is the most common cause of CIE. In a recent study, 64% 
of dogs with CIE were diagnosed with FRD (ALLENSPACH et al. 2016). Dogs with FRD are 
often younger than dogs with IBD, and they typically present with a lower clinical disease 
activity index than dogs with IBD (ALLENSPACH et al. 2007, ALLENSPACH et al. 2016, 
DANDRIEUX 2016). FRD is characterized by an adverse reaction to food that is a 
repeatable, undesired response to any dietary component (HALL and GERMAN 2010). This 
adverse reaction can be the result of an immunologic or a non-immunologic reaction. The 
former is considered as a true food hypersensitivity whereas the latter, non-immunologic 
reactions, are referred to as food intolerance and include food poisoning, pharmacologic 
intolerance (e.g., methylxanthines in chocolate poisoning), or gluttony (HALL and GERMAN 
2010).  
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Canine dietary hypersensitivity can be an IgE-mediated immediate reaction (type I) to 
ingested food allergens. However, non-IgE-mediated reactions such as a type II (immune-
complex mediated) or a delayed type IV reaction may also occur (DAY 2005, HALL and 
GERMAN 2010). Mechanisms that – either alone or in combination – have been 
hypothesized to be responsible for the breakdown of gastrointestinal immune tolerance 
include an altered presentation of dietary antigens to the mucosal immune system, a 
dysregulated immune system, and an inadequate mucosal barrier function (GERMAN et al. 
2003a, HALL and GERMAN 2010). Regardless of the underlying pathomechanism, adverse 
food reactions result in nonspecific gastrointestinal signs such as vomiting, diarrhea, 
abdominal pain, inappetence, or weight loss (HALL and GERMAN 2010). 
 
2.1.3.2 Diagnosis and Treatment 
The diagnosis of FRD is established based on the response to dietary modification, 
particularly the exclusion of the offending dietary antigen (HALL and GERMAN 2010, 
DANDRIEUX 2016). However, in most instances the offending antigen remains unknown. 
Therefore, feeding an elimination diet consisting of a novel source of protein and 
carbohydrate is advised for an exclusion dietary trial (SIMPSON and JERGENS 2011, 
DANDRIEUX 2016). A proper elimination diet trial requires strict feeding of only the 
elimination diet. Commercially available hydrolyzed protein diets have been shown to be an 
effective alternative to the feeding of a novel protein elimination diet (MARKS et al. 2002, 
MANDIGERS et al. 2010). In order to confirm the diagnosis of FRD, a challenge with the 
original diet needs to be performed once clinical remission is achieved, and this dietary 
challenge should demonstrate a relapse of clinical signs. For obvious reasons, many owners 
and clinicians are reluctant to perform such a provocation diet trial. Hence, affected dogs will 
often be kept on the elimination diet or transitioned from a hydrolyzed diet to a novel protein 
diet without rechallenge (HALL and GERMAN 2010, SIMPSON and JERGENS 2011). 
In addition to these diagnostic aspects, dietary modification is also the cornerstone of FRD 
treatment in dogs (SIMPSON and JERGENS 2011, DANDRIEUX 2016). An excellent long-
term response has been reported both with novel antigen diets (ALLENSPACH et al. 2007) 
and hydrolyzed protein diets (MANDIGERS et al. 2010, ALLENSPACH et al. 2016). 
Commercially available hydrolyzed protein diets are nutritionally well-balanced and can be 
used as a maintenance diet. If the owner prefers long-term feeding of a home-cooked meal 
with a novel antigen, a veterinary nutritionist should be consulted to formulate a recipe and 
ensure a balanced diet. If this option is considered, both home-cooked and commercial 
hydrolyzed diets are equivalent treatment options. Eventually some dogs with FRD can 
return to their original diet without relapse of clinical signs. However, this is a trial-and-error 
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approach (DANDRIEUX 2016) and the owners should be educated about the different 
treatment options. 
 
2.1.4 Antibiotic-Responsive Diarrhea 
Antibiotic-responsive diarrhea (ARD) currently represents the third subgroup of canine CIE. 
Several hypotheses exist on the pathogenesis of ARD, such as its development secondary to 
defects in the mucosal barrier function, abnormal mucosal immune responses, or qualitative 
changes in the intestinal bacterial microbiome, but the exact mechanisms are still to be 
resolved (HALL and GERMAN 2010, HONNEFFER et al. 2014). Adherent-invasive E. coli 
(AIEC) have been documented within the intestinal lamina propria of Boxer dogs 
(MANSFIELD et al. 2009), French Bulldogs (MANCHESTER et al. 2013), and mastiffs 
(STOKES et al. 2001) affected with histiocytic ulcerative colitis (formerly known as 
granulomatous colitis or Boxer colitis). Because resolution of clinical signs and eradication of 
mucosal AIEC was achieved after extensive treatment of 6 to 10 weeks (MANCHESTER et 
al. 2013, DANDRIEUX 2016) with enrofloxacin, histiocytic ulcerative colitis is currently the 
only CIE for which a causative agent has been found (MANSFIELD et al. 2009, 
MANCHESTER et al. 2013). 
Generally, dogs diagnosed with ARD are younger than dogs with IBD (GERMAN et al. 
2003a, ALLENSPACH et al. 2016), and a breed predisposition has been identified in the 
German shepherd dog (BATT et al. 1991, ALLENSPACH et al. 2010b). As part of the 
sequential diagnostic investigation of dogs with CIE, an antimicrobial trial is often instituted 
after appropriately designed dietary trials have failed. Metronidazole and tylosin are the most 
commonly used antibiotics (WESTERMARCK et al. 2005, DANDRIEUX 2016). Several 
studies have shown that tylosin can be effective for the treatment of chronic diarrhea, 
referred to as tylosin-responsive diarrhea (TRD) by some authors (WESTERMARCK et al. 
2005, KILPINEN et al. 2011, KILPINEN et al. 2014, KILPINEN et al. 2015). However, 
relapses of clinical signs occur frequently after cessation of antibiotic treatment 
(WESTERMARCK et al. 2005, ALLENSPACH et al. 2016). The exact mode of action of 
antibiotics in the absence of obvious pathogenic bacteria remains unclear. 
Immunomodulatory and anti-inflammatory properties in addition to a modification of the 
intestinal microbiota (e.g., a shift towards more beneficial bacterial species) are suspected to 
be associated with the positive effects of antibiotics (CAO et al. 2006, SUCHODOLSKI et al. 
2009, KILPINEN et al. 2015, DANDRIEUX 2016). However, it needs to be emphasized that 
the response to antimicrobial treatment is often rather short-lived, and with the emerging 
concerns regarding antimicrobial resistance, the true usefulness of antibiotic trials in the 
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treatment of CIE has come under scrutiny. Thus, other treatment options should always be 
considered first, unless a causative agent has been detected or is strongly suspected.  
 
2.2 The Canine Intestinal Microbiome 
2.2.1 Methods to Evaluate the Intestinal Microbiome 
The intestinal microbiome is composed of all microorganisms harbored in the gastrointestinal 
(GI) tract – which includes bacteria, viruses, fungi, and protozoa (SUCHODOLSKI 2016). 
Because bacteria represent the most abundant microorganisms in the intestinal lumen 
(SWANSON et al. 2011), the attention of this study is turned to the intestinal bacteria only. 
The term “microbiota” is generally accepted to describe bacterial communities, and therefore 
the author adopted this term for the subsequent analyses. 
It should be emphasized that, to date, there is no single detection method that is considered 
a “gold standard” for the evaluation of the intestinal microbiota (SUCHODOLSKI 2016). In the 
past, culture-dependent techniques were widely used to assess microbial communities 
(HANDL et al. 2011, SUCHODOLSKI 2016). However, it is now known that at most 20% of 
the intestinal bacteria can be cultivated (SUCHODOLSKI 2016). This low detection rate 
results mainly from the fact that the canine intestinal tract is composed of mostly anaerobic 
bacteria, which are very vulnerable and elusive to standard laboratory conditions. 
Furthermore, growth requirements of many bacteria are unknown (SUCHODOLSKI 2016). 
Yet, bacterial cultures are vitally important for the detection of specific enteropathogens, such 
as Salmonella spp., and antimicrobial sensitivity testing (SUCHODOLSKI 2016). 
The discovery of new molecular techniques has promoted further research on the intestinal 
microbiota and their functional implications. Identification of previously undetected bacteria is 
now possible. Fluorescence in situ hybridization (FISH) uses fluorescent dye-labelled 
oligonucleotide probes that are hybridized to bacterial ribosomal RNA sequences and can be 
subjected to subsequent microscopic evaluation (LANGER-SAFER et al. 1982, 
SUCHODOLSKI 2016). FISH analysis allows identification of most bacterial species and is 
the currently most accurate method for quantification of bacteria. Additionally, FISH can help 
to determine whether bacteria are within the intestinal lumen, adherent to cells, or invading 
the mucosa (SUCHODOLSKI 2016). When using quantitative real-time PCR (qPCR), 
bacteria are detected in real-time mode by fluorescent dye-labeled primers (SUCHODOLSKI 
2016). Both FISH and qPCR require probes and assay kits that are specifically designed for 
the bacterial group of interest. Next generation sequencing technologies (e.g., 454-
pyrosequencing, Illumina) are high-throughput sequencing platforms that permit massive 
parallel analyses and provide a large quantity of data (LIU et al. 2012, GOODWIN et al. 
2016). Here, universal primers are used to amplify bacteria and these PCR amplicons are 
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then analyzed with a high-throughput sequencer (SUCHODOLSKI 2016). Both 454-
pyrosequencing and Illumina implement the technology of sequencing by synthesis and 
detect bases as they are embedded into the growing DNA or RNA strands (LIU et al. 2012, 
GOODWIN et al. 2016). Pyrosequencing technology detects pyrophosphates which are 
released during nucleotide incorporation (LIU et al. 2012). When using Illumina, a charge-
coupled device detects the individually cleaved fluorescent dyes of the four deoxynucleotides 
after these have been incorporated into an extending complementary nucleotide strand (LIU 
et al. 2012, GOODWIN et al. 2016). Currently, next generation sequencing of 16S ribosomal 
RNA (16S rRNA) genes plays an important role in the further investigation of the intestinal 
microbiota. It allows for a general impression of the quantities and proportions of all bacterial 
groups present within the intestine (SUCHODOLSKI 2016). However, bacterial groups 
presenting at a very low abundance may be missed when using high-throughput sequencing. 
Hence, the additional use of group-specific PCR primers is advised (SUCHODOLSKI 2016). 
The term metagenomics refers to the shotgun sequencing of the whole metagenome. This 
approach evaluates DNA from the entire bacterial community by analyzing short reads of all 
existing genomes without prior PCR amplification (SEGATA et al. 2013, GUARD and 
SUCHODOLSKI 2016). Gathered sequences can then be annotated using a reference 
catalog of bacterial genes and genomes. This approach yields both identification of bacterial 
species and information about the function of microbial communities (GUARD and 
SUCHODOLSKI 2016), and as a consequence is currently one of the most promising 
methods. However, this method is very cost-intensive and requires advanced bioinformatics 
(SUCHODOLSKI 2016). Hence, metagenomics is currently only used in advanced sciences. 
In summary, the best approach to unravelling the intestinal microbiota would be a 
coordinated approach using a combination of all currently available molecular tools.  
 
2.2.2 The Intestinal Microbiome in Healthy Dogs 
The intestinal microbiota is of major relevance for host health. It aids in proper epithelial 
development and the defense against enteropathogens, for example by maintaining an intact 
epithelial barrier or by competitive exclusion of pathogens (NEISH 2009, SUCHODOLSKI 
2016). It also provides stimuli for the intestinal immune system and can modulate the 
immune response (NEISH 2009, SUCHODOLSKI 2016). Furthermore, the intestinal 
microbiota provides nutritional factors to the host, including the synthesis of essential 
vitamins and degradation of complex polysaccharides to short-chain fatty acids, which serve 
as an energy source for the host (NEISH 2009, SWANSON et al. 2011). Short-chain fatty 
acids also regulate intestinal motility (SUCHODOLSKI 2016) and have anti-inflammatory 
effects by inducing immunoregulatory T cells (ARPAIA et al. 2013). 
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In addition, primary bile acids that enter the lumen of the colon are converted to secondary 
bile acids by intestinal bacteria (PAVLIDIS et al. 2015, SUCHODOLSKI 2016). Conversion of 
bile acids is another example of a beneficial relationship between the intestinal microbiota 
and the host. Secondary bile acids are anti-inflammatory and can modulate insulin secretion 
and glucose metabolism, and are therefore essential contributors to gut homeostasis 
(PAVLIDIS et al. 2015, SUCHODOLSKI 2016). 
According to studies using the methodology of bacterial culture, the intestinal tract of healthy 
dogs harbors a large bacterial load approximating 102 - 105 and up to 109 colony forming 
units (CFU)/g intestinal juice in the small intestine (GERMAN et al. 2003b, SUCHODOLSKI 
2016). Due to a physiological increase in microbial numbers and diversity along the GI tract 
(SUCHODOLSKI et al. 2005), numbers of luminal bacteria are even higher in the colon, 
ranging from 108 to 1011 CFU/g (MENTULA et al. 2005). 
In healthy dogs, Firmicutes, Bacteroidetes, Proteobacteria and Fusobacteria are the most 
abundant bacterial phyla (SUCHODOLSKI et al. 2008, XENOULIS et al. 2008, 
SUCHODOLSKI et al. 2009, HANDL et al. 2011) in the intestine. While Firmicutes are found 
in all parts of the intestine, Fusobacteriales and Bacteroidales were only sporadically 
demonstrated in the proximal intestine, but were the most abundant bacterial orders in the 
intestinal content of the ileum and colon (MENTULA et al. 2005, SUCHODOLSKI et al. 
2008). Two studies evaluating fecal bacterial communities reported Bacteroidetes to be the 
second most abundant phylum detected in feces of healthy dogs (MIDDELBOS et al. 2010, 
HANDL et al. 2011). Proteobacteria, which also include E. coli-like organisms, on the other 
hand, are abundant especially in the small intestine and present at lower abundances in the 
colon (SUCHODOLSKI et al. 2008). One study reported Proteobacteria to be the second 
most abundant phylum in the duodenum (XENOULIS et al. 2008) and another study reported 
Proteobacteria to be the most abundant phylum in the jejunum (SUCHODOLSKI et al. 2009). 
Of all detected phyla, Firmicutes is overall the most abundant phylum (SUCHODOLSKI et al. 
2008, XENOULIS et al. 2008, SUCHODOLSKI et al. 2009, HANDL et al. 2011) and within 
this phylum the order Clostridiales has been shown to be the most diverse and prevalent in 
the canine intestinal tract (SUCHODOLSKI et al. 2008, HANDL et al. 2011). Members of the 
order Clostridiales form several clusters, of which Clostridium cluster XI and Clostridium 
cluster XIVa represent the predominant clusters (SUCHODOLSKI et al. 2008, HANDL et al. 
2011). Genera associated with Clostridium cluster XI were more abundant in the small 
intestine, whereas genera affiliated with Clostridium cluster XIVa (e.g., Eubacterium spp., 
Ruminococcus spp.) dominated in the colon (SUCHODOLSKI et al. 2008). Both clusters 
have been shown to produce short-chain fatty acids (SUCHODOLSKI 2016) and therefore 
might have a beneficial impact on the host (NEISH 2009, ARPAIA et al. 2013, 
REVIEW OF LITERATURE 
22 
 
SUCHODOLSKI 2016). Besides Clostridiales, another prevalent bacterial order in the canine 
intestine is Lactobacillales. Members of this order (e.g., Lactobacillaceae, Enterococcaceae, 
and Streptococcaceae) are present in large abundances in the duodenum, jejunum 
(SUCHODOLSKI et al. 2008, XENOULIS et al. 2008), and colon (SUCHODOLSKI et al. 
2008), whereas lower abundances are found in the ileum (SUCHODOLSKI et al. 2008). In 
addition to the aforementioned phyla, Spirochaetes and Actinobacteria (especially 
Coriobacteriales) also present at significant abundances (XENOULIS et al. 2008, 
SUCHODOLSKI et al. 2009). One study also identified four phyla in the jejunum of dogs that 
had not been identified in the canine intestine before: Tenericutes, Cyanobacteria, 
Verrucomicrobia and Chloroflex. All of these four phyla were only present in very low 
abundances (SUCHODOLSKI et al. 2009). Bifidobacterium spp. belong to the phylum 
Actinobacteria and are considered beneficial microorganisms, which are also used as 
probiotics (e.g., the strain Bifidobacterium sp. animalis) (SCHMITZ and SUCHODOLSKI 
2016). Interestingly, the detection of this genus has not been consistently reported. While 
one study reported an abundance of up to 1010 CFU/ml in the colon (DAVIS et al. 1977), 
Bifidobacterium spp. was not observed at all in two more recent studies evaluating intestinal 
content (DELLES et al. 1994, SUCHODOLSKI et al. 2008) and in one study evaluating the 
duodenal mucosa (DELLES et al. 1994). Bifidobacterium spp. were observed only at low 
abundance in one study evaluating canine feces (HANDL et al. 2011). Thus, future studies 
using advanced molecular tools and specific primers are warranted to reveal the true 
prevalence of this genus. 
 
2.2.3 The Intestinal Microbiome in Dogs with CIE 
Similar to the findings in human medicine (RIOUX et al. 2005, XAVIER and PODOLSKY 
2007, DUBOC et al. 2013), evidence has also grown in veterinary medicine that, in addition 
to other factors, host susceptibility (ALLENSPACH et al. 2010b, KATHRANI et al. 2012, 
KATHRANI et al. 2014) and the intestinal microbiota (XENOULIS et al. 2008, ALLENSPACH 
et al. 2010b, SUCHODOLSKI et al. 2012a, SUCHODOLSKI et al. 2012b, HONNEFFER et al. 
2014, MINAMOTO et al. 2015) play a pivotal role in the pathogenesis of inflammatory bowel 
disease (IBD). Alterations in the interaction between the host’s enteric microbiota and the 
intestinal mucosa (e.g., abnormal barrier function, altered innate and adaptive immune 
responses) (XAVIER and PODOLSKY 2007) and the functional profile of the microbiota 
appear to contribute to the development of IBD (DUBOC et al. 2013, SUCHODOLSKI 2016). 
To date, several studies have evaluated the intestinal microbial composition in dogs with IBD 
and generally have revealed an intestinal dysbiosis (SUCHODOLSKI 2016). 
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Proteobacteria, for example members of the Enterobacteriaceae (XENOULIS et al. 2008), 
Brevundimonas spp., Brucella spp., Pseudomonas spp. (SUCHODOLSKI et al. 2010), 
Acinetobacter spp. and Diaphorobacter spp. (SUCHODOLSKI et al. 2012a), were found to 
be enriched in duodenal brush cytologies (XENOULIS et al. 2008) and mucosal tissue 
biopsies (SUCHODOLSKI et al. 2010, SUCHODOLSKI et al. 2012a) in dogs with IBD, 
whereas members of Fusobacteria, Bacteroidetes, Spirochaetes and Clostridiaceae were 
significantly more abundant in the duodenum of healthy dogs (XENOULIS et al. 2008, 
SUCHODOLSKI et al. 2010). The study by XENOULIS et al. (2008) also reported 
significantly lower species richness in the duodenum of dogs with IBD. Another study 
examining microbial alterations in the ileal and colonic mucosa in dogs with chronic 
enteropathies revealed an increased total number of bacteria, but a decrease in 
Bacteroides spp. within the colonic mucosa in dogs with IBD compared to healthy dogs 
(CASSMANN et al. 2016). The number of total bacteria attached to the colonic mucosa was 
also positively correlated with clinical disease severity, assessed by the CIBDAI score, in 
dogs with IBD. Furthermore, dogs with IBD had increased numbers of Enterobacteriaceae 
and E. coli compared to dogs with other chronic enteropathies, such as histiocytic ulcerative 
colitis or malignant alimentary tract neoplasia (CASSMANN et al. 2016). Evaluation of the 
fecal microbiota did not reveal significant differences in the number of observed species 
between dogs with IBD and healthy control dogs (SUCHODOLSKI et al. 2012b, MINAMOTO 
et al. 2015, XU et al. 2016), but differentially expressed bacterial taxa could be identified. 
Again, Proteobacteria, particularly Gammaproteobacteria, were reported to be more 
abundant in dogs with IBD, whereas Erysipelotrichia (e.g., Turicibacter spp.), Clostridia (e.g., 
Blautia spp., Faecalibacterium spp.) and Bacteroidia were found at low abundance in dogs 
with IBD when evaluated using 454-pyrosequencing (MINAMOTO et al. 2015). On the 
contrary, another study using FISH analysis found Bacteroides spp. in larger numbers in 
dogs with chronic diarrhea than in healthy dogs (JIA et al. 2010). This discrepancy might be 
explained by the use of different methods to detect and quantify bacteria. SUCHODOLSKI et 
al. (2012b) showed differences in the presence of Faecalibacterium spp. and Fusobacteria 
between dogs with clinically active and clinically insignificant IBD, assessed by the CIBDAI 
score. Both taxa were decreased in times of clinically active disease (SUCHODOLSKI et al. 
2012b). Similarly, the fecal quantity of Lactobacillus spp. was negatively correlated with 
CCECAI scores in another study (XU et al. 2016). 
Currently, it is unclear if these microbial changes seen in dogs with IBD are more of a cause 
or the result of the disease. However, it is assumed that changes in the microbial 
composition also implicate changes of the microbial functional profile (e.g., altered amino 
acid metabolism, reduced production of short-chain fatty acids, altered bile acid metabolism) 
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(GUARD et al. 2015, MINAMOTO et al. 2015, SUCHODOLSKI 2016), which may possibly 
contribute to both the development and sustainment or perpetuation of IBD. 
Lastly, a fecal dysbiosis index (DI) has been published recently. Based on the assessment of 
the fecal abundance of eight bacterial groups shown to be frequently altered in dogs with CIE 
(total bacteria, Faecalibacterium spp., Turicibacter spp., Escherichia coli, Streptococcus spp., 
Blautia spp., Fusobacterium spp. and Clostridium hiranonis) by quantitative PCR and their 
analysis using a complex mathematical algorithm, this index distinguishes normobiosis (DI < 
0) from dysbiosis (DI > 0) and is ultimately able to separate healthy dogs from dogs with CIE 
(74% sensitivity, 95% specificity, area under the curve (AUC) of 0.93) (ALSHAWAQFEH et 
al. 2017). The DI may be a valuable tool to monitor treatment response and resultant 
changes of the fecal microbiota, allowing for an individual approach to patients. 
 
2.3 The Canine Lipidome 
2.3.1 Methods to Evaluate the Lipidome 
Lipids are defined as hydrophobic or amphipathic organic molecules that commonly dissolve 
in organic solvents (FAHY et al. 2005). According to the LIPID MAPS “Comprehensive 
Classification System for Lipids”, these molecules are classified into eight categories: fatty 
acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, 
saccharolipids, and polyketides (FAHY et al. 2005, FAHY et al. 2009). This enormous 
structural diversity of lipids, which is further increased by a large multitude of building blocks 
that can be either incorporated into or separated from the core structure of these molecules, 
poses a challenge for the research of lipids and their metabolism. However, recent advances 
in technology render lipidomics, the quantitative description and analysis of lipids and their 
functions possible (VAN MEER 2005, LAM and SHUI 2013, LI et al. 2014). In general, 
lipidomics can be classified as a targeted and untargeted approach. The targeted approach 
evaluates specific lipids, whereas the non-targeted approach aims at investigating the entire 
lipid structure of a given sample (LAM and SHUI 2013, ASTARITA and OLLERO 2015). 
Regardless of the approach, lipidomics usually combine several analytical steps, including 
the extraction, separation, and analysis of lipids (LI et al. 2014). Lipids are most commonly 
separated via chromatographic techniques, such as gas chromatography (GS) or liquid 
chromatography (LC) (LAM and SHUI 2013, LI et al. 2014). Mass-spectrometry (MS) is the 
major constituent of lipid analysis but a complete characterization of lipids usually requires a 
combination of MS, LC, and ionization techniques (WENK 2010, LI et al. 2014, ASTARITA 
and OLLERO 2015). In addition, the large structural and chemical diversity of lipids makes it 
almost impossible to analyze the entire lipidome of a specific sample using a single analytical 
method (WENK 2010, LI et al. 2014). Thus, a series of several different techniques and 
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analyses are usually necessary. Conventional ionization techniques are electrospray 
ionization (ESI), matrix-assisted laser desorption/ionization (MALDI), atmospheric pressure 
chemical ionization, and electron impact ionization (LAM and SHUI 2013, LI et al. 2014). 
Electrospray ionization is considered a soft-ionization technique, which is superior to electron 
impact ionization because it does not require derivatization of fatty acids. Thus, ESI offers an 
advantage over other techniques for analysis of non-volatile thermally unstable molecules 
(HO et al. 2003, LI et al. 2014). Currently, ESI is an important ionization source for mass 
spectrometry and coupling this technique with high performance liquid chromatography 
allows for the analysis of a larger number of lipid classes (HO et al. 2003, LI et al. 2014). 
Tandem mass spectrometry describes a series of two quadrupole mass spectrometers that 
are separated by a collision cell (VOGESER and PARHOFER 2007). A combination of liquid 
chromatography and tandem mass spectrometry is often used for the analysis of lipids with a 
low abundance (LI et al. 2014). The availability of all these analytical methods is an important 
prerequisite for the feasibility of lipidomics, even to the extent of a “shotgun” approach to 
lipidomics. However, despite the overall progress in the analysis of lipids, the field of 
lipidomics is still in its infancy and further advances in analytical methods, for example 
methods to discriminate between isobaric or isometric lipids (LI et al. 2014), are still needed 
to fully understand the features and complexity of lipid molecules. 
 
2.3.2 Functions of Lipids and their Importance to Health 
Similar to proteins, lipids are crucial for many physiologic processes to be maintained in 
cells, tissues, and organs. It has been known for decades that lipids are the basic 
components of bio- and cellular membranes and that lipids serve as an important means for 
energy storage (figure 7) (WENK 2005, VAN DER MEER-JANSSEN et al. 2010). Recently, 
additional important biological functions of lipids have been being discovered. Because 
second messengers can be derived from membrane lipids (BERRIDGE 1993), lipids play a 
central role in a number of signaling pathways. Furthermore, lipids have been shown to 
regulate membrane trafficking, for example by the recruitment of proteins or by modulation of 
the membrane structure and function (HAUCKE and DI PAOLO 2007). Due to these versatile 
functions it is obvious that lipid homeostasis is pivotal to the maintenance of health. 




Figure 7. Schematic diagram of a cellular membrane comprising phospholipids. 
In human medicine, impairment of lipid homeostasis has been shown to be involved in the 
pathogenesis of several diseases, such as infectious diseases, metabolic syndrome, 
neurodegenerative diseases, and cancer (FIORENZA et al. 2000, WENK 2005, VAN DER 
MEER-JANSSEN et al. 2010, LAM and SHUI 2013). Several pathogens are capable of 
exploiting the intricacy of lipids and their functions resulting in the modulation of host cell 
responses and survival of the pathogen. Such tactics of the pathogens include the molecular 
mimicry of lipids (both by de novo synthesis and incorporation of the host’s lipids), alterations 
of fatty acid compositions of membranes (e.g., Plasmodium spp. in erythrocytes, HIV-1 in 
lymphocytes), and injury to cellular or vacuolar host membranes through the action of 
phospholipases (VAN DER MEER-JANSSEN et al. 2010). 
The metabolic syndrome refers to a combination of dyslipidemia, systemic hypertension, and 
hyperglycemia or a disturbance in glucose homeostasis (BEILBY 2004). Until today, it is not 
fully understood how alterations in the lipidome result in metabolic syndrome, but recent 
studies have begun to shed some light on this association (LAM and SHUI 2013). Increased 
concentrations of circulating triglycerides and cholesterol, for example, can modulate cellular 
lipid metabolism and result in intracellular lipid accumulation and impairment of organ 
function (LAM and SHUI 2013). In line with that, it has been shown that the reduction of 
sphingolipid synthesis has a positive effect on tissue insulin sensitivity (VAN EIJK et al. 
2009). Thus, medical intervention to alter levels of circulating lipids might be an important 
aspect in the treatment of metabolic disorders (LAM and SHUI 2013). 
Alterations in cerebral lipid metabolism have been recognized to contribute, for example, to 
the pathogenesis of Alzheimer’s disease. Cholesterol, for instance, increases the secretion of 
the amyloid-ß peptide – an important factor in the development of Alzheimer’s disease. Thus, 
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increased concentrations of cholesterol and amyloid-ß peptide might promote the 
development of Alzheimer’s disease. Similarly, ceramide, which also stimulates the 
production of amyloid-ß peptide, has been reported to be increased in the cortex and the 
cerebrospinal fluid of patients with Alzheimer’s disease (CUTLER et al. 2004, LIU et al. 2007, 
HE et al. 2010, LIU and ZHANG 2014). 
Differences in the lipoprotein profile have also been reported between patients with cancer 
and patients with non-neoplastic diseases (FIORENZA et al. 2000), and an inverse 
association has been shown to exist between total cholesterol concentrations and the risk of 
breast cancer (TOUVIER et al. 2015). However, the true role of lipids in the pathogenesis 
and the risk of cancer is still unknown and further research is warranted to further understand 
the role of lipids in cancerogenesis. 
In addition to the aforementioned diseases, dyslipidemia has also been demonstrated in 
patients with IBD (AGOURIDIS et al. 2011). One study reported total and low-density 
lipoprotein (LDL)-cholesterol to be decreased in patients with active Crohn’s disease and 
ulcerative colitis, and total and high-density lipoprotein (HDL)-cholesterol was inversely 
correlated with markers of inflammation, such as C-reactive protein, in patients with Crohn’s 
disease (ROMANATO et al. 2009). Another study revealed that patients with Crohn’s disease 
have lower serum concentrations of total cholesterol than patients with ulcerative colitis (FAN 
et al. 2015). That study further found that several lipids, especially alkylphospholipids and 
plasmalogens, were significantly associated with Crohn’s disease, whereas no lipid class and 
only few lipid species varied significantly between patients with ulcerative colitis and healthy 
control subjects. That study also suggested that decreased concentrations of plasmalogens 
may contribute to the development of human IBD (FAN et al. 2015). Generally, a decrease in 
circulating total cholesterol and either no difference or an increase in triglycerides accounted 
for part of the dyslipidemia present in patients with IBD (LEVY et al. 2000, RIPOLLES 
PIQUER et al. 2006, SAPPATI BIYYANI et al. 2010). However, whether dyslipidemia is a 
cause or rather a consequence of IBD needs to be investigated in future studies. 
Similar to human medicine, lipid homeostasis and alterations thereof have also attracted 
great attention in veterinary medicine. To date, several studies have described the basic 
processes of the canine lipid metabolism (JOHNSON 2005, XENOULIS and STEINER 2010, 
2015). Triglycerides and cholesterol are transported in the plasma via lipoproteins. Among 
these lipoproteins are chylomicrons, very low-density lipoproteins (VLDL), low-density 
lipoproteins (LDL), and high-density lipoproteins (HDL) (JOHNSON 2005, XENOULIS and 
STEINER 2010, 2015). Chylomicrons are part of the exogenous pathway of lipid metabolism, 
and are generated in the intestinal epithelial cells and carry dietary lipids to muscles and fatty 
tissue. VLDL, LDL, and HDL, on the other hand, are part of the endogenous metabolic 
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pathway. VLDL and HDL are formed in the liver and consecutively altered in the plasma. For 
instance, triglycerides are separated from VLDLs by lipoprotein lipase and hepatic 
triglyceride lipase, which transforms VLDLs into VLDL remnants and LDLs. While LDL then 
transports cholesterol to the tissue, HDL is considered the “good lipoprotein” as it assembles 
tissue cholesterol and returns it to the liver (JOHNSON 2005, XENOULIS and STEINER 
2010, 2015). 
Hyperlipidemia, which is defined as an increased serum concentration of lipids (triglycerides 
and / or cholesterol) (XENOULIS and STEINER 2010, 2015), is a relevant disorder in dogs 
(JOHNSON 2005, XENOULIS and STEINER 2010, 2015). It can be either a primary or a 
secondary condition. Hypertriglyceridemia of the Miniature Schnauzer is the most studied 
form of primary hyperlipidemia in dogs (XENOULIS et al. 2007), but primary hyperlipidemia 
has also been documented in other breeds, such as hypercholesterolemia of the Briard, 
hyperlipidemia of the Shetland Sheepdog, hypercholesterolemia in Dobermann and 
Rottweilers (WATSON et al. 1993, MORI et al. 2010, XENOULIS and STEINER 2015). 
Overall, secondary hyperlipidemia is far more common than primary hyperlipidemia and has 
been reported with several diseases. Endocrine disorders, such as hypothyroidism, 
hyperadrenocorticism, and diabetes mellitus, are the most common underlying diseases 
associated with hyperlipidemia (XENOULIS and STEINER 2010, 2015, SEAGE et al. 2018). 
Further, obesity, protein-losing nephropathy, cholestatic liver disease, high-fat diets, and 
certain drugs (e.g., glucocorticoids, phenobarbital) have been linked to the development of 
hyperlipidemia (LITTMAN et al. 2000, JEUSETTE et al. 2005, JOHNSON 2005, KLUGER et 
al. 2008, XENOULIS and STEINER 2015). Hyperlipidemia is also believed to be associated 
with pancreatitis in dogs (HESS et al. 1998), but recent studies suggest that severe 
hyperlipidemia in dogs diagnosed with pancreatitis presents rather a separate condition or 
consequence of an additional endocrine disorder (XENOULIS and STEINER 2015). 
Regardless of its cause, hyperlipidemia itself may result in pancreatitis, gallbladder 
mucocele, vacuolar hepatopathy, ocular disease, and neurological signs including seizures 
(VITALE and OLBY 2007, ZARFOSS and DUBIELZIG 2007, XENOULIS and STEINER 
2010, XENOULIS et al. 2010, XENOULIS and STEINER 2015). One recent study also 
reported low‐grade systemic inflammation to be present in some Miniature Schnauzers with 
idiopathic hyperlipidemia (HEILMANN et al. 2019). Thus, severe hyperlipidemia requires 
therapeutic intervention, which should include treatment of the underlying disease, use of an 
(ultra)low-fat diet, supplementation of omega-3 fatty acids and, if further medical 
management is necessary, also lipid-lowering medications such as fibrates or nicacin 
(XENOULIS and STEINER 2015).  
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Alterations in lipid profiles have also been described in several other canine diseases. 
YILMAZ and SENTURK (2007) reported lower serum levels of total cholesterol, HDL- and 
LDL-cholesterol and higher serum levels of triglycerides in dogs diagnosed with parvoviral 
enteritis than in a control group of dogs. Also, serum HDL concentrations were found to be 
lower in non-survivors when compared to survivors and control dogs. However, further 
research is warranted to fully understand the role and prognostic use of hypocholesterolemia 
in dogs with parvovirus infection and evidence of sepsis (YILMAZ and SENTURK 2007). 
Dyslipidemia has also been reported in dogs with chronic kidney disease and nephrotic 
syndrome. Especially an increase in LDL and VLDL concentrations and a decrease in HDL 
concentrations accounted for the altered lipoprotein profile (BEHLING-KELLY 2014). Another 
study revealed differences in lipid species between tissue samples of canine transitional cell 
carcinomas of the urinary bladder and samples of adjacent normal tissue, with members of 
sphingolipids and glycerophospholipids being present at significantly different concentrations 
(DILL et al. 2009). Considering all of these findings, lipid homeostasis and dyslipidemia 
appears to play an important role in the pathogenesis of many canine diseases. To date, 
research on lipids in canine medicine is still in its early stages, thus opening new avenues for 
future studies investigating the functions and the potential diagnostic and therapeutic 
implications of the canine lipidome. The author postulates that the canine circulating lipid 
profile differs between different subclassifications of canine CIE and also within each disease 
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One sentence summary: This is the first study to evaluate the intestinal mucosal microbiota 
of dogs with idiopathic inflammatory bowel disease and dogs with food-responsive diarrhea 
before and after treatment 
ABSTRACT 
We report the first study to evaluate the intestinal mucosal microbiota of dogs with 
inflammatory bowel disease (IBD) and dogs with food-responsive diarrhea (FRD) before and 
after treatment. It was hypothesized that differences in the microbial composition exist 
between both disease groups and within groups pre- vs. post-treatment. Duodenal and 
colonic biopsies were obtained endoscopically from 24 dogs (15 FRD, 9 IBD) before and 
after treatment. The intestinal microbiota was evaluated by Illumina sequencing of the 
bacterial 16S rRNA gene. The global bacterial composition did not differ between IBD and 
FRD dogs, nor between treatment status. However, several bacterial taxa showed a 
difference in abundance. Comparing disease groups, an unclassified genus of Neisseriaceae 
was abundant in the duodenum in the IBD group, whereas Bilophila occurred more 
frequently in the duodenum and Burkholderia in the colon of FRD dogs. Comparing the 
microbiota pre- and post-treatment revealed Enterococcus, Corynebacterium and 
Proteobacteria to be enriched in the duodenum of FRD dogs pre-treatment, while 
Bacteroides was abundant in the colon post-treatment. In dogs with IBD, Bacteroides also 
reached significant abundance in the colon post-treatment. In conclusion, some differences 
in individual bacterial taxa were identified between IBD and FRD dogs and between 
treatment status. 
Keywords: mucosal microbiota; chronic enteropathies; canine; treatment; duodenum; colon 





Chronic enteropathies are a group of common disorders in dogs and are characterized by 
persistent or recurrent clinical signs of gastrointestinal disease, including diarrhea, vomiting, 
weight loss, inappetence or borborygm and flatulence (German, Hall and Day 2003; Hall and 
German 2010; Dandrieux 2016). Based on the response to treatment, chronic enteropathies 
are classified as food-responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD) or 
idiopathic inflammatory bowel disease (IBD) (Hall and German 2010; Dandrieux 2016). In 
dogs with FRD, clinical signs resolve after dietary modification to a novel source of protein 
and carbohydrate or to a hydrolyzed protein diet (Hall and German 2010; Mandigers et al. 
2010). Dogs with ARD respond to dietary management and antibiotic treatment, for example, 
with tylosin (German, Hall and Day 2003; Westermarck et al. 2005; Kilpinen et al. 2011). 
Idiopathic IBD is defined by the aforementioned chronic gastrointestinal signs and 
confirmation of intestinal inflammation by histology (German, Hall and Day 2003; Hall and 
German 2010; Dandrieux 2016). Until today, the pathogenesis of chronic enteropathies, and 
in particular idiopathic IBD, is not fully understood. The upregulation of Toll-like receptors in 
dogs with idiopathic IBD and the lack of significant changes after treatment in the face of 
obvious clinical improvement (Burgener et al. 2008) suggest a genetic susceptibility as a 
contributing factor. This concept is further supported by the differential expression of Toll-like 
receptors 4 and 5 in German shepherd dogs with chronic enteropathies (Allenspach et al. 
2010). Additionally, the identification of non-synonymous single nucleotide polymorphisms in 
exon 3 of the NOD2 gene (Kathrani et al. 2014) is in line with the findings of studies on the 
pathogenesis of IBD in human patients where several susceptibility genes could be identified 
(e.g., NOD2 gene) in patients with Crohn’s disease (Xavier and Podolsky 2007). 
Furthermore, dietary and environmental factors are suspected to be main contributors in the 
development of idiopathic IBD (Hall and German 2010; Dandrieux 2016). While the exact 
mechanisms of host–microbe interactions remain elusive, evidence has grown to support 
that the intestinal microbiota plays a major role in the pathogenesis of idiopathic IBD (Xavier 
and Podolsky 2007; Suchodolski et al. 2010, 2012a, 2012b; Minamoto et al. 2015; 
Cassmann et al. 2016; Vázquez-Baeza et al. 2016). Moreover, advanced scientific 
techniques, such as next-generation sequencing, metagenomics and metabolomics, can 
facilitate research on the clinical relevance of the intestinal microbiota and their metabolites. 
Several studies have assessed the gastrointestinal microbiome in healthy dogs, dogs with 
idiopathic IBD and dogs with acute diarrhea. An interindividual diversity in the abundance of 
bacterial classes has been shown to exist even in healthy dogs (Handl et al. 2011; Garcia-
Mazcorro et al. 2012; Guard and Suchodolski 2016), making inferences on the significance 
of changes in the intestinal microbiota somewhat difficult. Regardless of this overall variability 




with idiopathic IBD. The intestinal dysbiosis was reflected mainly by an increase in 
Proteobacteria and a decrease in Faecalibacterium when compared to healthy dogs 
(Suchodolski et al. 2010, 2012a, 2012b; Minamoto et al. 2015; Vázquez-Baeza et al. 2016). 
However, these recent studies have evaluated the fecal or duodenal mucosal microbiota of 
dogs with idiopathic IBD at a single timepoint only. To date, there is no study reported 
evaluating the mucosal microbiota in dogs with chronic enteropathies both before and after 
treatment. Furthermore, only little information is available on the differences in the intestinal 
microbiota of dogs diagnosed with IBD or FRD. Thus, the aims of this study were (i) to 
compare the duodenal and colonic mucosal microbiota between dogs with IBD and dogs with 
FRD, and (ii) to evaluate the effect of successful treatment on the microbial composition by 
comparing the mucosal microbiota of each dog before and after treatment. Our hypotheses 
were that (i) the mucosal microbial composition differs between the two disease 
classifications, and (ii) the mucosal microbiome also differs within each disease group 
depending upon the treatment status. 
 
MATERIALS AND METHODS 
Animals and study protocol 
Duodenal and colonic mucosal biopsies were retrieved from a former study on canine 
chronic enteropathies. The exact study protocol has been published elsewhere (Burgener et 
al. 2008; Dumusc et al. 2014) and is briefly summarized here. Dogs with chronic 
gastrointestinal signs were prospectively enrolled between 2006 and 2008. All of the dogs 
had diarrhea with or without vomiting for at least 6 weeks. Further inclusion criteria were the 
absence of an identifiable underlying disorder; histopathological evidence of intestinal 
inflammation; and no treatment with antibiotics, corticosteroids and/or antacids 2 weeks prior 
to enrollment into the study. Most dogs had already received dietary modifications prior to 
referral. Potential underlying disorders were ruled out by a CBC, biochemistry profile, 
measurement of serum trypsin-like-immunoreactivity (TLI), cobalamin and folate, ACTH 
stimulation test, urinalysis, parasitic and bacterial fecal examination, abdominal ultrasound 
and endoscopy of the gastrointestinal tract. Since the specific canine pancreatic lipase was 
not easily available between 2006 and 2008, the diagnosis of pancreatitis was ruled out 
considering amylase, lipase, TLI and sonographic findings. Also, all dogs received treatment 
with fenbendazole (50 mg/kg daily for 5 days) regardless of the fecal examination. All owners 
signed a letter of consent, and the study was reviewed and approved by the Cantonal 
Committee of Animal Experimentation, Bern, Switzerland. 
A clinical disease severity score (canine IBD activity index [CIBDAI]) (Jergens et al. 2003) 




enteropathy clinical activity index (CCECAI) (Allenspach et al. 2007) was published during 
the course of this study and was assigned in some dogs. However, to obtain consistent 
results for all dogs, the CCECAI score was not further evaluated in the current study. In 
addition, every dog was categorized to have either mainly upper or lower gastrointestinal 
signs, or a combination of both. Both a gastroduodenoscopy and colonoscopy were 
performed in each dog enrolled in the study. 
Following the complete diagnostic evaluation, including gastrointestinal endoscopy, all dogs 
received a standardized elimination diet for 14 days. The elimination diet was a selected 
protein diet based on codfish and rice only, with codfish being a novel source of protein for all 
dogs enrolled in the study. That dry diet was specially produced for the current study (Biomill 
SA, Granges-Marnand, Switzerland). The diet was tested for contamination, and the 
adequacy of the nutritional composition was calculated by a veterinary nutritionist. Owners 
were thoroughly instructed on the principle of an elimination diet, including the importance of 
strictly feeding the prescribed diet. If clinical signs improved significantly or resolved within 
the first 14 days of feeding the diet, dogs were assigned to the FRD group. Although it is 
possible that few dogs with FRD had not yet responded, this length of the elimination trial 
was chosen according to previous publications that showed that most dogs with FRD usually 
respond within the first 2 weeks of a dietary trial (Marks, Laflamme and McAloose 2002; 
Allenspach et al. 2007; Gaschen and Merchant 2011; Allenspach, Culverwell and Chan 
2016). Dogs that did not respond to the elimination diet alone were assigned to the idiopathic 
IBD/steroid-responsive group and received additional prednisolone (1 mg/kg BID) for 14 days 
followed by a slow tapering of the dose. Cyclosporine (5 mg/kg SID) or other 
immunosuppressants (e.g., budesonide) were given to dogs that did not improve on 
prednisolone. 
Post-treatment assessment included the re-evaluation of the CIBDAI score and a repeat 
gastrointestinal endoscopy in all dogs. The FRD group of dogs was reassessed 4 weeks 
after starting the elimination diet, whereas the IBD group of dogs was re-evaluated at 10 
weeks after starting treatment with prednisolone. 
 
Gastrointestinal endoscopy and histopathological evaluation 
Details on the endoscopic and the histopathological evaluation have been published 
elsewhere (Burgener et al. 2008). Briefly, mucosal biopsy specimens were retrieved from the 
duodenum (∼10 cm below the caudal duodenal flexure) and the colon (the middle portion of 
the descending colon) or from areas with visible lesions. Samples were placed in 4% neutral-
buffered formalin for 48 h before being embedded in paraffin and subsequently prepared for 




from each intestinal section and were placed in RNA-later solution followed by storage at  
-70°C until DNA extraction. 
The endoscopic biopsies were examined histologically by a board-certified pathologist 
blinded to the number of endoscopy, diagnosis and treatment. The pathologist assigned a 
histologic lesion score reflecting the degree of inflammation and cellular infiltration (Jergens 
et al. 1992). Updated histopathological guidelines were published by the World Small Animal 
Veterinary Association Gastrointestinal Standardization Group in 2008 (Day et al. 2008). 
Similar to the CCECAI, these guidelines were not used in this study in order to apply the 
same histopathological standards to all dogs. 
 
Bacterial 16S rRNA gene quantitation and sequencing 
Genomic DNA was extracted from duodenal and colonic biopsies using a commercially 
available DNA extraction kit (PowerSoil®, Mo Bio, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Amplification and sequencing of the V4 variable region (primers 
515F/806R) of the 16S rRNA gene was performed on a MiSeq (Illumina) at the Molecular 
Research MR DNA laboratory (www.mrdnalab.com, Shallowater, TX, USA) as described 
previously (Bell et al. 2014). The software Quantitative Insights Into Microbial Ecology 
(QIIME) v.1.8 (http://www.qiime.org) was used for processing and analysis of sequences 
(Caporaso et al. 2010). The raw sequence data were de-multiplexed, and low-quality reads 
were filtered using default parameters. Chimeric sequences were detected using USEARCH 
(Edgar 2010) and were removed prior to further analysis. The remaining sequences were 
then assigned to operational taxonomic units (OTUs) using an open-reference OTU picking 
protocol in QIIME against the Greengenes (DeSantis et al. 2006) database (v.13.8). Prior to 
the downstream steps, sequences that were assigned as chloroplast, mitochondria and low 
abundance OTUs were removed. The rarefaction depth was set at 15 170 sequences per 
sample for colon samples and 2530 sequences per sample for duodenal samples. The 
sequences were deposited in the Sequence Read Archive under the following accession 
number: SRP103535. 
Within-sample diversity was estimated with the alpha diversity indices Chao1, Shannon and 
Observed OTUs. Beta diversity, which refers to the similarity between samples and potential 
clustering patterns between sample groups, was visualized using principal coordinate 
analysis plot based on weighted and unweighted UniFrac distances. 
 
Statistical analysis 
Statistical analyses were performed using JMP® Pro v.12. A Shapiro-Wilk test was used to 




the assumption of a normal distribution, comparisons of the alpha diversity and the bacterial 
taxa between FRD dogs and IBD dogs were performed using a Mann-Whitney U test. A 
Wilcoxon signed-rank test was used for comparison of paired samples (pre- and post-
treatment) within each disease group. A Benjamini-Hochberg false discovery rate was used 
to control for multiple testing. P- and q-values < 0.05 were considered statistically significant. 
The analysis of similarities (ANOSIM) function in the statistical software package PRIMER 6 
(PRIMER-E Ltd, Luton, UK) was used on the weighted and unweighted UniFrac distance 
matrix to determine if any groups of samples contained significantly different bacterial 
communities. Linear discriminant analysis (LDA) effect size (LEfSe) (Segata et al. 2011) was 
performed to identify bacterial groups that were significantly associated with disease 
classification and/or treatment status. LEfSe was used in the Galaxy workflow framework 




Twenty-four dogs were included in the study: fifteen of these dogs responded to the dietary 
modification only (FRD group) and nine dogs needed additional immunosuppressant 
treatment (IBD group). Basic characteristics of all study dogs included in the study are 
summarized in Table 1. Two IBD dogs were panhypoproteinemic and were classified as 
having protein-losing enteropathy (PLE) as a result of severe lymphoplasmacytic 
inflammation due to idiopathic IBD. Both dogs responded to immunosuppressant therapy. 
One of these dogs, however, developed severe side effects while treated with prednisolone 
and was switched to budesonide (dosage 3 mg/m² SID), which was well tolerated. 
In one dog diagnosed with FRD, duodenal biopsy samples were not sufficient for Illumina 
sequencing. Because duodenum and colon were analyzed separately, the colonic biopsies of 
this dog were still included in the analysis. In another dog with a diagnosis of FRD, the post-
treatment sample did not meet the rarefaction depth that had been set for the analysis. 
Hence, this dog was excluded from the within-group evaluation of the effect of treatment on 
the mucosal microbial composition. 
 
Sequence analysis 
The sequence analysis yielded a total of 5 436 076 quality sequences for all analyzed 
samples (n = 96, mean ± SD = 55 877 ± 39 144). The average of Good’s coverage of all 





Table 1. Characteristics of dogs (n = 24) enrolled in the study. 
Disease Breed  Age   Sex  Weight (kg) BCS CIBDAI 
IBD Shar Pei  4 y  f 12.4 2/9 9 
IBD Golden Retriever  6 y 10 mo  mn 36.5 6/9 7 
IBD, PLE Beauceron  4 y  fs 28.9 na 14 
IBD, PLE Bernese Mountain Dog  5 y  fs 35.5 na 12 
IBD Am. Cocker Spaniel  3  y 7 mo  mn 10.8 5/9 6 
IBD Mixed breed medium size  12 y 10 mo  mn 27.4 5/9 3 
IBD Cavalier King Charles Spaniel  4 y 6 mo  m 8.6 5/9 4 
IBD Malinois  2 y 8 mo  mn 32.6 4/9 15 
IBD Mixed breed medium size  2 y 11 mo  fs 20.3 5/9 4 
FRD Mixed breed medium size  3 y  mn 30.0 7/9 9 
FRD Yorkshire Terrier  8 y 6 mo  fs 2.9 6/9 6 
FRD French Bulldog  1 y 4 mo  m 14.6 5/9 8 
FRD Weimaraner  2 y  fs 23.0 4/9 4 
FRD Tervuren/Irish Wolfshound  9 mo  f 25.5 4/9 5 
FRD Samoyed/Border Collie/Swiss 
Mountain Dog 
 5 y 10 mo  mn 23.0 4/9 7 
FRD Cairn Terrier  3 y  m 9.4 na 4 
FRD Golden Retriever  1 y 2 mo  f 20.1 3/9 11 
FRD West Highland White Terrier  1 y  f 6.4 6/9 4 
FRD Labrador  2 y  m 46.0 6/9 9 
FRD Berger Blanc Suisse  2 y  fs 32.0 na 8 
FRD Pomeranian   10 mo  f 1.8 5/9 2 
FRD Labrador  11 y 2 mo  mn 32.5 6/9 4 
FRD Mixed breed large size  6 y 2 mo  fs 49.0 7/9 1 
FRD Newfoundland  6 y 9 mo  m 44.2 4/9 4 
The canine inflammatory bowel disease activity index (CIBDAI) refers to the clinical activity 
score at the first visit. 
The body condition score (BCS) refers to the body condition score of the first visit.  
y, year; mo, months; f, female; m, male; n, neutered; s, spayed; na, not available. 
 
Microbial communities in dogs with IBD or FRD 
Diversity analysis 
Alpha diversity, as described by species richness, Chao 1 and Shannon diversity index, was 
not significantly different between dogs with IBD and dogs with FRD in neither the duodenum 
nor colon (Fig. 1, Table 2). Also, within each disease group, significant differences were not 
seen before and after treatment (Fig. 2, Table 2). 
Additionally, principal coordinate analysis on unweighted (considering presence/absence 
OTU) and weighted (community membership and abundance of OTUs) UniFrac distance 
matrices did not reveal any significant difference in the microbial communities between dogs 




This was further confirmed with ANOSIM test (P > 0.05) as shown in Table 3. Similarly, 
ANOSIM did not reveal any significant differences pre- and post-treatment within each 
disease group (Table 3). No significant association was identified between microbial 
communities and the clinical disease severity (i.e., CIBDAI score) before treatment (ANOSIM 
P > 0.05). 
To determine the differences in bacterial composition between the dogs with IBD and those 
dogs with FRD, an LEfSe was utilized. Several bacterial taxa were found to be enriched in 
the two disease groups. In the duodenum of dogs with IBD, Mycoplasmataceae, 
Microbacteriaceae and Unclassified_Rhizobiales were abundant at the family level (LDA 
scores: 3.659, 3.608 and 3.656, respectively), and one unclassified genus each of the 
families Neisseriaceae (LDA score: 4.156), Microbacteriaceae (LDA score: 3.659) and 
Rhizobiales (LDA score: 3.666) was abundant at the genus level. In dogs with FRD, the 
genus Bilophila (LDA score: 3.165) was abundant in the duodenal mucosa. Also, in dogs with 
FRD, the family Burkholderiaceae and the genera Carnobacterium, Burkholderia, 
Unclassified_Helicobacteraceae and Unclassified_Coriobacteriaceae (LDA scores: 3.176, 
2.869, 2.978, 3.192 and 2.899, respectively) were found to be enriched within the colonic 
mucosa. 
An LEfSe was also used to assess the mucosal microbial composition before and after 
treatment. Several bacterial taxa were identified to differ in their abundance either before or 
after treatment (Tables 4-7). In dogs with FRD, for example, the genera Enterococcus (LDA 
score: 3.633), Corynebacterium (LDA score: 3.989) and Delftia (LDA score: 4.010) were 
abundant in the duodenum before treatment, whereas Comamonas (LDA score: 3.419) was 
significantly abundant in the duodenum after treatment. In the colon of dogs with FRD, the 
genera Carnobacterium (LDA score: 3.624) and Burkholderia (LDA score: 3.472) were 
significantly abundant before treatment, and the genera Bacteroides (LDA score: 4.548), 
Gemella (LDA score: 3.497) and Peptococcus (LDA score: 3.337) were abundant after 
treatment. 
The family Micrococcaceae (LDA score: 3.407) and an unclassified genus of the family 
Neisseriaceae (LDA score: 4.254) were found to be enriched within the duodenum of dogs 
with IBD before treatment. Only an unclassified genus of the family Bradyrhizobiaceae (LDA 
score: 4.219) reached significant abundance in the duodenum after treatment. The families 
Planococcaceae (LDA score: 3.161) and Oxalobacteraceae (LDA score: 3.200), and the 
genera Citrobacter (LDA score: 4.254), Burkholderia (LDA score: 3.884) and Unclassified 
Oxalobacteraceae (LDA score: 3.868) were significantly abundant in the colonic mucosa of 
dogs with IBD before treatment, whereas the genus Bacteroides (LDA score: 4.549) was 





Figure 1. Rarefaction analysis of 16S rRNA gene sequences obtained from canine (A) 
duodenal and (B) colonic mucosa samples. Rarefaction depth was set at 15,170 (colon) and 
2,530 (duodenum) sequences per sample. The lines (red = dogs with FRD; blue = dogs with 
IBD) represent the average of each group. The error bars represent the standard deviation. 
 
Table 2. Summary of alpha diversity indices comparing dogs with IBD and FRD in colonic 
and duodenal samples. 
 Median (Min -Max)  
Duodenum 
FRD-Pre FRD-Post IBD-Pre IBD-Post 
FRD vs IBD 
P-value* 
    FRD 
Pre vs Post 
P-value** 
IBD 
Pre vs Post 
P-value** 
Chao1 347(220-542) 352(170-773) 305(187-792) 273(248-434) 0.640 0.946 1 
Observed OTU 153(103-250) 156(98-211) 168(127-230) 139(112-174) 0.480 0.893 0.129 
Shannon 4.8(2.5-6.1) 5.1(2.6-6.1) 5.06(3.7-5.9) 4.62(4.03-5.43) 0.689 0.541 0.359 
Colon 
FRD-Pre FRD-Post IBD-Pre IBD-Post 
FRD vs IBD 
P-value 
FRD 
Pre vs Post 
P-value 
IBD 
Pre vs Post 
P-value 
Chao1 1275(714-1747) 1397(911-1892) 1193(554-2118) 1409(898-1730) 0.975 0.833 0.468 
Observed OTU 511(340-741) 573(388-761) 531(316-651) 539(380-728) 0.850 0.570 0.2969 
Shannon 4.9(2.4-6.3) 5.4(4.4-6.3) 5.1(2.5-5.8) 5.5(3.5-6) 0.874 0.052 0.9375 
Rarefaction depth was set at 15,170 (colon) and 2,530 (duodenum) sequences/sample. 
∗P values obtained by Mann–Whitney U test. P values < 0.05 considered as significant. 






To our knowledge, this is the first study to evaluate the intestinal mucosal microbiota of dogs 
with IBD or FRD both before and after treatment. This study did not reveal any differences in 
the overall species richness in dogs diagnosed with IBD and dogs with FRD. This finding 
could be attributed to the fact that both conditions may represent a different spectrum of the 
same disease, reflected by similar histologic inflammatory lesions (Day et al. 2008), and that 
can only be differentiated by their response to treatment (German, Hall and Day 2003; 
Simpson and Jergens 2011; Dandrieux 2016). It appears reasonable to assume that similar 
inflammatory histologic lesions might be associated with a similar effect on the mucosal 
microbiome. However, further studies are warranted to prove or disprove this hypothesis. 
Analysis of the specific bacterial taxa in dogs with FRD and dogs with idiopathic IBD showed 
a differential abundance of mainly bacteria belonging to the phylum of Proteobacteria (e.g., 
Bilophila in the duodenum, Burkholderia and Unclassified Helicobacteraceae in the colon of 
FRD dogs; Unclassified Neisseriaceae and Unclassified Rhizobiales in the duodenum of IBD 
dogs). This finding agrees with recent studies revealing an increase of Proteobacteria in 
dogs with IBD (Suchodolski et al. 2010, 2012a; Minamoto et al. 2015). Proteobacteria have 
been shown to also belong to the most abundant phyla in the gastrointestinal tract of healthy 
dogs (Suchodolski, Camacho and Steiner 2008), where they are abundant especially in the 
small intestine and present at lower abundance in the colon (Suchodolski, Camacho and 
Steiner 2008; Schmitz and Suchodolski 2016). However, some members of this phylum have 
also been shown to have pathogenic characteristics. One variant of a novel family of 
Burkholderiales, for example, was associated with perianal Crohn’s disease in humans (Sim 
et al. 2010). However, the association of pathogenic Burkholderia and canine chronic 
enteropathies has not been investigated. 
Comparison of differentially abundant bacteria in dogs with FRD considering treatment status 
revealed the distinctive presence of bacteria in the duodenal mucosa before treatment. 
These bacteria belonged to the phyla Proteobacteria (Delftia), Actinobacteria 





Figure 2. Rarefaction analysis of 16S rRNA gene sequences obtained from canine (A) 
duodenal and (B) colonic mucosa samples. The analysis was performed on a randomly 
selected subset of Table 2. Rarefaction depth was set at 15,170 (colon) and 2,530 
(duodenum) sequences per sample. The lines represent the average of each group. The 




Figure 3. Three-dimensional principal coordinate analyses of unweighted uniFrac distances 
colored by disease in (A) duodenal and (B) colonic mucosal samples. Each dot represents 
the microbial composition of one dog. ANOSIM based on unweighted andweighted UniFrac 
distances did not showa significant difference between dogs diagnosed with FRD and dogs 
diagnosed with IBD in the duodenum and colon respectively (duodenum ANOSIM 






The abundance of Proteobacteria before treatment is in line with the increase in 
Proteobacteria previously documented in dogs with IBD (Suchodolski et al. 2012a; Minamoto 
et al. 2015). The pathogenicity of particular strains of Corynebacterium has been known for 
many years (Dalal and Likhi 2008; Bernard 2012; Wagner et al. 2012) and a recent study has 
also reported Corynebacterium to be associated with primary sclerosing cholangitis with 
concomitant colonic disease (Bajer et al. 2017). Thus, the abundance of Corynebacterium 
before treatment in the current study might suggest involvement in the pathogenesis of 
chronic enteropathies. Certain Enterococcus strains are associated with beneficial effects 
and are used as probiotics (Kilpinen et al. 2015; Schmitz and Suchodolski 2016). In our 
study, Enterococcus was significantly abundant before treatment in the duodenum of dogs 
diagnosed with FRD. This finding is in contrast to a previous study in dogs with FRD that 
showed no significant change in the abundance of Enterococcus spp. with treatment and 
with the addition of a probiotic mixture (Sauter et al. 2006). This discrepancy might be 
explained by the different sampling methods, different methods to evaluate the microbiota or 
the difference in the study population or diet. One possible explanation for the differential 
abundance before treatment in the current study might be that Enterococcus with a higher 
abundance is more likely to modulate the inflammatory response and to keep the intestinal 
ecosystem in balance. Another consideration is the potential of Enterococcus to express 
virulence factors as has been shown in children with IBD (Golińska et al. 2013). Such 
virulence factors could potentially contribute to the inflammatory state and could also be 
associated with the pathogenesis of the disease. However, in our study both Enterococcus 
and Corynebacterium were only identified at the genus level and the specific strain was not 
analyzed due to an inadequate amount of residual DNA. Therefore, no conclusions can be 
drawn from our findings as to the functional relationship between higher abundance of 
Enterococcus or Corynebacterium and chronic intestinal inflammation. Future studies 
analyzing the specific strains of significantly abundant bacteria via quantitative real-time PCR 
are warranted. 
In the colon of dogs with FRD, mainly bacteria of the phylum Firmicutes were differentially 
abundant both before and after treatment. However, one representative of the phylum 
Bacteroidetes – the genus Bacteroides – was also found to be enriched within the colonic 
mucosa after initiation of treatment. Since Bacteroidaceae have been detected to be more 
abundant in healthy dogs than in dogs with IBD (Suchodolski et al. 2012a; Minamoto et al. 
2015), this finding might be associated with the effect of treatment and disease amelioration. 
This conclusion is also supported by the fact that certain Bacteroides strains have been 
recognized to be very beneficial to their host due to an important role in microbial 
degradation of carbohydrates (Flint et al. 2012) and bile acid deconjugation (Pavlidis et al. 




abscess formation via their polysaccharide capsule, and could potentially have negative 
effects on the host (Wexler 2007; Reis et al. 2014). Therefore, Bacteroides can be either 
protective or have virulent features, opening new avenues for further investigation of its role 
in the pathogenesis of chronic enteropathies in dogs, at best including the identification of 
specific strains. 
Table 3. ANOSIM test based on weighted and unweighted UniFrac distances. 
 









Duodenum        
FRD vs IBD –0.0090  0.474  –0.0365  0.649 
FRD pre vs FRD post –0.0103  0.554  0.0318  0.233 
IBD pre vs IBD post –0.1020  0.947  0.0082  0.414 
Colon        
FRD vs IBD 0.0399  0.264  –0.1192  0.969 
FRD pre vs FRD post 0.0206  0.231  0.0338  0.181 
IBD pre vs IBD post 0.0323  0.207  –0.0250  0.741 
The ANOSIM test was used to determine if any groups of samples contained significantly 
different bacterial communities. R values close to 1 indicate high separation between 
groups. R values close to 0 indicate similarity between groups. P values < 0.05 considered 
as significant. 
 
Table 4. LDA scores for association between treatment status and bacterial taxa in duodenal 
mucosal specimens from dogs diagnosed with IBD (n = 9). 
Selected Taxa 




Phylum   
Tenericutes 3.245 IBD pre  
Class   
Mollicutes 3.245 IBD pre  
Order   
No differentially abundant features found   
Family   
Micrococcaceae 3.407 IBD pre  
Genus   
Unclassified 4.085 IBD pre  
Unclassified_Neisseriaceae 4.254 IBD pre 
Unclassified_Bradyrhizobiaceae 4.219 IBD post 
A LDA score >2.0 is considered significant. 




Table 5. LDA scores for association between treatment status and bacterial taxa in colonic 
mucosal specimens from dogs diagnosed with IBD (n = 9). 
Selected Taxa 




Phylum   
Bacteroidetes 5.026 IBD post 
Class   
Bacteroidia 5.024 IBD post 
Order   
Bacteroidales 5.025 IBD post 
Family   
Planococcaceae 3.161 IBD pre  
Oxalobacteraceae 3.200 IBD pre  
Bacteroidaceae 4.542 IBD post 
Genus   
Unclassified_Oxalobacteraceae 3.868 IBD pre 
Citrobacter 4.254 IBD pre  
Burkholderia 3.884 IBD pre 
Bacteroides 4.549 IBD post 
A LDA score >2.0 is considered significant.  
pre, status before treatment; post, status after treatment. 
 
Evaluation for possible differences in the bacterial taxa in dogs with IBD depending on 
treatment status revealed an increased abundance of mainly members of the phylum 
Proteobacteria (unclassified genus of the family Neisseriaceae in the duodenum; unclassified 
genus of the family Oxalobacteraceae, and the genera Citrobacter and Burkholderia in the 
colon) before treatment. Further, one representative of the phylum Firmicutes (family 
Planococcaceae in the colon) was found at a higher abundance before treatment. To the 
authors’ knowledge, no specific pathogenic characteristics have been reported for this 
particular family found in our study. Therefore, the relevance of our finding remains unclear. 
Only an unclassified genus of the family Bradyrhizobiaceae was found to be enriched in the 
duodenum of dogs with IBD post-treatment. Again, to the authors’ knowledge, no pathogenic 
or constitutional trait has been reported for this bacterium, leaving the relevance of this 
finding unclear. An important finding, however, is that just as in dogs with FRD Bacteroides 
also reached significant abundance in the colon of dogs with IBD after treatment. This 
increase of Bacteroides in both disease groups after treatment possibly suggests disease 
amelioration, and therefore this bacterium could potentially be used as a respective marker 





Table 6. LDA scores for association between treatment status and bacterial taxa in duodenal  






Phylum   
No differentially abundant features found   
Class   
No differentially abundant features found   
Order   
No differentially abundant features found   
Family   
Peptostreptococcaceae 3.694 FRD pre 
Enterococcaceae 3.789 FRD pre 
Oxalobacteraceae 3.766 FRD pre 
Comamonadaceae 4.280 FRD pre 
Bacillaceae 3.848 FRD pre 
Corynebacteriaceae 3.952 FRD pre 
Genus   
Unclassified_Peptostreptococcaceae 3.664 FRD pre 
Enterococcus 3.633 FRD pre 
Unclassified_Coriobacteriaceae 3.855 FRD pre 
Corynebacterium 3.989 FRD pre 
Delftia 4.010 FRD pre  
Comamonas 3.419 FRD post 
A LDA score >2.0 is considered significant. 
pre, status before treatment; post, status after treatment. 
 
The absence of a group of healthy control dogs poses a major limitation of this study. 
However, in order to follow a standardized study protocol, endoscopies involving general 
anesthesia would have been necessary before treatment and potentially also after a 
standardized treatment in these dogs. Because of this invasiveness and the fact that several 
studies evaluating the intestinal microbiota in healthy dogs have already been published 
(Suchodolski, Camacho and Steiner 2008; Handl et al. 2011), performing repeated 
gastrointestinal endoscopies under general anesthesia in healthy dogs was considered 
unethical. Examination of the microbiota in fecal samples of healthy controls both before and 
after treatment with the study’s diet could have been a less invasive alternative to 
endoscopy. However, a study by one of the authors (JS) has revealed bacterial diversity 
along the different sections of the canine intestine (Suchodolski, Camacho and Steiner 
2008). Therefore, a direct comparison of the fecal microbiota of healthy dogs and, for 
example, the duodenal mucosal microbiota of diseased dogs would not have been 
meaningful. The mucosal samples of this study were purposefully retrieved as part of a larger 




Unfortunately, residual fecal samples of the dogs diagnosed with IBD and FRD were not 
available for an additional analysis of the fecal microbiota in the current study. Moreover, in 
the authors’ opinion, mucosal samples are superior to fecal samples in assessing the true 
intestinal microbiota. 
Table 7. LDA scores for association between treatment status and bacterial taxa in colonic  






Phylum   
No differentially abundant features found   
Class   
Bacteroidia  4.821 FRD post 
Order   
Gemellales 2.911 FRD post 
Bacteroidales 4.491 FRD post 
Family   
Burkholderiaceae 3.132 FRD pre 
Bacteroidaceae 4.512 FRD post 
Peptococcaceae 3.342 FRD post 
Gemellaceae 3.517 FRD post 
Genus   
Burkholderia 3.472 FRD pre 
Carnobacterium 3.624 FRD pre 
Gemella 3.497 FRD post 
Peptococcus 3.337 FRD post 
Bacteroides 4.548 FRD post 
A LDA score >2.0 is considered significant. 
pre, status before treatment; post, status after treatment. 
 
Genomic DNA was extracted using the Mo Bio PowerSoil® DNA Isolation Kit, which is used 
in the Human Microbiome Project and is currently recommended for the extraction of DNA. 
The use of this method yielded the currently most effective DNA extraction (Wagner 
Mackenzie, Waite and Taylor 2015) and kept the possible influence of sample preparation on 
this study’s results to a minimum. 
The different time scales for the follow-up endoscopies in the two disease groups could have 
possibly influenced the results. However, as glucocorticoids were not instituted until there 
was no significant clinical improvement on the elimination diet only on day 14, those dogs 
had to be given more time to respond to treatment. In general, FRD dogs are considered to 
respond faster to appropriate treatment, whereas dogs requiring immunosuppressants 




previous studies (Allenspach et al. 2007; Burgener et al. 2008; Dumusc et al. 2014) and are 
considered more representative of a similarly controlled disease status. 
As most dogs diagnosed with FRD show a significant clinical response to a dietary trial within 
14 days (Marks, Laflamme and McAloose 2002; Allenspach et al. 2007; Gaschen and 
Merchant 2011; Allenspach, Culverwell and Chan 2016), the elimination trial was limited to 
that period of time. Furthermore, this short period provided for good owner compliance. 
Dietary modification is also an inherent part of treatment in dogs with IBD. Thus, it is possible 
that some dogs with IBD could have initially improved on the diet alone and could have been 
erroneously grouped in the FRD group. Yet, in the authors’ experience, dogs diagnosed with 
IBD generally only show minor improvement on elimination diet and would have probably not 
been assessed as significant improvement, much less as clinical remission. 
Another limitation of our study is the small number of dogs included and the fact that 
endoscopic biopsies were only obtained from the duodenum and colon. A larger study cohort 
of dogs and inclusion of additional biopsy sites (particularly the ileum) might have yielded 
more obvious differences in the mucosal microbial composition. Another shortcoming of our 
study is that the possibility of a continuing effect of previous medications (e.g., antibiotic 
treatment) on the mucosal microbiota cannot be definitively excluded, although all efforts 
were made to minimize such an effect by including only dogs not given an antibiotic 2 weeks 
prior to enrollment in the study. According to studies in human medicine, a 4-week wash-out 
period (Dethlefsen et al. 2008; Langdon, Crook and Dantas 2016) may be more appropriate 
than a 2-week period and may have resulted in finding a more restored and original intestinal 
microbial composition. A study in veterinary medicine by one of the authors (JS), however, 
showed that the intestinal microbiota of dogs that received metronidazole returned to its 
original composition within 14 days after cessation of therapy in the majority of dogs (Olson 
et al. 2015). Until now, there are only limited studies examining the effect of glucocorticoids 
on the intestinal microbial composition. One study revealed no effect of prednisolone on the 
fecal microbiota of dogs (Igarashi et al. 2014) and to the authors’ knowledge, there are no 
studies evaluating the influence of budesonide on the intestinal microbiota. The authors did 
not expect a major impact of budesonide on the microbial composition, and therefore, the 
one dog receiving budesonide was still included in the analysis. 
The possibility of a long-term effect of the previous diet and prebiotics or probiotics given 
prior to the study can also not be entirely ruled out. Studies in both human and veterinary 
medicine have shown that the diet, in particular macronutrients, influences the intestinal 
microbial composition (Hang et al. 2012; Conlon and Bird 2014; Xu and Knight 2015; Herstad 
et al. 2017; Li et al. 2017). However, the diets used in those studies were diets with 




commonly used diets. Moreover, a recent study showed that alpha diversity did not correlate 
with fat or protein intake in a population of dogs with IBD and control dogs (Vázquez-Baeza 
et al. 2016), concluding that the disease effect is stronger than the diet’s effect on the 
microbial composition. It has been recognized that obese individuals harbor a different 
intestinal microbiota with especially a decreased abundance of Bacteroides and an increased 
abundance of Firmicutes, which leads to an increased capacity to harvest energy (Ley et al. 
2005; Turnbaugh et al. 2006, 2009). Thus, the body condition score (BCS) of dogs could 
have affected the results of the current study. However, 16 dogs were assigned a BCS 
between 4 and 6 out of 9 at their initial visit, representing a similar BCS for the majority of 
dogs. Furthermore, the study by Vázquez-Baeza et al. also revealed no correlation of the 
BCS and alpha diversity in the enrolled dogs. Therefore, the authors consider the influence 
of the BCS on this study’s results negligible. An influence of lifestyle (e.g., smoking, 
exercising, stress) on the intestinal microbiota has been shown in humans (Conlon and Bird 
2014), with, for example, a higher diversity of the intestinal microbes in extreme athletes 
(Clarke et al. 2014). Although similar effects can be assumed in athletic or working dogs and 
dogs living in a smoking household, these effects are again only expected with extreme 
lifestyles, not reflecting the average companion dog. One study reported both age and breed, 
respectively size, to have an impact on the intestinal microbial composition in dogs (Simpson 
et al. 2002), whereas another study did not find a correlation between age and the alpha 
diversity in dogs (Vázquez-Baeza et al. 2016). More studies are needed to evaluate the true 
impact of these factors on the intestinal microbiota. All of the aforementioned possible 
influences could not be fully excluded in this study, as the dogs’ characteristics and 
environment could not be standardized in the case of a clinical trial. However, in the authors’ 
opinion, the diversity of dogs enrolled in this study represents a more realistic and therefore 
meaningful patient population. 
In conclusion, this study is the first to assess the intestinal mucosal microbiota in dogs with 
IBD or FRD before and after treatment. Some differences in individual bacterial taxa were 
identified both between disease groups and in relation to the treatment status. The relevance 
of these bacterial groups in the pathogenesis of IBD and FRD requires further research. 
However, our results suggest that Bacteroides might be a possible marker of successful 
response to treatment. Larger scale studies are warranted to confirm our findings and to 
shed more light on the functional consequences of the changes in the intestinal microbial 
composition shown in this study. Evaluation of their role in the pathophysiology of IBD and 
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3.2 Comparison of the Systemic Phospholipid Profile in Dogs Diagnosed with 
Idiopathic Inflammatory Bowel Disease or Food-Responsive Diarrhea 
before and after Treatment 
I contributed to this second study by being responsible for the project administration including 
all management and coordination responsibilities for pursuing this project. I was further 
responsible for interpretation of the results in view of the clinical aspects and the relevance of 
the findings for the general veterinary and the greater scientific community. I gathered and 
analyzed the data acquired by hydrophilic interaction liquid chromatography (HILIC) 
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Inflammatory bowel disease (IBD) and food-responsive diarrhea (FRD) are common chronic 
enteropathies in dogs, of which the exact pathogenesis has not been fully understood. In 
people dyslipidemia has been reported in patients with IBD, and potential therapeutic 
benefits of polyunsaturated fatty acids (PUFA) in the treatment of IBD have been 
investigated. Studies on the phospholipid profile in dogs with IBD and FRD are still lacking. 
 
Aim 
To investigate the systemic phospholipid profile of dogs with IBD or FRD and to evaluate 
possible differences in phospholipids before and after treatment. 
 
Methods 
The phospholipids in whole blood and EDTA plasma of 32 dogs diagnosed with either IBD 
(n=16) or FRD (n=16) were analyzed by hydrophilic interaction liquid chromatography 




A clear separation of the phospholipids between whole blood and plasma was demonstrated 
on principal component analysis plots. In addition to the type of specimen, treatment and 
disease severity were the most significant factors determining the variance of the 
phospholipid profile. An increase in lysolipids was observed after treatment. The 
phosphatidylcholine (PC) species changed from PC 38:4 before treatment to mainly 
lysophosphatidylcholine 18:0 after treatment. Furthermore, several differences in the 
abundance of individual phospholipids were identified between dogs with IBD and dogs with 
FRD and between treatment statuses using random forest analysis. 
 
Conclusion 
Significant variances were identified in the phospholipid profiles of dogs with IBD and FRD. 
These were particularly determined by type of specimen used, disease severity and 
treatment status. After treatment, a shift of phospholipid species towards 
lysophosphatidylcholine 18:0 was observed. Future studies should further investigate the role 






Chronic inflammatory enteropathies (CIE) are a group of common disorders in dogs, which 
are categorized based on the patient’s response to treatment as either food-responsive 
diarrhea (FRD), antibiotic-responsive diarrhea (ARD), or idiopathic inflammatory bowel 
disease (IBD) [1-4]. Dogs with FRD will show a complete clinical response after dietary 
modification to a novel source of protein and carbohydrates or to a commercially available 
hydrolyzed protein diet [5,6], whereas dogs with ARD require the use of antibiotic treatment, 
for example with tylosin, in addition to dietary management for clinical signs of 
gastrointestinal disease to resolve [7-9]. Idiopathic IBD is defined as chronic gastrointestinal 
signs of a complex pathogenesis, histologic confirmation of intestinal inflammation, and the 
necessity for anti-inflammatory and / or immunosuppressive treatment [2,4,7,10]. To date, 
the etiopathogenesis of CIE, in particular of idiopathic IBD, has not been fully unraveled. 
However, the current state of knowledge strengthens the notion that a combination of a 
genetic susceptibility [11-15], dietary and environmental factors, the intestinal microbiota, and 
an exaggerated immune response contribute to the development of idiopathic IBD in dogs 
[16-20]. This complexity involving the pathogenesis of IBD urgently asks for potential novel 
treatment strategies in addition to the currently used stepwise treatment approach of dietary 
modification, antibiotic trials, and immunosuppressive treatment [2,3]. Novel approaches, 
including beneficial alterations in the intestinal microbiota through the administration of 
probiotics and / or prebiotics [21-26] or fecal microbial transplants [27-29], have recently 
attracted great attention and warrant further research to fully elucidate their therapeutic 
potential or benefit. 
In human medicine, alterations in lipid profiles and lipid homeostasis have been reported with 
several diseases, including metabolic syndrome [30], diabetes mellitus [30,31], myocardial 
infarction [31], Alzheimer’s disease [32,33], and cancer [34]. Likewise, dyslipidemia has been 
detected in patients diagnosed with IBD [35-37]. Similar to the findings in humans, altered 
lipid profiles have been recognized in dogs diagnosed with idiopathic hyperlipidemia [38,39], 
diabetes mellitus [40], parvoviral infection [41], cancer [42], renal disease [43,44], or systemic 
infections [45]. Besides possibly contributing to the pathogenesis of those diseases, several 
studies have demonstrated lipids, in particular polyunsaturated fatty acids (PUFA), to also 
have immunomodulatory, anti-inflammatory, and potentially other beneficial effects both in 
human [46-48] and in veterinary patients [49,50]. These characteristics of PUFAs appear to 
be very promising from a therapeutic and even a preventative [51] perspective. However, 
there is currently only very limited data suggesting that dietary supplementation with PUFAs 
yields a clinical benefit in humans with IBD [36,47,48]. In veterinary medicine, only two 
studies have investigated the effect of supplemental PUFAs in dogs diagnosed with CIE. 




[52] and also modulate the expression of genes affecting intestinal fatty acid uptake [53], 
both of which appear to be beneficial in dogs with CIE. 
Phospholipids are amphiphilic lipids and represent fundamental components of biological 
membranes, where they are organized as lipid bilayers [54,55]. Due to their essential 
abundance in cell membranes their fatty acid composition has a major influence on 
membrane quality and phospholipids further serve as sources of fatty acids, including 
PUFAs, lipid mediators and molecules of cell signaling [55,56]. Thus, phospholipids and their 
membrane composition have great influence on health [55] and, similar to PUFAs, they have 
been reported to have beneficial effects in several diseases in humans [54,57-61]. 
To the authors’ knowledge, the systemic phospholipid profiles have not been reported in 
dogs with CIE (neither before nor after initiation of treatment). Therefore, the objectives of 
this study were (1) to compare the phospholipid profiles between dogs with idiopathic IBD 
and dogs diagnosed with FRD, and (2) to evaluate the effect of treatment including dietary 
supplementation with PUFAs on the phospholipid composition in dogs with CIE by comparing 
the phospholipid profiles before and after induction therapy. It was hypothesized (1) that the 
phospholipid profiles differ between the two disease categories, and (2) that the phospholipid 
profiles also differ within each disease group depending upon the treatment status. 
 
Materials and Methods 
Animals and study protocol 
Stored whole blood and plasma samples of a previously reported study on canine chronic 
enteropathies by one of the authors (Iwan A. Burgener) [11,62] were used for the current 
investigation. In that original study, dogs with chronic gastrointestinal signs, in the form of 
diarrhea with or without vomiting or weight loss for at least six weeks, were prospectively 
enrolled between December 2006 and November 2008. Additional inclusion criteria 
comprised the absence of an identifiable underlying disorder, histopathologic evidence of 
intestinal inflammation, and no treatment with antibiotics, corticosteroids, antisecretory 
medications, or combinations of these for at least two weeks prior to enrollment of dogs into 
the study. As most dogs had already received dietary modifications prior to referral, previous 
dietary trials did not preclude a dog’s participation in this project. To exclude possible 
underlying disorders, a complete blood count, serum biochemistry profile, urinalysis, 
measurement of serum canine trypsin-like-immunoreactivity (cTLI), serum cobalamin and 
folate concentrations, adrenocorticotropic hormone stimulation test, parasitic and bacterial 
fecal examination (including Clostridium spp, Campylobacter spp and Salmonella spp), 




dogs. The specific canine pancreatic lipase test was not readily available in Europe between 
2006 and 2008. Thus, a diagnosis of pancreatitis was ruled out based on a normal serum 
amylase and lipase activity, a normal serum cTLI concentration, and absence of abdominal 
ultrasound findings consistent with pancreatitis. All dogs were treated with an antiparasitic 
(fenbendazole 50 mg/kg p.o. SID for 5 days) irrespective of the results of the fecal parasite 
examination. Further, the body condition score (BCS) was recorded in the majority of dogs 
[63]. As the original sample collection was performed by Iwan A. Burgener at the Small 
Animal Teaching Hospital of the Vetsuisse Faculty, University of Bern, Switzerland, the 
design of the study was reviewed and approved by the Cantonal Committee of Animal 
Experimentation, Bern, Switzerland (permit number BE 118/05), and all owners gave written 
consent prior to inclusion of the dog in the study. 
All dogs were assigned a clinical disease severity score (canine IBD activity index [CIBDAI] 
[64]) both prior to and after initiation of treatment. Each dog in the study was further classified 
as having signs of either predominantly small intestinal or large intestinal disease, or a 
combination of both. A gastroduodenoscopy and colonoscopy were performed in each dog 
enrolled in the study except for four dogs with severe hypoalbuminemia due to protein-losing 
enteropathy (PLE). In these dogs the preparatory 36-hour fast necessary for colonoscopy 
was considered potentially harmful, thus the endoscopic examination was limited to a 
gastroduodenoscopy. 
After completion of this standard diagnostic work-up, including gastrointestinal endoscopy 
with collection of tissue biopsies, all dogs were fed a standardized elimination diet for 14 
days. The study diet was a dry single protein diet based on codfish and rice only, with codfish 
being a novel source of protein for all dogs enrolled in the study. This elimination diet was 
specially produced for the study (Biomill SA, Granges-Marnand, Switzerland) and was 
enriched with PUFAs, yielding a concentration of omega-3 PUFAs of 1% and a concentration 
of omega-6 PUFAs of 3.5% (S1-S3 Files). The adequacy of the diet’s nutritional composition 
was calculated by a veterinary nutritionist. Owners received detailed instructions on the 
concept of an elimination diet, strictly prohibiting table scraps and treats other than the 
prescribed diet. If clinical signs improved significantly or resolved within the first 14 days of 
feeding the study diet, dogs were assigned to the food-responsive (FRD) group. Dogs that 
did not improve clinically on the elimination diet were additionally treated with prednisolone (1 
mg/kg p.o. BID) for 14 days followed by a slow tapering of the dose. These dogs were 
allocated to the idiopathic IBD / steroid-responsive disease group. Dogs that did not respond 
to prednisolone further received cyclosporine (5 mg/kg p.o. SID) or other 




The clinical evaluation after initiation of treatment consisted of a re-evaluation of the CIBDAI 
score in all dogs and a follow-up gastrointestinal endoscopy in the majority of dogs. The FRD 
group of dogs was reassessed four weeks after starting the elimination diet, whereas the IBD 
group of dogs was re-evaluated at 10 weeks after starting treatment with prednisolone. 
Gastrointestinal endoscopy and histopathologic evaluation 
Details on the endoscopic and the histopathologic evaluation have been published elsewhere 
[11]. Briefly, mucosal biopsy specimens were retrieved from the duodenum (approximately 
10 cm proximal to the caudal duodenal flexure) and the colon (the middle portion of the 
descending colon) or from areas with any obvious lesions. Samples were placed in 4% 
neutral-buffered formalin for 48 hours before being embedded in paraffin and subsequently 
prepared for histopathologic evaluation. 
The endoscopic biopsies were examined histologically by a board-certified pathologist 
blinded to clinicopathological findings, the number of endoscopy, diagnosis, and treatment. 
The pathologist assigned a histologic lesion score reflecting the degree of inflammation and 
cellular infiltration [65]. 
Blood sample collection and analysis of the phospholipid profile 
During the initial diagnostic work-up and the reassessment of the dogs after initiation of 
treatment, whole blood and EDTA-plasma samples were collected and immediately stored 
frozen at -20 °C until lipid extraction. 
For analysis of the phospholipid profile, 20-200 µL of sample (whole blood or plasma) was 
mixed with 3.75 volumes of mass spectrometry (MS) grade chloroform:methanol (1:2 [v/v]). 
After 30 minutes, samples were centrifuged for 5 minutes at 2000×g to remove protein 
precipitate. The supernatant was then transferred to glass autosampler vials for immediate 
analysis. Hydrophilic interaction liquid chromatography (HILIC) of polar lipid classes was 
performed on the extracts as described previously [66,67]. The column effluent was 
introduced into an Orbitrap Fusion mass spectrometer (MS; Thermo Scientific, Waltham, MA) 
operated at an orbitrap resolution of 120k for MS1 and with data-dependent MS2 in a linear 
ion trap. Ion spray ionization was used in the negative mode throughout the entire assay run. 
Data was converted to mzML format and was analyzed by XCMS v3.00 under R v3.4.2 (R 
Core Team, 2017. R: A language and environment for statistical computing. R Foundation for 
Statistical Computing. Available at: https://www.R-project.org/) [68]. Chromatographically 
obtained m/z peaks were classified based on their retention time and were matched against 
an in silico generated lipid database. Lipid signals were corrected for 13C isotope 
contributions. An exemplary base peak chromatogram with identified phospholipids of one 





In order to allow for a large number of measured phospholipids and to maintain practicality of 
the statistical analysis, yet allowing for the detection of significant differences, a data 
reduction was performed first by means of a principal component analysis (PCA), which was 
performed with the R package ‘PCAMethods’ (version 1.70.0) using the nonlinear iterative 
partial least squares (nipals) algorithm with pareto scaling [69]. Principal component analysis 
was performed on the complete data set, including all identified phospholipid species of both 
whole blood and plasma samples. These principal components (PrComp) were used as new 
variables for subsequent analyses. In the full dataset, the majority of phospholipidic variance 
could be explained by the type of specimen used. Thus, further statistical analysis of the 
obtained PrComps was performed separately for whole blood and plasma. In order to 
evaluate the effect of several different variables (including the aforementioned treatment of 
dogs with FRD or IBD, disease category, interaction of treatment and disease category, age, 
breed, weight, BCS, and sex) on the variance of the phospholipid profile, the R package 
‘LME4’ (version 1.1-17) was used to compare the full linear model with mixed effects to the 
same model excluding specific factors or interactions. An analysis of variance (ANOVA) was 
then performed to assess the significance of the effect of a given factor. P values < 0.05 
were considered statistically significant. The model used for comparisons was chosen 
according to the lowest Akaike information criterion (AIC) score, and both fixed (treatment, 
disease category, age, BCS, and weight, including the interaction between treatment and 
disease category) and random factors (breed, sex, and disease category nested within dog 
subject) were included in the model. Furthermore, all individual phospholipids were analyzed 
using the same linear mixed model as for the principal component analysis. The p-values 
obtained by this method were adjusted for false discovery rate using the Benjamini-Hochberg 
procedure. In addition, random forest analysis was performed using the web-based program 
MetaboAnalyst 4.0 to identify phospholipids that possibly contribute to the differentiation 




Thirty-two dogs were enrolled in the study. Sixteen of the dogs were categorized as FRD, as 
their clinical signs improved to the extent of being clinically insignificant (CIBDAI score 0-3) 
after dietary modification. The remaining 16 dogs required additional immunosuppressant 
treatment based on which these dogs were classified as having IBD. Tables 1 and S1 





Table 1. Basic characteristics of the dogs included in the study (n = 32). 
Disease Breed Age Sex Weight BCS CIBDAI 
IBD, PLE Papillon 3 y mn 3.0 kg 3/9 14 
IBD, PLE Rottweiler 10 y fs 31.6 kg 6/9 9 
IBD Golden Retriever 6 y 10 mo mn 36.5 kg 6/9 7 
IBD Rottweiler 7 y 7 Mo f 60.0 kg 8/9 6 
IBD, PLE Beauceron 4 y fs 28.9 kg n/a 14  
IBD, PLE Bernese Mountain Dog 5 y fs 35.5 kg n/a 12  
IBD American Cocker Spaniel 3 y 7 mo mn 10.8 kg 5/9 6  
IBD, PLE Yorkshire Terrier/Shi Tzu mix 11 y fs 4.0 kg 4/9 11 
IBD Mixed breed medium size 12 y 10 mo mn 27.4 kg 5/9 3  
IBD Cavalier King Charles Spaniel 4 y 6 mo m 8.6 kg 5/9 4  
IBD, PLE Pug 3 y 6 mo m 11.2 kg 6/9 8 
IBD, PLE Mixed breed medium size 5 y 11 mo mn 11.5 kg 3/9 n/a  
IBD Malinois 2 y 8 mo mn 32.6 kg 4/9 15  
IBD, PLE Labrador mix 3 y mn 23.2 kg 3/9 5 
IBD, PLE Pug 6 y 10 mo f 7.2 kg 5/9 4 
IBD Mixed breed medium size 2 y 11 mo fs 20.3 kg 5/9 4  
FRD Mixed breed medium size 3 y mn 30.0 kg 7/9 9 
FRD Dachshund 3 y fs 7.0 kg 4/9 5 
FRD Yorkshire Terrier 8 y 6 mo fs 2.9 kg 6/9 6 
FRD French Bulldog 1 y 4 mo m 14.6 kg 5/9 8 
FRD Weimaraner 2 y fs 23.0 kg 4/9 4 
FRD Tervuren-Irish Wolfshound mix 9 mo f 25.5 kg 4/9 5 
FRD Samoyed-Border Collie-Swiss Mountain Dog mix 5 y 10 mo mn 23.0 kg 4/9 7 
FRD Cairn Terrier 3 y m 9.4 kg n/a 4 
FRD Golden Retriever 1 y 2 mo f 20.1 kg 3/9 11 
FRD West Highland White Terrier 1 y f 6.4 kg 6/9 4 
FRD Labrador Retriever 2 y m 46.0 kg 6/9 9 
FRD Berger Blanc Suisse 2 y fs 32.0 kg n/a 8  
FRD Labrador 11 y 2 mo mn 32.5 kg 6/9 4  
FRD Mixed breed large size 6 y 2 mo fs 49.0 kg 7/9 1  
FRD Newfoundland 6 y 9 mo m 44.2 kg 4/9 4  
FRD German Shepherd Dog 1 y 1 mo m 34.3 kg 5/9 n/a 
The canine inflammatory bowel disease activity index (CIBDAI) refers to the clinical activity 
score at the first visit. 
The body condition score (BCS) refers to the body condition score of the first visit. 
y, year; mo, months; f, female; m, male; n, neutered; s, spayed; n/a, not available 
 
Nine dogs with IBD (56%) showed hypoalbuminemia and were diagnosed with protein-losing 
enteropathy as a result of severe lymphoplasmacytic inflammation due to idiopathic IBD. 
Three of these dogs significantly improved with prednisolone (1 mg/kg p.o. BID) 
monotherapy, while one dog required treatment with prednisolone and cyclosporine, and 




replaced by budesonide later on. Four of the dogs with PLE (44%) were eventually 
euthanized due to clinical deterioration, with three dogs having received a combination of 
prednisolone and cyclosporine and one dog having received budesonide and cyclosporine. 
All other dogs with IBD and normoalbuminemia responded to prednisolone (starting dose 1 
mg/kg p.o. BID) which could either be gradually reduced to only a small dose (e.g., 0.25 
mg/kg p.o. EOD) or dogs could be taken off of prednisolone completely during the course of 
treatment. One dog, however, developed severe side effects of prednisolone and was 
switched to budesonide, which was better tolerated. A total of 24 dogs were included in the 
within-group evaluation of the effect of treatment on the phospholipid profile. In addition to 
the four dogs with PLE that were euthanized, one dog with FRD was censored from further 
analysis due to the owners declining a second endoscopy under general anesthesia. Another 
dog with FRD had to be excluded because of its refusal to eat the study diet, and two 
additional dogs with IBD were excluded from the study due to one owner declining further 
participation in the study and the other owner not following the study protocol. 
Phospholipid profiles 
Principal component analysis revealed a clear differentiation between the phospholipid 
profiles of whole blood and plasma regardless of the disease category (Fig 1), thus 
subsequent analyses were performed separately for whole blood and plasma. Furthermore, 
as PrComp1, PrComp2 and PrComp3 represented the principal components comprising the 
majority of the original phospholipid variance, these three PrComps were used for further 
statistical analysis. 
Phospholipid analysis of whole blood did not identify any factors that significantly affected the 
variance of the phospholipid composition on PrComp1 (Table 2). Despite not reaching 
significance, breed seemed to have the biggest effect on the variance. However, on 
PrComp2 the phospholipid profile changed significantly depending on treatment status, with 
an increase in lysolipids (especially lysophosphatidylcholine [lysoPC] and 
lysophosphatidylinositols [lysoPI]) after initiation of treatment (Fig 2). Interestingly, after 
initiation of treatment the originally most abundant phosphatidylcholine (PC) species PC 38:4 
(of which the most common molecular species is PC 18:0/20:4 ) was mainly converted into 
lysoPC 18:0 and arachidonic acid (i.e., 20:4 fatty acid) (S2 Fig), with a significant change in 
the ratio of PC 38:4 to lysoPC 18:0 (p < 0.0024, S4 Table). Furthermore, the effect of 
treatment depended on the disease category, and this effect was largest for dogs diagnosed 
with PLE due to IBD. Disease category and BCS also showed a significant effect on the 
phospholipid composition of whole blood in PrComp2 (Fig 3). In contrast, in PrComp3 none 





Fig 1. Principal component analysis (PCA) of the phospholipid profile in plasma and 
whole blood samples. In the score plot (left panel) each dot represents one analyzed 
sample and similar phospholipid profiles cluster together. A clear separation between plasma 
and blood samples is observed. In both types of specimen, the three disease categories are 
similarly positioned to each other, indicating a similar shift in the phospholipid profile in both 
sample types. Samples are color-coded by sample type and disease classification. The 
principal component loadings plot (right panel) visualizes the contribution of each 
phospholipid species to the total variance in the phospholipid profile, to which phospholipid 
species with the largest distance from the origin contributed the most. Each dot represents a 
different phospholipid species and the same color is used for the same phospholipid class. 
Dot sizes are proportional to the MS signal intensity of the phospholipid species. PrComp, 
principal component; PC, phosphatidylcholine; SM, sphingomyelin; PI, phosphatidylinositol. 
https://doi.org/10.1371/journal.pone.0215435.g001 
 
The analysis of phospholipids in plasma also revealed significant associations of specific 
variables and the composition of the phospholipid profile (Table 2). On PrComp1, both 
treatment and the interaction between treatment and disease category had a significant 
effect. Similar to whole blood, the most significant effects were detected on PrComp2 in 
plasma. In addition to treatment and the interaction of treatment with disease classification, 
age and weight also had an effect on the phospholipid composition (Fig 4). Treatment, 
disease category, the interaction between treatment and disease category, and body weight 
were all found to be significant predictors on PrComp3. Sex did not have a significant impact 





Table 2. Summary of ANOVA p-values of all evaluated parameters. 
 
P-value 
PrComp1 PrComp2 PrComp3 
Whole blood    
Interaction treatment & disease category 0.3942 0.5353 0.0828 
Treatment 0.7334 0.0027 0.2082 
Disease category 0.8411 0.0082 0.1021 
Weight 0.9088 0.1303 0.5920 
Age 0.8647 0.3694 0.3668 
BCS 0.6296 0.0296 0.4735 
Breed 0.3097 0.0081 1.0000 
Sex 1.0000 1.0000 1.0000 
Plasma    
Interaction treatment & disease category 0.0332 0.0472 0.0107 
Treatment 0.0249 0.0238 0.0039 
Disease category 0.9593 0.1015 0.0233 
Weight 0.6662 0.0075 0.0155 
Age 0.1469 0.0105 0.5661 
BCS 0.1467 0.4361 0.1654 
Breed 0.9840 0.1100 1.0000 
Sex 1.0000 1.0000 0.6163 
PrComp, principal component; BCS, body condition score. 






Fig 2. Principal component analysis (PCA) of the phospholipid profile in whole blood 
samples. In the score plot (left panel, for annotations see Fig 1) samples are color-coded by 
disease category and treatment status. The post-treatment samples are clustered in the 
upper right quadrant. In the corresponding loadings plot (right panel) lysolipid species are the 
predominant phospholipids in the upper right quadrant, indicating that the level of lysolipids 
increases after treatment. PrComp, principal component; PC, phosphatidylcholine; SM, 







Fig 3. Effect of selected variables on variance of the phospholipid profile on PC2 in 
whole blood. Fixed effects are plotted with 95% confidence intervals. Treatment, body 
condition score (BCS), and disease category do not overlap with 0, thus representing 





Fig 4. Effect of selected variables on variance of the phospholipid profile on PC2 in 
plasma. Fixed effects are plotted with 95% confidence intervals. The interaction between 
treatment and disease category, age, body weight, and treatment do not overlap with 0 and 
thus significantly affect the variance of the phospholipid composition (ANOVA p < 0.05). 





Random forest analysis revealed several phospholipids with the highest discriminatory power 
between disease categories and between treatment statuses within one disease category. 
Figs 5-7 depict the 15 most important phospholipids each that separate either between 
disease categories (Fig 5) or treatment statuses (Figs 6 and 7). 
Fig 5. Random forest analysis of phospholipids and their association with disease 
category. Fifteen phospholipids with the highest discriminatory power between the disease 
categories are presented. The abundance of the phospholipids is color-coded, with red 
boxes representing a high abundance and green boxes representing a low abundance of a 
given phospholipid. PC, phosphatidylcholine; SM, sphingomyelin; PI, phosphatidylinositol; 
PE, phosphatidylethanolamine; PG, phosphatidylglycerol. 'A' indicates an ether species; the 
XX:y notation specifies the total number of carbon atoms in the radyl chains ('XX') followed 






Fig 6. Random forest analysis of phospholipids and their association with treatment in 
IBD. The 15 top phospholipids based on their importance to discriminate between the 
treatment statuses of dogs with IBD are shown. Red boxes represent a high abundance, 
green boxes a low abundance of a given phospholipid. PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; 'A' indicates an ether species; the XX:y notation specifies the 







Fig 7. Random forest analysis of phospholipids and their association with treatment in 
FRD. The 15 top phospholipids based on their importance to discriminate between the 
treatment statuses of dogs with FRD are shown. Red boxes represent a high abundance, 
green boxes a low abundance of a given phospholipid. PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; 'A' indicates an ether species; the XX:y notation specifies the 





This is the first study to investigate the systemic phospholipid profile in samples from dogs 
diagnosed with IBD or FRD and to evaluate changes in the phospholipid profile following the 
initiation of treatment in these dogs. Significant differences were observed in the 
phospholipid profiles in dogs with CIE, especially between the two different types of 
specimen used (whole blood vs. plasma), disease category (IBD vs. FRD), and treatment 
status. An explanation for the distinct phospholipid profiles in whole blood and plasma 
samples as discovered by PCA could be the difference in the number of cells within these 
sample types. As lipids, including phospholipids, are essential components of cellular 




composition between whole blood (which contains erythrocytes, leukocytes, and platelets) 
and plasma (which is essentially devoid of these cells but contains lipoproteins). An influence 
of different packed cell volumes or numbers of leukocytes of the patients on the findings of 
this study can currently not be fully excluded. In the current study, slightly more significant 
effects were found in plasma samples than in whole blood samples. This finding, in addition 
to a generally better storage stability of plasma [72] as well as less disturbance of the 
interpretation due to a lower number of unrelated lipids present in the cell membranes, 
leaves – in the authors’ opinion – plasma the preferable sample type for future studies on the 
phospholipid profile. 
Overall, treatment and disease category were the most significant variables affecting the 
phospholipid profiles. A significant shift of PC species was detected from PC 38:4 (18:0/20:4) 
before treatment to the corresponding lysolipid PC 18:0 after treatment. The loss of 
arachidonic acid (20:4) from the sn-2 position after initiation of treatment might be explained 
by an activation of phospholipase A2 and thus the liberation of arachidonic acid as a 
precursor for the synthesis of pro-inflammatory (e.g., prostaglandins and leukotrienes) or 
anti-inflammatory mediators (e.g., lipoxins and resolvins) [73-75]. Clinical improvement of 
most of the dogs after treatment would also render a shift towards anti-inflammatory 
mediators a likely explanation. Furthermore, therapeutic intervention in this study involved an 
elimination diet based on fish with additional enrichment of PUFAs. PUFAs have been shown 
to exert several anti-inflammatory actions [47,48,51,76]. Amongst others they decrease the 
production of arachidonic acid-derived pro-inflammatory eicosanoids (e.g., prostaglandin E2, 
4-series leukotrienes) in favor of anti-inflammatory eicosanoids (e.g., prostaglandin E3, 5-
series leukotrienes) and they generate further anti-inflammatory mediators such as resolvins 
and protectins [47,48,75,77]. Thus, the shift to lysoPC 18:0 after treatment might represent 
an increase in anti-inflammatory mediators, which may be associated with the amelioration of 
clinical signs observed in the dogs after treatment. 
The significant effect of disease category on the phospholipid profile found in this study is 
interesting and might be due to the severity of the disease. This theory is supported by 
finding that the significant effect of treatment on the phospholipid profile in whole blood (see 
above) was linked to disease category, being largest for dogs diagnosed with IBD with PLE. 
Clinical severity usually increases from FRD to IBD to IBD with PLE [3,5]. Thus, the loss of 
20:4 from PC appears to be largest in dogs with the most severe clinical signs. It also 
appears to be reasonable to assume that the amount of anti-inflammatory mediators required 
to counteract inflammation is higher with more severe disease. In the current study, disease 
severity and also clinical improvement were judged using the CIBDAI score. The canine 




included the additional criteria hypoalbuminemia, assessment of ascites, peripheral edema 
and pruritus, was introduced during the current study in 2007 [5], and an attempt was made 
to use this index for the present investigation. However, as a proper retrospective 
assessment of the dogs enrolled in this study prior to the CCECAI score’s publication was 
not possible, and in order to obtain comparable results for all dogs, the CCECAI score was 
not further assessed in this study. 
Age has been shown to affect the lipid profile [78,79]. In this study, dogs with IBD are 
significantly older than dogs with FRD. Hence, this difference in age could also have 
contributed to the significant effect of disease category on the phospholipid profile. However, 
dogs diagnosed with IBD have generally been reported to be older at the time of diagnosis 
than dogs diagnosed with FRD [3,5] and so, these study dogs represent a typical group of 
patients in a realistic clinical setting. Although age-matched study groups would have been 
desirable, the authors still consider the comparison of their representative groups of patients 
justifiable. 
Random forest analysis identified some phospholipids which contribute to the separation of 
disease category and treatment status. When evaluating the different disease categories, 
sphingomyelin species were shown to be differentially abundant in dogs with FRD. 
Sphingomyelin has been reported to promote apoptosis in intestinal epithelial cells and to 
increase inflammation in mice with induced colitis [80]. The relevant abundance of 
sphingomyelin species in dogs with FRD could thus result from the inflammatory process of 
dogs with CIE. Yet, this finding raises the question why sphingomyelin was found to be of 
importance only in the least severe disease category. The authors, unfortunately, do not 
have a plausible explanation for this finding at the moment. Also, phosphatidylcholine 
species were important to differentiate between treatment statuses both in dogs with IBD and 
FRD. Former studies have demonstrated phosphatidylcholine to possess anti-inflammatory 
properties and to be beneficial in humans with ulcerative colitis [61,81]. Moreover, patients 
with ulcerative colitis were reported to have significantly lower levels of phosphatidylcholine 
and lysophosphatidylcholine compared to healthy controls [82,83]. In the current study, 
lysophosphatidylcholine species were also significantly relevant to differentiate between 
treatment statuses in dogs with FRD, with lysophosphatidylcholine species being important 
after treatment. As all dogs with FRD improved clinically after treatment, this finding is in line 
with previous studies. However, overall, the true relevance of the phospholipids identified on 
random forest analysis in the pathogenesis of CIE still remains elusive. 
In the current study, the BCS only appeared to influence the phospholipid profile to some 
degree in whole blood, whereas body weight (but not BCS) presented a significant predictor 




between obesity and variations in the lipid profile. While one study found no significant 
difference in total cholesterol concentrations between obese dogs and lean controls [84], 
other studies did reveal a clear discrepancy in both cholesterol concentration and lipoprotein 
profiles when comparing overweight to healthy dogs [79,85]. Mori et al. also suggested that 
changes in plasma lipoprotein concentrations are more significant in older dogs with obesity 
(> 8 years of age) and that – as already mentioned above – both age and gender 
independently affect lipoprotein concentrations. Those findings are also in accordance with 
other studies [78,86]. In addition, lipid metabolism has been reported to be potentially 
influenced by breed [78]. The low impact of BCS and body weight on the phospholipid profile 
observed in the current study might be explained by the fact that the majority of dogs were 
assigned a BCS between 4/9 and 6/9 at their initial visit, representing a similar and close to 
ideal BCS in most dogs. Furthermore, as only three dogs were assigned a BCS ≥ 7/9, the 
influence of obesity could not be evaluated in this study cohort. Also, more advanced 
diagnostics to determine body fat (e.g., measured by dual-energy x-ray absorptiometry) were 
not performed in this study. Contrary to previous studies, sex had no effect on the lipid profile 
in the present study. Neither did the effect of breed reach significance, even though this was 
the most crucial effect on variance on PrComp1 in whole blood samples. The difference 
between our findings and those of others might be explained by the focus on different types 
of lipids. Whereas the current study examined phospholipids, former studies have mostly 
investigated concentrations of cholesterol and lipoproteins. 
The lack of a control group presents a limitation of this study. However, previous studies 
have already evaluated the lipid profile in healthy dogs [84,87-91] and the main objective of 
the current study was to describe and compare the phospholipid profile of dogs with IBD or 
FRD before and after treatment. Nevertheless, a control group of dogs with CIE receiving the 
same treatment but short of PUFAs would have allowed for assessing the sole effect of 
supplemental PUFAs on the phospholipid profile and the dogs’ clinical response. The stability 
of fatty acids during storage poses an additional limitation, as recent studies have reported 
fatty acids to be affected by degradation during long-term storage and have revealed storage 
at -80 °C to be the most stabilizing [72,92-94]. In this study, all samples had been stored 
frozen at -20 °C for approximately 10 years without discontinuity of the cooling chain. To the 
authors’ knowledge, the exact mechanisms and kinetics of phospholipid degradation over a 
period of ten years have not been reported, but a similar risk of degradation is most likely for 
the current samples because all samples were subjected to the exact same storage 
conditions. An increase in lysolipids due to degradation cannot be excluded in this study, but 
the effect of storage on the phospholipid profile represents a methodic error, leaving – in the 
authors’ opinion – the findings of this study (e.g., significant variance of the phospholipid 




cohort of our investigation. A larger number of dogs might have revealed a more distinct 
phospholipid signature in each disease group and with response to treatment. However, the 
number of dogs in this study was clearly affected by both the ethical aspect of performing a 
repeat endoscopy in dogs that had clinically improved as well as the willingness of the 
owners to consent to repeat examinations. 
In addition, a confounding effect of the different time period between pre- and post-treatment 
evaluation in the two disease groups cannot be excluded in this study. However, as the 
treatment with immunosuppressant medication in dogs with IBD was started 14 days after 
the dietary modification and based on the absence of clinical improvement on the diet alone, 
those dogs had to be allowed more time to respond to treatment. Clinical signs in dogs with 
FRD typically improve faster on appropriate treatment, while dogs needing 
immunosuppressant treatment can take longer to respond. Thus, the different time scales 
were necessary to ensure correct classification of the disease status and were also chosen 
according to previous studies [5,11,62]. 
The duration of the elimination diet trial was set to 14 days. Potentially, few dogs with FRD 
could have not yet responded within that time period. However, this duration was chosen for 
the dietary trial according to current consensus that dogs with FRD typically show significant 
clinical improvement within 14 days of a strict dietary trial [3,5,95,96]. In addition, this time 
frame assisted with proper owner compliance. Similarly, few dogs with IBD may have 
improved on the diet at first and thus, could have been incorrectly classified as FRD. 
However, despite dietary modification being important in the management of canine IBD, it is 
the authors’ experience that dogs with IBD respond only to a certain extent to an elimination 
diet alone. Thus, it appears to be unlikely that dogs with IBD showed either significant 
improvement or clinical remission on the elimination diet resulting in incorrect classification. 
The histopathologic score was assigned in this study according to a publication by Jergens et 
al. [65]. The World Small Animal Veterinary Association (WSAVA) Gastrointestinal 
Standardization Group released a new guideline for histopathological evaluation of 
gastrointestinal tissues in 2008 [97], which was revised and released as an ACVIM 
consensus statement in 2010 [10]. Similar to the extended clinical scoring system (CCECAI 
[5]), the 2008 WSAVA gastrointestinal histopathology guideline was not adopted during the 
course of the current study in order to apply the same histopathologic criteria to all dogs 
included. 
Glucocorticoids, regardless of endogenous or exogenous excess, have been recognized to 
cause hyperlipidemia in dogs, mainly reflected in a mild hypercholesterolemia and 
hypertriglyceridemia and increased very low density lipoproteins [38,84,86,98,99]. Similarly, 




hypercholesterolemia and increased serum concentrations of low density lipoprotein 
cholesterol [100-102]. Furthermore, glucocorticoids are known to modulate arachidonic acid 
metabolism and alter membrane phospholipids [103,104]. Hence, an effect of 
immunosuppressant medication on the phospholipid profile cannot be excluded. As 
immunosuppressants are crucial in the treatment of canine IBD, this influence on the results 
could not be avoided. Comparison of the findings in this study to the plasma phospholipid 
composition in a healthy cohort receiving the study diet together with an immunosuppressant 
could have helped distinguishing the effects of the disease from those of the 
immunosuppressant on the plasma phospholipid profile. However, the use of 
immunosuppressant medications in healthy pet dogs was considered unethical by the 
authors and would have been also very difficult to get approved by the local ethics 
committee. 
Finally, several studies have concluded that diet composition can considerably affect lipid 
metabolism and cholesterol concentrations [78,85]. A study by Jeusette et al. revealed that a 
nutritional modification to a high-protein low-energy diet had advantageous effects on plasma 
lipids in obese dogs [85]. Pasquini et al. described, amongst other findings, that serum 
cholesterol concentrations were the lowest in dogs fed a diet with a high content of fish. Also, 
diet composition has been shown to impact the phospholipid composition and characteristics 
of cell membranes (e.g., lipid rafts, membrane fluidity), rendering dietary phospholipids a 
potential therapeutic avenue [49,105,106]. Furthermore, an effect of the diet given prior to 
inclusion of a dog in the study on the pre-treatment systemic phospholipid profile remains a 
possibility. The dogs received a large variety of different diets including both dry and canned 
diets of various brands as well as home-made diets before entering the study. A 
standardization of the dogs’ diets prior to enrollment in this study would have been extremely 
difficult if not impossible due to the variety of previous diets as well as the medical situation 
of the dogs presented, often showing severe clinical symptoms and the owner’s 
understandably strong desire to obtain timely medical treatment – without first standardizing 
the patient’s diet for a longer period of time. Hence, a meaningful comparison of the 
nutritional content of previous diets and the study diet would have been ideal, but 
unfortunately was not feasible given the medical conditions of the dogs in this study. 
In summary, this is the first study to analyze the systemic phospholipid profile in dogs with 
IBD or FRD before and also after treatment. The severity of the disease and the effect of 
treatment most significantly determined the composition of the phospholipid profile, and a 
significant shift in the phospholipid species was observed after treatment (PC 38:4 to lysoPC 
18:0). These findings suggest that the phospholipid profile is an informative tool and might 




sample storage conditions are warranted to verify the results of this study in a larger group of 
dogs, to further investigate the association of different lipids with the pathophysiology of 
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S1 Fig. Base peak chromatogram of one of the samples. Base peak chromatogram of the 
separation by hydrophilic interaction liquid chromatography of phospholipids extracted from 
blood of a dog with FRD before treatment. Colored dots indicate retention time and m/z ratio 
of phospholipids detected by orbitrap ultrahigh resolution mass spectrometry. 
S2 Fig. Effect of treatment on the individual phospholipids. The dashed red horizontal 
line is located at p = 0.05, with dots above the line having p-values < 0.05; p values < 0.05 
considered as significant. 
S1 Table. Characteristics of the dogs with IBD (n=16) or FRD (n=16) included in the 
study. 
S2 Table. Raw peaklist of annotated phospholipids. Raw peaklist including the numbers 
of all 331 phospholipid signals in the samples analyzed. Phospholipids were annotated 
based on retention time and mass to charge (m/z) ratio. Phospholipids annotated with an '*' 
had a difference between theoretical and observed m/z of > 0.015 Da (but < 0.050) and 
should be considered 'tentatively identified'. Retention times and observed m/z values are 
included in the peaklist. Disease category: red = IBD; blue = IBD with PLE; green = FRD. 
S3 Table. Sample identification and patient information. 
S4 Table. P-values of effect of treatment, disease category and sample type on 
individual phospholipids. 
S1 File. Nutritional composition of the study diet. 
S2 File. Table of nutritional content (original in French). 







4.1 Objective of this Study 
The aim of this study was, first, to compare the mucosal microbiota in the duodenum and 
colon between dogs diagnosed with IBD and dogs with FRD. Secondly, the duodenal and 
colonic mucosal microbiota in each dog was evaluated before and after the induction phase 
of treatment in order to evaluate the possibility of an effect of treatment on the intestinal 
microbial composition. The third objective of our study was to comparatively investigate the 
systemic phospholipid profile (i.e., the lipidome) of dogs with FRD and dogs with IBD, both 
before and after treatment including supplemental PUFAs. 
Several studies have revealed alterations in the intestinal microbiota in dogs with IBD by 
examining fecal specimens (SUCHODOLSKI et al. 2012b, MINAMOTO et al. 2015, XU et al. 
2016) or brush cytology samples (XENOULIS et al. 2008). To date, only few studies have 
used endoscopic biopsy samples to assess the mucosal microbial composition in dogs with 
IBD, whereby these studies were focused either on the duodenum (SUCHODOLSKI et al. 
2010, SUCHODOLSKI et al. 2012a) or the ileum and colon (CASSMANN et al. 2016) only. 
To the author’s knowledge, this study is the first to evaluate the intestinal microbiota of dogs 
with IBD examining both duodenal and colonic mucosal biopsies. Additionally, it is the first 
study to compare the intestinal microbiota of dogs with IBD and FRD, and also with 
consideration of the treatment status. 
Furthermore, the lipid profile and potential alterations thereof have been the subject of a 
number of studies in healthy dogs (DOWNS et al. 1993, PASQUINI et al. 2008) and dogs 
with various diseases, such as hypertriglyceridemia (XENOULIS and STEINER 2015), 
endocrine disorders (BARRIE et al. 1993, SEAGE et al. 2018), obesity (JEUSETTE et al. 
2005), cancer (DILL et al. 2009, TAMAI et al. 2014), parvovirus infection (YILMAZ and 
SENTURK 2007), renal disease (BEHLING-KELLY 2014), and infection with Leishmania 
(GÜLTEKIN et al. 2017). However, these previous studies investigated mainly the serum 
concentrations of cholesterol and lipoproteins. To date, there is no report about the 
circulating lipid profile of dogs with chronic inflammatory enteropathies (CIE). Thus, the 
current study is the first to evaluate the systemic phospholipid profile in dogs with IBD or 
FRD both prior to and after the induction phase of treatment. 
Both materials and methods as well as the results of these studies have been released and 
also discussed in the two publications. This closing discussion aims to further elaborate on 






4.2 Important Aspects of the Evaluation of the Intestinal Microbiota in Dogs 
with IBD and FRD 
4.2.1 Further Discussion of the Results of the Microbiome Analysis 
The global species richness was not significantly different between dogs diagnosed with IBD 
and dogs with FRD, neither in the mucosa of the duodenum nor in the colon. Also, within 
each disease group, significant differences in species richness were neither seen before nor 
after the induction phase of treatment. Furthermore, no significant differences in the overall 
microbial communities were identified based on the clinical disease severity – assessed by 
the CIBDAI score – prior to treatment. This is in accordance with a previous study, which 
reported no significant differences in the global composition of the intestinal microbiota 
between dogs with severe IBD and dogs with moderate IBD (SUCHODOLSKI et al. 2012a). 
These findings may be explained by the fact that both IBD and FRD represent inflammatory 
conditions with overlapping histological features (DAY et al. 2008) that can only be 
differentiated based on the response to treatment (ALLENSPACH et al. 2016, DANDRIEUX 
2016). Thus, a comparable type and degree of histologic inflammation might affect the 
intestinal microbiome in a comparable manner. A lack of an association between the clinical 
disease activity score and histologic severity of disease (ALLENSPACH et al. 2007) would 
also be in line with finding no significant association between the overall microbial 
communities and the CIBDAI score. However, further studies are warranted to evaluate the 
intestinal microbiota of dogs with CIE in correlation to disease classification and the severity 
of microscopic intestinal disease. 
Despite no differences in the global intestinal microbial communities, several bacterial taxa 
were found to be enriched in the two disease groups of dogs when applying LEfSe, a 
statistical tool to identify biomarkers between groups based on relative abundances 
(SEGATA et al. 2011). Similar to previous studies (XENOULIS et al. 2008, SUCHODOLSKI 
et al. 2010, SUCHODOLSKI et al. 2012a, MINAMOTO et al. 2015), abundances of 
Proteobacteria differed among dogs with CIE in our study. On the one hand, abundances of 
members of this phylum differed between both disease groups (e.g., unclassified genus of 
Neisseriaceae in the duodenum of dogs with IBD, Bilophila spp. in the duodenum of dogs 
with FRD). On the other hand, abundances of bacterial taxa within this phylum differed within 
each disease group and also based on the treatment status. Proteobacteria were found to be 
enriched, for example, in the duodenum of dogs with FRD (e.g., Delftia spp.) and in the colon 
of dogs with IBD (e.g., Citrobacter spp., Burkholderia spp.) before treatment when compared 
to their numbers after treatment. Finding Proteobacteria in large quantities is not surprising 
as they belong to the most abundant phyla in the gastrointestinal tract of healthy dogs 




the increased presence in both the duodenum and colon of dogs with FRD and dogs with 
IBD before treatment might suggest a causative role in the development of CIE. One variant 
of a novel family of Burkholderiales, for example, was associated with perianal Crohn’s 
disease in humans (SIM et al. 2010). Burkholderia spp. also represented a member of 
Proteobacteria that was more abundant in dogs with FRD and in dogs with IBD before 
treatment in this study. However, in the study by SIM et al. (2010), the disease-associated 
variant was identified in the ileal mucosa, whereas in the current study, Burkholderia spp. 
was detected in the colonic mucosa of dogs both with FRD and IBD. Also, lack of 
identification of the exact strain of Burkholderia spp. in the current study does not allow for 
further conclusions and leaves room for future investigations on the role of Burkholderia spp. 
in canine chronic enteropathies. 
The genus Bacteroides spp. was abundant in the colon of dogs with FRD and also in dogs 
with IBD after treatment. Members of Bacteroidia have been identified more commonly in 
healthy dogs than in dogs diagnosed with IBD (XENOULIS et al. 2008, MINAMOTO et al. 
2015, CASSMANN et al. 2016). Thus, our finding of increased abundances of 
Bacteroides spp. post-treatment might reflect a positive response to treatment and a trend 
towards amelioration of the disease. Conversely, certain strains of Bacteroides spp. also 
express virulence factors (e.g., production of a polysaccharide capsule, biofilm formation, 
modification of surface polysaccharides with resultant evasion of host immune system, 
expression of virulent proteases, and production of enterotoxins) (WEXLER 2007, REIS et al. 
2014) and can potentially promote abscess formation via their polysaccharide capsule 
(WEXLER 2007). The latter proves to be a particular risk in human patients (WEXLER 2007) 
but – to the author’s knowledge – this has not been reported to be a common clinical finding 
in dogs. Despite their potential virulence factors, it should be emphasized that 
Bacteroides spp. play a central role in the microbial degradation of carbohydrates (FLINT et 
al. 2012). Short-chain fatty acids, such as acetate, propionate, and butyrate, are essential 
factors for the host’s intestinal health due to the provision of energy (NEISH 2009, 
SWANSON et al. 2011), regulation of intestinal motility (SUCHODOLSKI 2016), and anti-
inflammatory properties (ARPAIA et al. 2013). Lastly, certain species of Bacteroides play a 
role in intestinal bile acid deconjugation and therefore are of additional benefit to the host 
(PAVLIDIS et al. 2015).Thus, altogether the overrepresentation of Bacteroides spp. in dogs 
with CIE after treatment in the current study leads the author to propose that 
Bacteroides spp. should be seen as “a friend” rather than “a foe”. In addition, the quantitative 
identification of Bacteroides spp. might be a marker of the response to treatment. However, 





4.2.2 Critical Appraisal of the Study’s Protocol 
A diagnosis of IBD requires chronic gastrointestinal signs, histologic evidence of mucosal 
inflammation, exclusion of any other underlying disorder that can mimic the clinical signs of 
IBD, and the need for anti-inflammatory and / or immunosuppressive treatment after failure to 
respond to appropriate therapeutic (e.g., antiparasitic, antimicrobial) treatment and at least 
three to four weeks of an elimination dietary trial (WASHABAU et al. 2010, SIMPSON and 
JERGENS 2011, ALLENSPACH et al. 2016, DANDRIEUX 2016). In the current study, the 
dietary trial was performed for 14 days and dogs that did not respond significantly within that 
period were assigned to the IBD group. Usually, the clinical response to an elimination diet is 
observed within a few days in dogs with FRD, but in some dogs it may take up to 14 days or 
even longer (up to three to four weeks) for a clinical improvement to be noticed (MARKS et 
al. 2002, ALLENSPACH et al. 2007, GASCHEN and MERCHANT 2011, ALLENSPACH et al. 
2016). Therefore, some dogs with FRD might have been classified incorrectly as IBD in this 
study. However, the short duration of the dietary trial was chosen to ensure owner 
compliance. Because the majority of dogs with FRD respond within the chosen time frame of 
14 days (MARKS et al. 2002, ALLENSPACH et al. 2007, GASCHEN and MERCHANT 2011, 
ALLENSPACH et al. 2016), it is the author’s opinion that the benefit of owner compliance 
outweighs the risk of incorrect classification. A standardized antimicrobial trial was not 
included in the protocol of this study. While some studies have reported antibiotics to be 
effective for the treatment of chronic diarrhea (WESTERMARCK et al. 2005, KILPINEN et al. 
2011, KILPINEN et al. 2014, KILPINEN et al. 2015), relapses of clinical signs after cessation 
of antimicrobial treatment are common (WESTERMARCK et al. 2005, ALLENSPACH et al. 
2016). Thus, the true usefulness of antibiotics in the treatment of CIE has been questioned. 
In addition, the rapid increase of antimicrobial resistance in recent years argues against the 
standard practice of such treatment trials. 
The endoscopic biopsy specimens used for this study were archived tissue samples that had 
been collected between 2006 and 2008 and were stored frozen until analysis. DNA is 
generally regarded as stable but it is still susceptible to hydrolysis, oxidation, and non-
enzymatic methylation (LINDAHL 1993). Growing interest in the human microbiome, the 
Human Microbiome Project (TURNBAUGH et al. 2007), required further study to find the 
ideal technique to preserve DNA. This led to research undertakings on the optimal 
processing and storage conditions of DNA for subsequent microbiome analysis (GORZELAK 
et al. 2015, KLYMIUK et al. 2016). One study evaluating the microbiome of skin swabs after 
storage for different time periods revealed differences in the relative abundance of certain 
bacterial genera that predominate on the skin and also in the numbers of certain main phyla 
between different storage durations (KLYMIUK et al. 2016). Hence, an effect of DNA storage 




efforts to standardize and improve microbiome analysis (SINHA et al. 2015), there are 
currently no guidelines about the processing of mucosal samples for subsequent microbiome 
analysis. In the current study, DNA was stored and handled to the best of our knowledge. 
DNA was extracted using the Mo Bio PowerSoil® DNA Isolation Kit. This method was also 
used in the Human Microbiome Project and is currently the most effective method of DNA 
extraction (WAGNER MACKENZIE et al. 2015). Thus, this method is currently recommended 
for extraction of DNA. In addition, further analysis of samples was performed at a highly 
respected laboratory in terms of microbiome analysis in companion animals (Gastrointestinal 
Laboratory, Texas A&M University, USA), minimizing unfavorable effects due to the handling 
of DNA. 
The influence of diet on the intestinal microbial composition has been reported both in 
humans and in companion animals (SCOTT et al. 2013, PINNA et al. 2016, HERSTAD et al. 
2017, LI et al. 2017). However, most of those studies revealing a dietary effect on the 
microbiome used diets with significant alterations in the composition of macronutrients, which 
does not compare to commonly used diets. Furthermore, one recent study showed that 
bacterial alpha diversity did not correlate with either dietary fat or protein intake in a 
population of dogs with IBD and control dogs (VÁZQUEZ-BAEZA et al. 2016), concluding 
that the disease effect is stronger than the diet’s effect on the microbial composition. Further, 
to minimize the possibility of a delayed or persistent effect of the previous diet on the 
intestinal microbiota, dogs in this study would have had to be fed a standardized diet for 
several weeks before inclusion in the study. This, however, is very difficult to realize in a 
clinical trial. Taking the findings of VÁZQUEZ-BAEZA et al. (2016) into account, the author 
considers the variation among dogs, especially in terms of their previous diet, a realistic and 
valuable feature for a clinical patient population. 
 
4.3 Important Aspects of the Evaluation of the Systemic Phospholipid Profile 
in Dogs with IBD and FRD 
4.3.1 Further Discussion of the Results of the Phospholipidome Analysis 
The phospholipid profile differed among samples dependent on the type of specimen (whole 
blood versus plasma), and among dogs based on the disease category and treatment status. 
The most relevant difference was found by principal component analysis (PCA) between 
whole blood and plasma samples. Phospholipids, and lipids in general, are essential 
constituents of cellular membranes (DE GIER and VAN DEENEN 1961, SCHROIT and 




than plasma, the lipids of which are mainly comprised of lipoproteins. Thus, the observed 
difference likely results from the different cellular contents in the two types of specimens. 
Altogether, treatment and disease category were found to be the most significant factors 
affecting the phospholipidome. As for the treatment status, a remarkable shift of 
phosphatidylcholine (PC) species was noticed from PC 38:4 (18:0 / 20:4) prior to treatment to 
the corresponding lysolipid PC 18:0 after treatment. Arachidonic acid (20:4) has been 
reported to be exclusively attached to the second carbon, also referred to as sn2-position, of 
the glycerol backbones of phospholipids (BEERMANN et al. 2005). The loss of arachidonic 
acid from the sn-2 position after initiation of treatment could potentially result from an 
activation of phospholipase A2, which releases arachidonic acid. Arachidonic acid, in turn, 
serves as a precursor for the synthesis of pro-inflammatory (e.g., prostaglandins and 
leukotrienes) and also anti-inflammatory mediators (e.g., lipoxins and resolvins) (KUEHL and 
EGAN 1980, SERHAN et al. 1984, BANNENBERG et al. 2005). The fact that the majority of 
dogs in our study showed considerable clinical improvement after the initiation of treatment 
might suggest such mechanisms (e.g., a loss of arachidonic acid in favor of anti-inflammatory 
mediators) to contribute to the amelioration of clinical signs. The treatment protocol in this 
study included an elimination diet based on fish, which was further enriched with dietary 
PUFAs. Several studies have evaluated the beneficial and anti-inflammatory effects of 
PUFAs of marine origin (SHORES et al. 2011, CALDER 2013, UNGARO et al. 2017, 
CHARPENTIER et al. 2018). PUFAs have been shown to reduce leucocyte chemotaxis and 
the expression of adhesion molecules, decrease the production of inflammatory cytokines, 
lower arachidonic acid-derived pro-inflammatory eicosanoids (e.g., prostaglandin E2, 4-series 
leukotrienes) in favor of anti-inflammatory eicosanoids (e.g., prostaglandin E3, 5-series 
leukotrienes), and decrease T cell reactivity (CALDER 2013, UNGARO et al. 2017). 
Furthermore, PUFAs can aid in the generation of additional anti-inflammatory mediators, 
such as resolvins and protectins (SERHAN et al. 2000, HONG et al. 2003, BANNENBERG et 
al. 2005). All of these beneficial characteristics of PUFAs support the hypothesis that the 
observed shift to lysoPC 18:0 after initiation of treatment reflects an increase in anti-
inflammatory mediators, which might contribute to the improvement of clinical signs seen in 
the dogs with CIE after treatment. 
Noteworthy is also the significant association of disease classification with the phospholipid 
profile observed in this study. A possible explanation for this finding could be the 
corresponding severity of the disease. Generally, clinical severity of canine CIE increases 
from FRD to IBD to IBD with PLE (ALLENSPACH et al. 2007, ALLENSPACH et al. 2016). 
This study found a significant effect of treatment on the phospholipidome in whole blood to 




with IBD with PLE. Hence, the loss of pro-inflammatory arachidonic acid might be greatest in 
those dogs with CIE that have the most severe clinical signs. Because the quantity of anti-
inflammatory mediators required to modulate or counteract inflammation is likely higher the 
more severe the disease process, it might explain that the largest effect (e.g., loss of 
arachidonic acid and the change in the phospholipid profile) is present in those dogs with the 
most severe clinical disease. 
The body condition score (BCS) only had a significant effect on the phospholipid profile in 
whole blood samples in PrComp2, and body weight (but not BCS) appeared to have some 
effect on the phospholipidome in plasma. However, both BCS and body weight only 
presented minor predictors of the phospholipid variance in this study, which is contrary to the 
results of previous studies. Those studies compared the lipidome of healthy and overweight 
dogs and identified a clear difference in both cholesterol concentration and lipoprotein 
profiles (JEUSETTE et al. 2005, MORI et al. 2011), particularly increased cholesterol and 
triglyceride concentrations in obese dogs (JEUSETTE et al. 2005). The low impact of BCS as 
well as body weight on the phospholipidome in the current study could be due to the fact that 
most of the dogs were assigned a similar and close to ideal BCS (BCS between 4/9 and 6/9) 
at their first visit. In addition, only three dogs had a BCS ≥ 7/9 and more advanced 
diagnostics to determine body fat (e.g., measured by dual-energy x-ray absorptiometry) were 
not performed in this study, rendering the evaluation of a potential effect of obesity 
impossible. Previous studies further reported age, gender, and breed to affect the lipoprotein 
concentrations of dogs (BARRIE et al. 1993, PASQUINI et al. 2008, MORI et al. 2011). While 
one study proposed more significant changes in plasma lipoprotein concentrations in older 
obese dogs (MORI et al. 2011), another study reported increased plasma concentrations of 
LDL-cholesterol in puppies and also increased cholesterol concentrations in certain breeds 
such as Rottweilers and Pyrenees Mountain dogs (PASQUINI et al. 2008). Different from 
those previous findings, neither gender nor breed had a significant effect on the lipid profile in 
the current study. However, it should be noted that despite not reaching statistical 
significance, the effect of breed was the most important effect on the phospholipidic variance 
on PrComp1 in whole blood specimens in the present study. A possible explanation for the 
discrepancy between our findings and those of previous studies could be the focus on 
different classes of lipids. While our study investigated primarily phospholipids, other studies 
mostly evaluated the plasma levels of cholesterol and lipoproteins. 
 
4.3.2 Effect of Diets on the Systemic Lipid Profile 
Similar to the effect of diet on the intestinal microbiota, a number of studies also suggest the 




1997, JEUSETTE et al. 2005, WRIGHT-RODGERS et al. 2005, PASQUINI et al. 2008). One 
study revealed that dogs receiving a diet with a high content of fish and fish by-products had 
the lowest serum cholesterol concentrations (PASQUINI et al. 2008). Another research group 
found that dietary modification to a high-protein low-energy diet resulted in a significant 
decrease in circulating cholesterol and triglyceride concentrations in obese dogs, and these 
beneficial effects on the plasma lipid profile were already present before any weight loss had 
occurred (JEUSETTE et al. 2005). Furthermore, diet composition has been reported to affect 
both phospholipid structure and characteristics of cellular membranes (e.g., lipid rafts, 
membrane fluidity), drawing attention to dietary phospholipids as a potential novel treatment 
option (MUELLER et al. 2004, GOLDBERG and KATZ 2007, MARION-LETELLIER et al. 
2013). Overall, an influence of the pre-study diet on the pre-treatment systemic phospholipid 
profile of dogs is likely in this study. Feeding a standardized diet for several weeks before the 
dogs’ enrollment in the study more likely would have avoided such a possible effect. 
Standardization of the diet, however, would have been very difficult, if not impossible, in the 
setting of a clinical trial. 
 
4.4 Outlook: Strategies for Novel Treatment Options in Dogs with CIE 
4.4.1 Prebiotics and Probiotics 
The discovery of disease-associated alterations in the microbial composition led to further 
research to find novel treatment options with the goal of modulating the intestinal 
microbiome. Thus, the use of pre- and probiotics has become a focus of several 
investigations (SCHMITZ and SUCHODOLSKI 2016, WHITTEMORE and SUCHODOLSKI 
2016). Probiotics are live microorganisms administered for their possible beneficial effects on 
the host, whereas prebiotics are dietary ingredients that are fermented by intestinal bacteria 
and can change the microbial composition and activity, again resulting in a benefit for the 
host (SCHMITZ and SUCHODOLSKI 2016). Synbiotics are mixtures of both pre- and 
probiotics (SCHMITZ and SUCHODOLSKI 2016). The exact mechanisms of how probiotics 
act to the benefit of the host are not fully understood, but probiotics have been shown to 
modulate the host’s immune system (e.g., by their metabolites, cell wall components, and 
DNA), affect other microorganisms directly (e.g., through production of bacteriocins or 
competition for substances and / or space), and also to affect microbial and host products 
(e.g., by inactivation of bacterial toxins or detoxification of dietary components) 
(OELSCHLAEGER 2010). One study reported preventative effects of probiotics in antibiotic-
associated diarrhea in humans (VIDELOCK and CREMONINI 2012). Short-term treatment 
with antibiotics can cause alterations in the fecal microbiota composition and an increase in 
antimicrobial resistance genes for up to several years in humans (JAKOBSSON et al. 2010). 




reported to outlast the period of antimicrobial administration in dogs (SUCHODOLSKI et al. 
2009). Thus, the potential to prevent antibiotic-associated adverse effects poses a major 
advantage for the use of probiotics. 
A large number of different probiotics is currently commercially available, but only four 
bacterial products have been investigated by the European Food Safety Authority for their 
efficient and harmless use in dogs: Enterococcus faecium NCIMB 10415 E1705, 
Enterococcus faecium NCIMB 10415 E1707, Lactobacillus acidophilus DSM 13241 25, and 
Bifidobacterium sp. animalis (SCHMITZ and SUCHODOLSKI 2016). Of these strains, only 
the two Entercoccus faecium strains have been considered reliably safe and efficient by the 
European Food Safety Authority (SCHMITZ and SUCHODOLSKI 2016). However, SCHMITZ 
et al. did not demonstrate any effect on clinical severity score, histologic lesion score, or the 
expression of inflammasome genes in dogs with CIE when administered the probiotic 
Entercoccus faecium NCIMB 10415 E1707 (SCHMITZ et al. 2015a, SCHMITZ et al. 2015b), 
thus questioning the true efficacy of this product. In general, the number of studies evaluating 
and providing evidence of true efficiency of probiotic strains in the clinical setting is currently 
rather small, especially in the treatment of canine chronic enteropathies. One ex-vivo study 
showed favorable effects of a probiotic mixture of two Lactobacillus acidophilus strains and 
one Lactobacillus johnsonii strain on regulatory cytokines in dogs with CIE, which have the 
potential effect to ameliorate inflammation (SAUTER et al. 2005). A later in-vivo study of the 
same research group, however, showed that such effects of probiotics on inflammatory 
cytokines were inconsistent in dogs with FRD (SAUTER et al. 2006). This discrepancy 
emphasizes the need of well-designed and sufficiently powered clinical trials to allow for 
more definitive conclusions about the benefit of probiotics. A probiotic mixture with VSL#3 
strains has been reported to show efficacy in the treatment of ulcerative colitis in humans 
(BIBILONI et al. 2005). VSL#3 is a probiotic product that contains four strains of 
Lactobacilllus spp. (L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii subsp. 
bulgaricus), three strains of Bifidobacterium spp. (B. longum, B. breve, B. infantis), and one 
strain of Streptococcus sulivarius subsp. thermophilus (ROSSI et al. 2014, SCHMITZ and 
SUCHODOLSKI 2016). Recently, the use of VSL#3 strains was compared to a treatment 
protocol with prednisolone and metronidazole in dogs with IBD (ROSSI et al. 2014). That 
study showed effectiveness of the VSL#3 strains, with a decrease in clinical disease activity, 
histologic lesion score, and the number of intestinal CD3+ T lymphocytes. The increase of a 
regulatory T cell marker (FoxP3+) in the probiotic group further supports the existence of 
protective effects of VSL#3. Additionally, an increase in Faecalibaterium spp. was only 
observed in those dogs treated with VSL#3 (ROSSI et al. 2014). Because a decrease in 
Faecalibacterium spp. has been associated with intestinal dysbiosis (MIQUEL et al. 2013), 




clinical use of VSL#3 strains in dogs with chronic enteropathies. It is noteworthy that, despite 
the finding that a decrease of Faecalibacterium spp. has been associated with intestinal 
dysbiosis (SOKOL et al. 2008, MIQUEL et al. 2013) and despite the proposed use of this 
bacterium as a probiotic in human medicine (SOKOL et al. 2008, MARTÍN et al. 2015), there 
is – to the author’s knowledge – currently no study evaluating strains of 
Faecalibacterium spp. as probiotics in dogs. 
In the current study, Bacteroides spp. presented at significant abundance in the colon of 
dogs with FRD and IBD after treatment. In addition to their possible virulent effects 
(WEXLER 2007), Bacteroides spp. have generally been recognized to play an important role 
for the host because of their involvement in carbohydrate degradation and bile acid 
deconjugation (FLINT et al. 2012, PAVLIDIS et al. 2015). Furthermore, Bacteroides fragilis 
has been shown to possess immunoregulatory properties (DENG et al. 2016) and to protect 
animals from experimental colitis (MAZMANIAN et al. 2008). Likewise, Bacteroides uniformis 
has been reported to have a higher prevalence in breast-fed infants with a lower risk to 
develop celiac disease compared to those with a higher genetic risk (SÁNCHEZ et al. 2011). 
The strain B. uniformis CECT 7771 has further been reported to ameliorate metabolic and 
immune dysfunction induced by a high fat diet (GAUFFIN CANO et al. 2012). Because of all 
of these promising findings, Bacteroides spp. have recently attracted attention with regard to 
their value as a probiotic. However, to the author’s knowledge, no study has assessed 
strains of Bacteroides spp. as probiotics in dogs to date. Since probiotic qualities of bacteria 
are strain specific (LIN et al. 2009, SCHMITZ and SUCHODOLSKI 2016), and the bacterial 
species was the lowest identified bacterial taxon in the current study, no definitive 
conclusions can be drawn from the high abundance of Bacteroides spp. after treatment in 
this study. However, considering all aspects outlined above, the author regards 
Bacteroides spp. and also Faecalibacterium spp. as promising bacteria that warrant further 
evaluation for their potential clinical utility as a probiotic. 
One study demonstrated that probiotic strains of a synbiotic mixture (a blend of seven strains 
of lactic acid bacteria, fructooligosaccharides, and arabinogalactans), that was given to 
healthy dogs and cats, could be detected in the feces in almost all dogs and cats during the 
time of synbiotic administration, but neither before nor after the administration (GARCIA-
MAZCORRO et al. 2011). Furthermore, despite a significant increase in the abundance of 
two of the probiotic strains at some time point during the administration of the synbiotic 
(Enterococcus spp., Streptococcus spp.), no changes in the major bacterial phyla were 
observed (GARCIA-MAZCORRO et al. 2011). These findings suggest that the administration 





To conclude, probiotics may be a promising option in the prevention of antibiotic-associated 
diarrhea, and certain probiotic strains might be beneficial in the treatment of CIE. However, 
more studies are needed to fully understand the mutual reaction of probiotic bacteria and the 
host’s distinct microbiome and to identify and further evaluate more specific bacterial strains 
that are able to affect the host in a beneficial but more sustained manner. 
 
4.4.2 Fecal Microbiota Transplantation 
The current lack of a lasting effect and the necessity to affect the intestinal microbial 
composition more extensively than has been achieved by single bacterial strains has drawn 
the attention to the concept of fecal microbial transplantation. Fecal microbiota 
transplantation (FMT), also referred to as fecal bacteriotherapy, is defined as “administration 
of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to 
directly change the recipient’s microbial composition and confer a health benefit” (GUPTA et 
al. 2016). Albeit being in its infancy, this treatment modality has gained importance in the 
treatment of recurrent Clostridium difficile infections in humans with a cure rate of nearly 90% 
(GOUGH et al. 2011, KASSAM et al. 2013, KELLY et al. 2015, GUPTA et al. 2016). In 
addition, FMT has recently been used in the treatment of human IBD with a clinical remission 
rate of approximately 36% and an overall good tolerance (COLMAN and RUBIN 2014). 
Sporadically, FMT has also been used in the treatment of irritable bowel syndrome (KELLY 
et al. 2015, GUPTA et al. 2016) and has been advocated for the treatment of obesity, 
metabolic syndrome, and diabetes mellitus (VRIEZE et al. 2012, KELLY et al. 2015, GUPTA 
et al. 2016). However, validated clinical data on these latter indications for FMT is limited 
rendering definite conclusions currently impossible. 
To date, studies evaluating the use of FMT in companion animals are still scarce and are 
limited to anecdotal reports (CHAITMAN et al. 2016). In one study, three dogs with antibiotic-
responsive diarrhea received FMT from the same donor dog resulting in a shift of the fecal 
microbial composition towards that of the donor and an improvement of the microbial 
diversity in all three dogs. However, a true clinical response was only seen in two dogs 
(GERBEC 2016). One case report of a dog with eosinophilic IBD revealed that the dog’s 
fecal consistency had improved within 24 hours, and species richness of the fecal microbiota 
resembling the donor’s microbiota had increased within two days after FMT (WEESE et al. 
2013). Another study including eight dogs with refractory Clostridium perfringens-associated 
diarrhea reported an immediate resolution of diarrhea in all dogs and negative results on 
follow-up PCR panels for Clostridium perfringens-alpha toxin in 6 of 8 dogs after FMT 
(MURPHY et al. 2014). Furthermore, a current study on FMT in puppies with acute 




standard treatment yielded a faster resolution of diarrhea and a shorter time of patient 
hospitalization when compared to standard treatment alone. That study also reported FMT to 
be safe and well tolerated (PEREIRA et al. 2018). Thus, FMT appears to be a feasible and 
promising treatment option, especially in clinical cases where standard treatment protocols 
fail. Without doubt, larger-scale standardized prospective treatment trials are needed to 
investigate the true value of FMT and allow for general recommendations on the selection of 
donors, processing, and administration of FMT. 
 
4.4.3 Health-Promoting Effects of Phospholipids and Polyunsaturated Fatty Acids 
Phospholipids are amphiphilic lipids present in all cellular membranes of animals and plants 
(KÜLLENBERG et al. 2012). Glycerophospholipids represent the most prevalent 
phospholipids in biological membranes and are composed of a glycerol backbone with three 
carbons, fatty acids that are esterified to carbon 1 and 2, and a phosphate group with a 
hydrophilic residue (e.g., choline or inositol; resulting in phosphatidylcholine or 
phosphatidylinositol) esterified to carbon 3 (KÜLLENBERG et al. 2012, YAMASHITA et al. 
2014). Glycerophospholipids found in food products such as dairy products, eggs, meat, 
seafood, and soybeans are classified as dietary glycerophospholipids (LORDAN et al. 2017). 
These dietary phospholipids usually have a saturated fatty acid on their first carbon (sn-1), 
while unsaturated fatty acids, such as oleic acid, arachidonic acid, or eicosapentaenoic acid 
(EPA), are located on the sn2-position. Because of the abundance of glycerophospholipids in 
biological membranes, their fatty acid composition has a major effect on membrane quality 
and stability (KÜLLENBERG et al. 2012). Furthermore, it has been shown that fatty acids 
provided by dietary phospholipids can be incorporated into cellular membranes (TAYLOR et 
al. 2010). Thus, dietary glycerophospholipids are able to alter the fatty acid composition of 
biological membranes, allowing for their ability to modulate cellular functions (e.g., signaling 
and transport) and membrane-bound enzymes (KÜLLENBERG et al. 2012, LORDAN et al. 
2017). This ability is likely one reason for the positive effects on health that have been 
attributed to dietary phospholipids in several diseases in humans (KÜLLENBERG et al. 
2012). Dietary phospholipids, for example, have been shown to lower cholesterol levels 
(COHN et al. 2010) and to be effective adjuvants in the treatment of liver disease 
(POONGOTHAI et al. 2005, GUNDERMANN et al. 2011, GUNDERMANN et al. 2016). 
Furthermore, phosphatidylcholine derivatives in cheese and yogurt have been reported to 
have antithrombotic, anti-inflammatory, and cardioprotective properties (TSOROTIOTI et al. 
2014, MEGALEMOU et al. 2017). Another group of researchers also showed that soybean 
phosphatidylcholine can reduce the risk of cardiovascular disease by decreasing plasma 
concentrations of homocysteine, which in high concentration is suspected to be associated 




revealed beneficial effects of phospholipids in patients diagnosed with cancer. Those effects 
include the potential to inhibit tumor growth and metastasis (HOSSAIN et al. 2008, 
SAKAKIMA et al. 2009, JANTSCHEFF et al. 2011, KÜLLENBERG et al. 2012). Another 
study demonstrated that oral supplementation of phospholipids for several weeks was 
associated with a stabilization of body weight with improved appetite and quality of life in 
cancer patients (TAYLOR et al. 2010). In addition, the glycerophospholipid composition of 
neural membranes has been shown to be altered in neurological disorders and aging, with 
the amount of phosphatidylcholine, phosphatidylserine, and PUFAs in the brain being of 
greatest importance (FAROOQUI et al. 2000, KÜLLENBERG et al. 2012). Hence, several 
studies have investigated the potential benefits of administering phospholipids to patients 
with neurological disorders. Those studies led to the current consensus that supplementation 
of phospholipids, particularly of phosphatidylserine, can significantly improve cognition, 
memory function, and also the general mood (LOUIS-SYLVESTRE 1999, BENTON et al. 
2001, RICHTER et al. 2013). Thus, phospholipids hold promising health-promoting effects, 
ostensibly without severe adverse effects. The exact mechanisms of these beneficial effects 
are currently not completely understood, but some effects can be attributed to fatty acids, 
particularly polyunsaturated fatty acids, delivered by phospholipids. As outlined above, 
phospholipids primarily contain PUFAs on their sn2-position, and can be cleaved from that 
position and made available for further conversion and cellular processes (KÜLLENBERG et 
al. 2012, LORDAN et al. 2017). 
Polyunsaturated fatty acids have been recognized to play a role in inflammatory processes, 
with the omega-6 PUFA arachidonic acid and the omega-3 PUFAs eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) being of vital importance (CALDER 2013). While 
eicosanoids derived from arachidonic acid (e.g., several prostaglandins, thromboxane A2, 
leukotriene E4) are mainly pro-inflammatory, eicosanoids generated from EPA and DHA 
(e.g., resolvins, leukotriene E5, protectins) are usually less immunostimulatory and have 
rather anti-inflammatory properties. Besides competing against arachidonic acid metabolites, 
the latter substances also impede leukocyte chemotaxis, interfere with endothelial adhesion, 
reduce cytokine synthesis, and affect T cell function (CALDER 2010, BARBALHO et al. 
2016, UNGARO et al. 2017). Thus, PUFAs have been widely used as dietary supplements in 
both human and veterinary medicine as adjuvant treatment modalities in various disorders 
(SIMOPOULOS 2002, BAUER 2011, CALDER 2013). In human medicine, attention has 
recently also been turned to possible benefits of omega-3 PUFAs in patients with IBD, and 
several studies support their clinical use (CALDER 2013, BARBALHO et al. 2016, UNGARO 
et al. 2017, CHARPENTIER et al. 2018). One study, for example, showed that omega-3 
PUFAs are protective against oxidative stress in patients with ulcerative colitis (BARBOSA et 




Crohn’s disease (CHAN et al. 2014). On the other hand, a number of studies have failed to 
confirm a true clinical benefit of omega-3 fatty acids in patients with IBD (CALDER 2013, 
BARBALHO et al. 2016), such as one study that could not identify a beneficial effect of 
omega-3 PUFAs on the risk of relapse of active Crohn’s disease (FEAGAN et al. 2008). 
Thus, evidence of a true therapeutic benefit of omega-3 PUFAs in human IBD is still lacking. 
In veterinary medicine, PUFAs are commonly administered in the treatment of cardiovascular 
disease, renal disease, ostheoarthritis, and canine atopic dermatitis (MUELLER et al. 2004, 
OLIVRY et al. 2010, BAUER 2011, BAUER 2016). When used to treat atopic dermatitis, 
PUFAs seem to also have a cyclosporine-sparing effect alongside their anti-inflammatory 
properties (MÜLLER et al. 2016). Furthermore, when highly enriched in the diet, DHA might 
favorably affect cognitive, retinal, and immunologic functions in young dogs (ZICKER et al. 
2012). However, only few studies have investigated the potential benefits of PUFAs in the 
treatment of canine chronic enteropathies to date. One study reported significantly altered 
intestinal mucosal mRNA levels of membrane proteins involved in cholesterol homeostasis 
after feeding dogs a diet supplemented with PUFAs. These alterations in mucosal gene 
expression have been suggested to improve cellular cholesterol metabolism, thus having a 
positive effect in dogs with IBD (ONTSOUKA et al. 2010). The same group of researchers 
also reported significant differences in the mucosal abundance of genes regulating fatty acid 
uptake in dogs fed an omega-3 PUFA-enriched diet. These differences, again, suggest a 
benefit in dogs with CIE, especially for those diagnosed with FRD (ONTSOUKA et al. 2012). 
Therefore, both studies support the addition of omega-3 PUFAs to the treatment plan of dogs 
with CIE. However, PUFAs can also have adverse effects, for instance, by altering platelet 
function, causing diarrhea and vomiting, and impairing immune function (LENOX and 
BAUER 2013). In the present study, the PUFA-enriched diet was well-tolerated with no 
evidence of side effects. Nonetheless, the possibility of a sole effect of supplemental PUFAs 
on the phospholipid profile and the dogs’ clinical improvement cannot be assessed based on 
the results of this study because of the lack of a control group of dogs with CIE receiving the 
same treatment but short of PUFAs. Thus, no conclusion on the particular benefit of PUFAs 
in the treatment of canine CIE can be drawn from the findings of this study. Additional 
research is warranted to further explore the potential benefit of administering omega-3 






This study identified some differences in individual bacterial taxa both between the disease 
groups of dogs with IBD and FRD and also with regard to the treatment status. The 
relevance of these bacterial groups in the pathogenesis of IBD and FRD is currently 
unknown. Further larger-scale studies are warranted to shed more light on the role of the 
intestinal microbiota in the pathophysiology of different CIE forms and to evaluate their 
potential therapeutic benefit. In the author’s opinion, especially Bacteroides spp. should be a 
focus of future studies and can potentially serve as a marker of treatment response. 
 
This study further detected significant variances in the systemic phospholipid profiles of dogs 
with IBD and dogs with FRD. These variances were predominantly associated with the type 
of specimen used, clinical disease severity, and treatment status. After initiation of treatment, 
a shift of phospholipid species from phosphatidylcholine PC 38:4 (18:0 / 20:4) towards 
lysophosphatidylcholine 18:0 was identified, which likely represents a loss of arachidonic 
acid. This loss of arachidonic acid likely happens in favor of anti-inflammatory mediators 
contributing to the amelioration of clinical signs. Thus, the loss of arachidonic acid might 
indicate disease amelioration. Future studies should further investigate the role of lipids in 
the pathophysiology of IBD and FRD. 
The search for novel extended-effect treatment options has drawn attention to the 
modification of the intestinal microbiota and the administration of dietary phospholipids. 
Preliminary studies revealed promising results on the use of the probiotic mixture VSL#3, 
FMT, and dietary phospholipids, specifically PUFAs, in the treatment of canine CIE. Again, 
more standardized studies are needed in order to further evaluate the safety and true clinical 
efficacy of these therapeutic approaches. 
In conclusion, this study aimed to assess both the intestinal mucosal microbiota and the 
systemic phospholipid profile in dogs diagnosed with IBD and FRD, and to evaluate potential 
differences associated with the treatment status. Though not a large number of differentiating 
bacterial species and phospholipids was detected, this study revealed some important 
factors and differences in the mucosal microbiota and the phospholipid profile. This study 
showed an increase of Bacteroides spp. and a shift towards lysophosphatidylcholine 18:0 – 
with a loss of arachidonic acid – after treatment. Both findings hold potential to serve as 
indicators of disease amelioration and as indicators of treatment response. This study should 
be considered a pilot study, encouraging future large-scale studies to confirm our findings 
and to further our understanding of the role of the intestinal microbiota and systemic 
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Background: Idiopathic inflammatory bowel disease (IBD) and food-responsive diarrhea 
(FRD) are common categories of chronic inflammatory enteropathy (CIE) in dogs. The 
intestinal microbiota is considered a major contributing factor to the pathogenesis of IBD. 
Intestinal dysbiosis has been identified in dogs with IBD, but only little information is available 
on differences in the mucosal microbiota of dogs diagnosed with IBD and FRD. In humans, 
dyslipidemia has also been described in patients with IBD. However, studies on the lipid 
profile in dogs with IBD or FRD are currently lacking. 
Objectives: This is the first study to (1) compare the intestinal mucosal microbiota of dogs 
with IBD and FRD in the duodenum and the colon, (2) evaluate differences in the mucosal 
microbiota of each dog before and after the induction phase of treatment, and (3) evaluate 
the systemic phospholipid profile of dogs with IBD or FRD also both prior to and after the 
induction phase of treatment. 
Materials and Methods: Duodenal and colonic mucosal biopsies from 24 dogs with CIE (15 
FRD, 9 IBD) and EDTA-plasma and whole blood from 32 dogs (16 FRD, 16 IBD) were 
retrieved from a former study on canine CIE. All client-owned dogs were prospectively 
enrolled in the study. All dogs received a standardized diagnostic work-up and treatment 
including a dietary trial. Dogs that responded to the elimination diet within 14 days were 
classified as FRD; the remaining dogs requiring additional immunosuppressant treatment 
were classified as IBD. Biopsy specimens of duodenum and colon were obtained 
endoscopically both before and after standard therapy. DNA was extracted from these 
biopsies and the intestinal mucosal microbiota of the duodenum and colon were evaluated by 
Illumina sequencing of the bacterial 16S rRNA gene. The phospholipids in whole blood and 
EDTA plasma, collected both before and after treatment, were analyzed by hydrophilic 




assessed by alpha diversity indices, principal coordinate analysis, analysis of similarities 
(ANOSIM) and linear discriminant (LDA) analysis effect size (LEfSe) for the microbiota and 
by principal component analysis (PCA), analysis of variance (ANOVA) and random forest 
analysis for the phospholipid profile. 
Results: All differences in the microbial composition and phospholipid profile described 
below are statistically confirmed with significance set at p-value < 0.05 or LDA score > 2.0. 
No difference in the global bacterial composition was identified neither between the two 
disease groups of dogs nor with the treatment status. However, abundances of several 
bacterial taxa varied between disease groups and also with the treatment status. When 
comparing disease groups, an unclassified genus of Neisseriaceae was more abundant in 
the duodenum in the IBD group, whereas Bilophila spp. occurred more frequently in the 
duodenum of the FRD group. Comparison before and after treatment revealed 
Enterococcus spp., Corynebacterium spp. and Proteobacteria to be enriched in the 
duodenum of FRD dogs before treatment. Bacteroides spp. was more abundant in the colon 
in the FRD group post-treatment. In the IBD dogs, Unclassified_Neisseriaceae was more 
abundant in the duodenum and mainly Proteobacteria (Burkholderia spp., Citrobacter spp.) in 
the colon prior to treatment. Bacteroides spp. was significantly more abundant in the colon 
after treatment. 
The phospholipidome differed dependent on the type of specimen (whole blood vs. plasma). 
In addition, treatment and disease severity presented the most significant factors determining 
the variance of the phospholipid profile. An increase in lysolipids and a significant shift of the 
phosphatidylcholine (PC) species from PC 38:4 (18:0 / 20:4) to mainly 
lysophosphatidylcholine 18:0 was observed after treatment. 
Conclusions: Some differences in individual bacterial taxa were identified both between 
disease groups of dogs and with regard to treatment status. The role of these bacterial 
groups in the pathogenesis of IBD and FRD is still unknown. However, Bacteroides spp. 
might be of importance, and this species could potentially serve as marker of treatment 
response. Furthermore, significant variances were identified in the phospholipid profiles of 
dogs with IBD and FRD, which were particularly associated with the type of specimen used, 
disease severity, and treatment status. These alterations in the phospholipid profile could 
potentially aid in monitoring the response to treatment. Subsequently, specific modulation of 
the intestinal microbiota and the phospholipid profile might also present novel therapeutic 
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Einleitung: Die idiopathische Inflammatory Bowel Disease (IBD) und die Futter-responsive 
Diarrhoe (FRD) sind häufige Formen der chronisch-entzündlichen Enteropathie (CIE) beim 
Hund. Die intestinale Mikrobiota wird als ein wichtiger Faktor in der Pathogenese der IBD 
angesehen. Eine intestinale Dysbiose wurde bei Hunden mit IBD nachgewiesen, allerdings 
liegen bisher nur wenig Informationen zu Unterschieden in der mukosalen Mikrobiota bei 
Hunden mit IBD und FRD vor. In der Humanmedizin ist zudem eine Dyslipidämie bei an IBD 
erkrankten Patienten beschrieben. Bisher gibt es allerdings noch keine Studien über das 
Lipidprofil bei Hunden mit IBD und FRD. 
 
Zielstellung: Diese Studie vergleicht erstmals (1) die intestinale mukosale Mikrobiota bei 
Hunden mit IBD und FRD im Duodenum und im Kolon, (2) untersucht zusätzlich 
Unterschiede in der mukosalen Mikrobiota bei jedem Hund vor und nach der 
Induktionsphase der Therapie und (3) evaluiert das systemische Phospholipidprofil von 
Hunden mit IBD oder FRD ebenfalls sowohl vor als auch nach Therapie. 
 
Material und Methoden: Archivierte Mukosabiopsien von Duodenum und Kolon von 24 
Hunden mit CIE (15 FRD, 9 IBD) und EDTA-Plasma und Vollblut von 32 Hunden (16 FRD, 
16 IBD) wurden aus einer früheren Studie über CIE übernommen. Alle Privathunde wurden 
ursprünglich prospektiv in die Studie eingeschlossen. Bei allen wurde eine standardisierte 
diagnostische Abklärung und Therapie inklusive einer Eliminationsdiät durchgeführt. Hunde, 
die innerhalb von 14 Tagen klinisch auf die Eliminationsdiät ansprachen, wurden als FRD 
klassifiziert. Die übrigen Hunde, die eine zusätzliche immunsuppressive Therapie benötigten, 
wurden als IBD-Patienten eingestuft. Biopsien von Duodenum und Kolon wurden sowohl vor 
als auch nach der standardisierten Therapie endoskopisch entnommen. DNA wurde aus 
diesen Biopsien extrahiert und die intestinale mukosale Mikrobiota mit Hilfe von Illumina-




und EDTA-Plasma, welche ebenfalls jeweils vor und nach Therapie abgenommen wurden, 
wurden mit hydrophiler Interaktions-Flüssigchromatographie (HILIC) analysiert. Unterschiede 
in der Zusammensetzung wurden für die Mikrobiota mit Hilfe von Alpha-Diversität Indizes, 
Hauptkoordinatenanalyse, Ähnlichkeitsanalyse (ANOSIM) und lineare Diskriminanzanalyse 
(LDA) Effektgröße (LEfSe) und für das Phospholipidprofil mit Hauptkomponentenanalyse 
(PCA), Varianzanalyse (ANOVA) und Random Forest Analyse ermittelt. 
 
Ergebnisse: Alle nachfolgend beschriebenen Unterschiede der Mikrobiota und des 
Phospholipidprofils sind mit einer Signifikanz bei p-Wert < 0,05 oder LDA-Wert > 2,0 
statistisch belegt. Es wurden weder zwischen den zwei Krankheitsgruppen noch zwischen 
den Behandlungszeitpunkten Unterschiede in der globalen mukosalen bakteriellen 
Zusammensetzung gefunden. Allerdings waren einige bakterielle Taxa in den 
Krankheitsgruppen und in Hinblick auf den Behandlungsstatus unterschiedlich vorhanden. 
Beim Vergleich der Krankheitsgruppen war in der IBD-Gruppe eine unklassifizierte Gattung 
der Neisseriaceae im Duodenum stärker vorhanden, wohingegen Bilophila spp. im 
Duodenum der FRD Gruppe verstärkt vorkam. Der Vergleich vor und nach Therapie zeigte, 
dass Enterococcus spp., Corynebacterium spp. und Proteobakterien im Duodenum von 
Hunden mit FRD vor Therapie vermehrt vorkamen. Bei Hunden mit IBD waren vor Therapie 
eine unklassifizierte Gattung der Neisseriaceae im Duodenum und insbesondere 
Proteobakterien (Burkholderia spp., Citrobacter spp.) im Kolon differenziell vorhanden. Nach 
Therapie kam Bacteroides spp. im Kolon sowohl von Hunden mit FRD als auch von Hunden 
mit IBD vermehrt vor. 
Das Phospholipidom differierte in Abhängigkeit von der Blutprobe (Vollblut vs. Plasma). 
Zusätzlich stellten Therapie und Schweregrad der Erkrankung die wichtigsten 
Einflussfaktoren auf die Variation im Phospholipidprofil dar. Nach Therapie wurde ein Anstieg 
an Lysolipiden und eine signifikante Verschiebung der Spezies Phosphatidylcholin (PC) von 
PC 38:4 (18:0 / 20:4) zu hauptsächlich Lysophosphatidylcholin 18:0 beobachtet. 
 
Schlussfolgerungen: Sowohl zwischen Krankheitsgruppen als auch im Hinblick auf den 
Behandlungsstatus konnten einige Unterschiede in einzelnen bakteriellen Taxa 
nachgewiesen werden. Die Bedeutung dieser Bakteriengruppen in der Pathogenese der IBD 
und FRD bleibt leider weiterhin ungeklärt. Jedoch schien Bacteroides spp. von großer 
Bedeutung zu sein, da diese Bakterienart möglicherweise als Marker für einen 
Behandlungserfolg dienen könnte. Zusätzlich wurden signifikante Varianzen in den 
Phospholipidprofilen von Hunden mit IBD und FRD festgestellt, welche abhängig waren von 
der Blutprobenart, dem Schweregrad der Erkrankung und dem Behandlungsstatus. Diese 
Varianzen im Phospholipidprofil könnten bei der Überwachung des Therapieerfolgs hilfreich 
sein. Insgesamt kann eine gezielte Beeinflussung der intestinalen Mikrobiota und des 
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Supporting Information of Publication “Comparison of the Systemic 
Phospholipid Profile in Dogs Diagnosed with Idiopathic Inflammatory Bowel 
Disease or Food-Responsive Diarrhea before and after Treatment” (see chapter 
3.2) 
 
S1 Fig. Base peak chromatogram of one of the samples. Base peak chromatogram of the 
separation by hydrophilic interaction liquid chromatography of phospholipids extracted from 
blood of a dog with FRD before treatment. Colored dots indicate retention time and m/z ratio 






S2 Fig. Effect of treatment on the individual phospholipids. The dashed red horizontal 
line is located at p = 0.05, with dots above the line having p-values < 0.05; p values < 0.05 






S1 Table. Characteristics of the dogs with IBD (n=16) or FRD (n=16) included in the 
study. 
Group characteristic IBD FRD P-value 
Total number 16 16 - 
   
Age in years, median (IQR) 4.8 (3.1–7.4) 2.5 (1.2–6.1) 0.020* 
Sex, male/female 9/7 8/8 0.723** 
Body weight in kg, median (IQR) 21.8 (9.2–32.4)  24.3 (10.7–33.9)  0.665* 
Body condition score, median (IQR) 5 (4–6)  5 (4–6)  0.638* 
Breed, n (%)   
0.694**  Pure-bred dogs 11 (69%) 12 (75%) 
 Mixed breed dogs 5 (31%) 4 (25%) 
CIBDAI score, median (IQR) 7 (4–12) 5 (4–8) 0.201* 
∗P-values obtained by Wilcoxon rank-sum test. P-values < 0.05 considered as significant. 




S2 Table. Raw peaklist of annotated phospholipids. Raw peaklist including the numbers 
of all 331 phospholipid signals in the samples analyzed. Phospholipids were annotated 
based on retention time and mass to charge (m/z) ratio. Phospholipids annotated with an '*' 
had a difference between theoretical and observed m/z of > 0.015 Da (but < 0.050) and 
should be considered 'tentatively identified'. Retention times and observed m/z values are 
included in the peaklist. Disease category: red = IBD; blue = IBD with PLE; green = FRD. 
https://doi.org/10.1371/journal.pone.0215435.s004 
 
S3 Table. Sample identification and patient information. 
https://doi.org/10.1371/journal.pone.0215435.s005 
 







S1 File. Nutritional composition of the study diet. 
 
Adult Sensitive Gastrointestinal 
Codfish and Rice * 
 
AVERAGE ANALYSIS   MINERALS  
Moisture 8 % Calcium 1.1 % 
Crude protein 24 % Phosphorus  0.8 % 
Crude fat 13 % Potassium  0.54 % 
Crude ash 6.5 % Sodium  0.4 % 
Crude fiber 2.5 % Magnesium  0.1 % 
Carbohydrates (NfE) 45 % Iron  125 mg/kg 
       Dietary fibers 6 % Copper  15 mg/kg 
       Starch  Manganese  20 mg/kg 
  Zinc  200 mg/kg 
  Iodine  2 mg/kg 
  Selenium 200 mcg/kg 
    
    
VITAMINS  FATTY ACIDS  
Vitamin A 13000 UI Fatty acids (Omega 6)  3.5 % 
Vitamin D3  1500 UI Fatty acids (Omega 3)  1.0 % 
Vitamin E 100 mg   
Vitamin B1  10 mg   
Vitamin B2 20 mg ENERGY /kg 
Pantothenic acid  30 mg Metabolizable E. (Atwater) 3939  kcal 
Niacin (PP)  40 mg Metabolizable E. (AAFCO) 3520 kcal 
Vitamin B6  8 mg Metabolizable E. (NCR) 3680 kcal 
Vitamin B12  100 mcg   
Biotin 0.8  mg   
Folic acid  2 mg SPEC.  
Choline  1900 mg L-Carnitine 100 mg/kg 
 Biocholine  225 mg DL-Methionine 330 mg/kg 
    
 
 
Biomill Adult Sensitive Gastrointestinal is a quality product made in Switzerland, developed in 
cooperation with the University of Bern and distributed by Biomill AG, 1523 Granges-










S2 File. Table of nutritional content (original in French). 
 
 
A L L I X ²
 Edition Recettes en colonne BIOMIL
Groupe Blum Dossier Fab

















Prix de la Recette 92.90 114.39 122.80
0001 POIDS    100 100.00 100.00 100.00
0002 MS       % 88.71 90.50 90.50
0003 PROTEINE % 23.74 26.65 26.65
0004 GRAISSE  % 13.01 16.51 16.51
0004 C18 2 n6 % 2.72 3.86 3.12
0004 C18 3 n3 % 0.58 0.74 1.37
0005 CELL     % 2.13 2.12 2.12
0005 FIBRES % 6.31 6.74 6.74
0006 MIN  cendres    % 6.37 7.77 7.77
0007 NfE % 43.46 37.45 37.45
0007 GE KJ/ 1816.50 1919.11 1919.11
0007 sV GE % 88.46 88.48 88.48
0008 Energy NCR KJ/ 1516.51 1600.09 1600.09
0009 Energie AAFCO KJ/ 1447.21 1526.36 1526.36
0009 Energie AAFCO CA 345.75 364.65 364.65
0011 LYS      % 1.48 1.87 1.87
0012 MET      % 0.48 0.65 0.65
0013 CYS      % 0.44 0.43 0.43
0014 M+C      % 0.93 1.10 1.10
0015 THR      % 1.00 1.17 1.17
0016 TRP      % 0.25 0.28 0.28
0017 ARGIN % 1.22 1.41 1.41
0018 HISTID % 0.53 0.61 0.61
0019 ISOLEU % 1.11 1.29 1.29
0020 CARNITI Gr 0.10 0.10 0.10
0029 CA       % 1.09 1.28 1.28
0030 PHOS     % 0.82 0.92 0.92
0031 PHOD     % 0.74 0.75 0.75
0032 K % 0.52 0.58 0.58
0033 NA % 0.41 0.43 0.43
0034 CL % 0.66 0.70 0.70
0035 MAGNE % 0.10 0.11 0.11
0036 FER Gr 0.10 0.10 0.10
0037 CU Gr 0.01 0.01 0.01
0038 MANGAN Gr 0.02 0.02 0.02
0039 ZINC Gr 0.20 0.20 0.20
0040 IODE Gr 0.00 0.00 0.00
0041 SELENIUM mg 0.20 0.20 0.20
0042 COBALT mg 0.12 0.11 0.11
0039 ZINC org. Gr 0.05 0.05 0.05
0045 VIT. A Kui 13.40 13.40 13.40
0046 VIT. D3 Kui 1.50 1.50 1.50
0047 VIT. E Gr 0.10 0.10 0.10
0050 VIT. B1 Gr 0.01 0.01 0.01
0051 VIT. B2 Gr 0.02 0.02 0.02
0052 PANTOTH A Gr 0.03 0.03 0.03
0053 NIACIN B3 Gr 0.04 0.04 0.04
0054 PYRIDOX  B6 Gr 0.01 0.01 0.01
0055 FOLIQUE A Gr 0.00 0.00 0.00
0056 VIT. B12 mg 0.10 0.10 0.10
0057 BIOTINE mg 0.80 0.76 0.76
0058 CHOLINE Gr 1.98 2.78 2.78
0058 BiochoLIN Gr 0.22 0.22 0.22
0061 amidon % 35.89 27.95 27.95
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